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CHAPTER I 
 
OVERVIEW 
 
 There are approximately 6 million pregnancies in the United States each year and 
about 1 million (~17%) of these have complications which result in fetal loss (Ventura et 
al., 2008). Multiple maternal environmental risk factors including smoking, infection and 
nutrition have been identified. Studies have examined genetic variants for association 
with many of these disorders and while there has been some success, this field remains 
unstudied or poorly understood. The focus of this dissertation is on examining the 
epidemiology and genetic mechanisms of two very common reproductive disorders: 
bacterial vaginosis (BV) and preterm birth (PTB).  
 The introduction and background of both BV and PTB are presented in Chapter 
II, part A. Clinical diagnosis, treatment, epidemiology and genetic associations for both 
disorders are discussed. Additionally, strategies for studying these disorders are 
presented. Part B lays out the hypothesis and specific aims of this dissertation. 
 To understand the epidemiology and immunology of BV, cervical cytokine levels 
are examined in Chapter III. Part A identifies differences in cervical cytokine 
concentrations by BV status and race. Part B examines cervical cytokine network 
differences by BV status and race. These studies show that BV positive (BV+) European 
Americans (EA) have significantly lower levels of the pro-inflammatory cytokines 
interferon gamma inducible protein (IP10) and monocyte chemotactic protein (MCP1) 
compared to BV negative (BV-) women; while BV+ African Americans (AA) have 
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significantly higher levels of the pro-inflammatory cytokine interleukin 1 alpha (IL-1α). 
Additionally, correlation analysis reveals that AA have a stronger correlated response to 
infection than EA. 
 Chapter IV examines the genetic regulation of some of the pro- and anti-
inflammatory cytokines examined in Chapter III. Part A examines single nucleotide 
polymorphisms (SNPs) in anti-inflammatory cytokine genes and receptors for 
associations with cervical anti-inflammatory cytokine concentrations. In Part B, SNPs in 
pro-inflammatory cytokine genes and receptors that associate with cervical pro-
inflammatory cytokine concentrations are identified. Part C determines if SNPs in toll-
like receptor 2 (TLR2) and toll-like receptor 4 (TLR4) are associated with pro- and anti- 
inflammatory cytokine concentrations. These studies indicate that in EA SNPs in 
interleukin 6 receptor (IL-6R) and interleukin 10 receptor alpha (IL-10RA) are associated 
with cervical concentrations of interleukin 6 (IL-6) and interleukin 10 (IL-10), 
respectively and these associations are influenced by BV status. In AA, variants in tumor 
necrosis factor alpha receptor 2 (TNFR2), interleukin 8 receptor alpha (IL-8RA) and 
interleukin 1 receptor accessory protein (IL-1RAP) are associated with cervical 
concentrations of tumor necrosis factor alpha (TNF-α), interleukin 8 (IL-8) and 
interleukin 1 beta (IL-1β), respectively; these associations are also influenced by BV 
status. Additionally, in EA but not AA, SNPs in TLR4 are associated with levels of IL-6, 
IL-1β and TNF-α and are influenced by BV status. These studies reveal that the gene 
receptors, not necessarily the genes themselves are important in regulating cervical 
cytokine levels and that genetic regulation differs by BV status and race. 
3 
 Chapter V identifies maternal and fetal SNPs associated with PTB. Part A focuses 
on single locus associations with PTB, and part B highlights associations that overlap 
with an independent analysis of PTB in an EA population. These studies indicate that the 
strongest single locus maternal and fetal associations, including those that are strongly 
associated in a pooled population of two independent EA populations, are involved in the 
following pathways: extracellular matrix strength (COL1A2), inflammation and infection 
(IL1RAP), complement and coagulation (TFPI and PON1) and prostaglandin synthesis 
(PTGER3).  
4 
CHAPTER II 
 
INTRODUCTION 
 
A. Introduction and Background 
 
Bacterial Vaginosis 
 
Epidemiology 
Prevalence. BV is one of the most prevalent vaginal disorders in adult women. It is 
currently estimated that approximately 30-50% of AA and 10-20% of EA are affected 
(Eschenbach, 1993; Hillier et al., 1995; McGregor and French, 2000; Cauci et al., 2002). 
Additionally, BV occurs in approximately 15-50% of pregnant women and is the most 
common type of lower genital tract infection in pregnancy (Eschenbach, 1993; Hillier et 
al., 1995; McGregor and French, 2000; Wadhwa et al., 2001; Cauci et al., 2002). 
However, because nearly 50% of affected women do not experience symptoms, and 
consequently do not seek diagnosis or treatment, the true prevalence of BV may be 
higher (Mitchell, 2004).   
BV is associated with endometritis, nonchlamydial pelvic inflammatory disease, 
an increase in risk of contracting and transmitting HIV and urinary tract infections (Taha 
et al., 1998; Sweet, 2000; Ness et al., 2004b). Pregnant women with BV are at an 
increased risk for adverse reproductive outcomes such as miscarriage, PTB, premature 
rupture of the membranes (PROM), amniotic fluid infection, chorioamnionitis and 
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postpartum endometritis (Koumans and Kendrick, 2001; CDC, 2002; O'Brien, 2005). 
Infants born to women with BV have an increased risk for localized infectious 
complications, bacteremia, culture-negative sepsis syndrome and necrotizing enterocolitis 
(Dammann and Leviton, 1997; Amaya et al., 2002; Stelmach et al., 2004).  
 
Table 2-1. Risk factors for BV 
Risk Factor Referent Group OR 1Reference 
AA EA 2.5-2.8 (Culhane et al., 2001; Koumans et 
al., 2007) 
Mexican American EA 1.6 (Koumans et al., 2007) 
Douching between 
1-5 times per month 
No douching in past 
6 months 
2.1-2.5 (Culhane et al., 2001; Koumans et 
al., 2007) 
Lifetime number of 
sex partners (1-5) 
0 1.4-2.4 (Culhane et al., 2001; Koumans et 
al., 2007) 
Birth control pill use No use 0.65 (Koumans et al., 2007) 
High school 
education or less 
Continued education 
after high school  
1.4 (Koumans et al., 2007) 
Moderate to high 
stress 
Low-stress 2.2-2 (Culhane et al., 2001) 
1
 
Culhane et al 2001 included 454 pregnant women at ~14 weeks gestation and Koumans 
et al 2007 included 2,906 women from the National Health and Nutrition Examination 
Survey (NHANES) 
 
Risk Factors. Common risk factors for BV include race, stress, education, sexual 
activity, contraceptive use,  and frequent douching (Table 2-1) (Culhane et al., 2001; 
O'Brien, 2005). AA women are at a two times greater risk for developing BV than EA 
after adjusting for socio-demographic variables such as education and income (Ness et 
al., 2003). The reasons why AAs are more susceptible to BV than EAs are poorly 
understood and very few studies have directly addressed this issue.  
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Diagnosis and treatment 
Clinical Diagnosis. BV is a serious reproductive disorder that is most often 
asymptomatic and therefore difficult to diagnose. Women with symptoms are clinically 
diagnosed by the Amsel criteria characterized by three of the four symptoms: 1) 
increased vaginal pH (>4.5), 2) presence of an amine fishy odor after adding 10% 
potassium hydroxide to the vaginal secretion, 3) a white-grayish adherent discharge and 
4) presence of “clue-cells”, which are epithelial cells covered by adherent anaerobic 
bacteria (Amsel et al., 1983).   
Microbiology. BV is characterized by the presence of Gardnerella vaginalis, 
Bacteroides and Mobiluncus and the absence of lactobacilli. G. vaginalis and Bacteroides 
are facultative anaerobic gram-negative rods. However, G. vaginalis is often referred to 
as gram-variable because the cell wall of the micro-organism sometimes stains gram-
positive. Mobiluncus species are curved anaerobic gram variable rods that generally stain 
gram-positive. Lactobacilli are facultative anaerobic gram-positive bacteria that are 
components of the healthy vaginal microflora. 
The Spiegel method demonstrated that gram staining is an acceptable procedure 
for identifying the various bacteria associated with BV (Spiegel et al., 1983). The Nugent 
score expands this method by quantifying the micro-organisms in the vaginal tract and is 
the gold standard for diagnosing BV (Nugent et al., 1991). The presence of Lactobacillus 
species, Gardnerella species (such as G. vaginalis, Prevotella, Bacteroides and 
Porphyromonas species) and Mobiluncus species are detected by gram stain. An 
individual gram stain score ranging from 0 to 4 for Lactobacillus and Gardnerella and 0 
to 2 for Mobiluncus is determined based on the number of morphotypes or colonies 
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present per oil-immersion field under a microscope (Table 2-2). This score is totaled with 
0-3 indicating normal flora, 4-6 indicating intermediate flora and 7-10 indicating BV. The 
Nugent score not only has a high degree of interobserver reproducibility but also 
correlates well with clinical signs and symptoms of the disorder (Joesoef et al., 1991; 
Hillier et al., 1992)            
 
Table 2-2. Nugent scoring system 
Score 
Lactobacillus 
species 
Gardnerella and 
Bacteroides  
Mobiluncus 
species 
0 >30 0 0 
1 5-30 1 1-4 
2 2-4 2-4 >5 
3 1 5-30  
4 0 >30   
    Average number of colonies corresponds to gram stain score 
 
Treatment. Treatment generally includes the administration of the antibiotics 
metronidazole or clindamycin (CDC, 2006). Metronidazole inhibits DNA replication of 
anaerobic bacteria; while clindamycin inhibits protein synthesis of gram-positive bacteria 
and other anaerobes. However, studies have shown that several microbes associated with 
BV develop resistance to these antibiotics after treatment; therefore, the chance of re-
occurrence is high (Beigi et al., 2004; Ferris et al., 2004). Additionally, the effectiveness 
of these treatments in reducing adverse pregnancy outcomes associated with BV such as 
PTB is inconsistent and unclear (McGregor et al., 1994; Joesoef et al., 1995; Vermeulen 
and Bruinse, 1999; Hay et al., 2001; Lamont et al., 2003).  
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Cervical and vaginal immunity  
Local innate immunity plays a critical role in regulating the response to micro-
organisms in the genital tract (Fidel, 2003; Russell et al., 2004). Pro-inflammatory 
cytokines such as IL-1 alpha (IL-1α), IL-1β, IL-6, IL-8 and TNF-α are critical mediators 
of inflammation and the response to infection; while anti-inflammatory cytokines such as 
interleukins -4 (IL-4), -10 (IL-10) and -13 (IL-13) keep the pro-inflammatory response in 
check. Toll-like receptors are important factors of the innate immune system and are 
essential for initiating pro- and anti-inflammatory responses (Janssens and Beyaert, 2003; 
O'Connell et al., 2005). The regulation of the immune response to infection is a delicate 
network of pro- and anti- inflammatory cytokines. Any disruptions, genetic or 
environmental, may alter cytokine gene expression and predispose individuals to an 
increased risk of developing infections such as BV. 
Vaginal and cervical cytokine expression. Elevated vaginal, cervical and amniotic fluid 
pro-inflammatory levels are associated with a wide range of reproductive disorders 
including PTB, PROM and recurrent miscarriage (Poniedzialek-Czajkowska et al., 2000; 
Kurkinen-Raty et al., 2001; Holst et al., 2005; Menon et al., 2007; Hattori et al., 2007; 
Menon et al., 2008a; Menon et al., 2008b). In general, these levels do not fluctuate 
throughout pregnancy; however, BV+ women have significantly higher cervical and 
vaginal pro-inflammatory cytokine levels, particularly IL-1β, which has been replicated 
in multiple studies (Imseis et al., 1997; Mattsby-Baltzer et al., 1998; Donders et al., 2003; 
Cauci et al., 2003; Wasiela et al., 2005; Basso et al., 2005; Hedges et al., 2006; St John E. 
et al., 2007). Furthermore, studies have shown that vaginal levels of IL-1α, and IL-8 are 
higher in BV+ compared to BV- women; however, these results have failed to replicate 
9 
(Imseis et al., 1997; Cauci et al., 2003; Wasiela et al., 2005; Basso et al., 2005; Hedges et 
al., 2006). Generally, vaginal levels of IL-6 and TNF-α are not significantly different 
between BV+ and BV- women (Imseis et al., 1997; Mattsby-Baltzer et al., 1998; Alvarez-
Olmos et al., 2004; Wasiela et al., 2005; Basso et al., 2005; Hedges et al., 2006). Few 
studies have examined anti-inflammatory cytokine levels between BV+ and BV- women. 
However, one study showed levels of IL-4 are higher in BV+ compared to BV- women 
and another study showed concentrations of IL-10 are lower in BV+ compared to BV-
Genetics. Polymorphisms in pro-inflammatory, anti-inflammatory and toll-like receptor 
genes have been tested for associations with BV; however, many of these studies are 
either not significant or fail to replicate (Table 2-3). Additionally, the studies that do 
detect association with BV only detect moderate effect sizes (risk genotype OR 2.2 or 
less uncorrected). Serum cytokine concentration heritability for IL-6, IL-10 and TNF-α 
range from 53-72% and IL-1β has the highest heritability of the cytokines at 83% (Reuss 
et al., 2002; de Craen et al., 2005; Worns et al., 2006). However, few studies have 
examined polymorphisms for associations with vaginal or cervical cytokine 
concentrations even though several polymorphisms in innate immunity genes have been 
associated with serum cytokine levels (Nakashima et al., 2002; Reuss et al., 2002; Rafiq 
et al., 2007).  
  
women (Cherpes et al., 2007; Anton et al., 2008). 
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Table 2-3. Abbreviated list of genes studied for associations with BV 
Gene Gene Name Result Reference 
IL-1β Interleukin-1 beta Association (Goepfert et al., 2005; Cauci et 
al., 2007) 
IL-1RN Interleukin-1 receptor 
antagonist 
Association 
No Association 
(Genc et al., 2004a) 
(Annells et al., 2004; Genc et 
al., 2004a; Cauci et al., 2007) 
IL-6 Interleukin-6 Association (Goepfert et al., 2005) 
IL-8 Interleukin-8 No Association (Goepfert et al., 2005) 
IL-10 Interleukin-10 Association (Goepfert et al., 2005) 
TLR2 Toll-like receptor 2 No Association (Hartel et al., 2004) 
TLR4 Toll-like receptor 4 Association (Goepfert et al., 2005)  
TNF Tumor necrosis factor 
alpha 
No Association (Goepfert et al., 2005) 
 
 
Of the few studies that have tested for genetic association with vaginal cytokine 
concentrations, one described a significant association between TNF-α-308 (rs1800629), 
Nugent score and vaginal TNF-α levels (Genc et al., 2006). Women with the AA 
genotype at this SNP and a Nugent score of greater than 7 have significantly higher 
vaginal TNF-α levels compared to those with the GG genotype and a Nugent score 
greater than 7 or the AA genotype and a Nugent score less than 7 (Genc et al., 2006). 
Another study found that TLR4+896A (rs4986790) homozygotes infected with 
Prevotella, Bacteroides, Porphyromonas species and/or G. vaginalis have significantly 
higher vaginal levels of IL-1β and interleukin 1 receptor antagonist (IL-1RN) compared 
to those not infected (Genc et al., 2004b).  The lack of additional significant associations 
and replicated studies illustrates the importance of not only examining intermediate 
phenotypes such as vaginal, cervical or amniotic fluid cytokine concentrations but also 
examining other genes in the biological pathway such as cytokine receptors (Annells et 
al., 2004; Genc et al., 2004a; Genc et al., 2004b; Goepfert et al., 2005; Cauci et al., 2007).  
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Spontaneous Preterm Birth 
 
Epidemiology  
Prevalence. There are 5 million infants born each year, approximately 12% of which are 
born preterm (defined as less than 37 weeks of gestation) (Martin et al., 2005). 
Prematurity-related conditions are responsible for approximately one-third of all infant 
deaths, making this one of the leading causes of infant mortality in the United States 
(MacDorman et al., 2008). PTB can be divided into two categories: indicated PTB, which 
accounts for about 25% of all PTBs and spontaneous PTB (sPTB), which accounts for 
about 75% of all PTBs (Meis et al., 1987; Meis et al., 1995a; Meis et al., 1998). 
Preeclampsia, fetal distress, intrauterine growth restriction, placental abruption and fetal 
demise account for the majority of indicated PTBs; while infection and preterm PROM 
(PPROM) are responsible for two thirds of all sPTBs (Figure 2-1) (Meis et al., 1987; 
Tucker et al., 1991; Meis et al., 1995a; Meis et al., 1998). The remaining third of sPTBs 
are idiopathic meaning there are no clear mechanistic reasons for the early delivery.  
Preterm infants are at a higher risk to suffer from necrotizing enterocolitis, 
hyaline membrane disease, intraventricular hemorrhage, respiratory distress, jaundice and 
sepsis (Creasy and Resnik, 2004). Also, since preterm infants generally have very low 
birth weight, they have an increased risk of cerebral palsy and mental retardation (Creasy 
and Resnik, 2004). It is important that the mechanisms of PTB, especially sPTB, are fully 
examined to develop better diagnostic and treatment methods that could lead to 
prevention of PTB.  
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Figure 2-1. Main types and causes of PTB. The prevalence of the two types of PTB, 
spontaneous and indicated, are presented. Also described is the breakdown of common 
factors causing each type of PTB. 
 
 
Risk factors. Maternal risk factors for PTB include multiple gestations, African ancestry, 
stress, maternal age less than19 or greater than 35, smoking, poor nutrition and low body 
mass index (Table 2-4) (Von Der Pool, 1998). AA are at an increased risk for PTB 
compared to EA (Creasy and Resnik, 2004). The rate of PTB for AA is 18% compared 
with 12% in EA (Martin et al., 2007). This disparity remains after accounting for socio-
demographic differences such as income, age, marital status, smoking and health 
insurance coverage (Giscombe and Lobel, 2005). Additionally, history of preterm 
delivery and second-trimester abortion are also risk factors for PTB (Von Der Pool, 
1998). Obesity has been associated with an increased risk for PTB; however, one study 
found obesity was protective against PTB (Hendler et al., 2005; Driul et al., 2008; Salihu 
et al., 2008; Hacini et al., 2008). Also, all of these factors combined only explain a 
fraction of PTBs, especially sPTBs.  
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Table 2-4. Risk factors for PTB a) sPTB b) indicated PTB 
 
a) 
Risk Factor Referent Group OR 1Reference 
African Ancestry Non-African 1.5 (Goldenberg et al., 1998) 
Maternal age <19 
years 
Maternal age >19 
years 
1.8-2.4 (Meis et al., 1995b; 
Goldenberg et al., 1998) 
Body mass index 
<19.8 
Body mass index 
>19.8 
2.5 (Goldenberg et al., 1998) 
Maternal smoking 
(≥10 cigarettes/day) 
No maternal 
smoking 
1.5 (Meis et al., 1995b) 
Parity ≥3 Parity = 1 1.6 (Meis et al., 1995b) 
Previous sPTB No previous sPTB 2.7 (Goldenberg et al., 1998) 
Vaginal bleeding Absence of vaginal 
bleeding 
1.5-2 (Meis et al., 1995b; 
Goldenberg et al., 1998) 
Pelvic infection Absence of pelvic 
infection 
1.3 (Goldenberg et al., 1998) 
Positive fetal 
fibronectin 
Negative fetal 
fibronectin 
3.3 (Goldenberg et al., 1998) 
Cervical length 
≤25mm 
Cervical length 
>25mm 
3.5 (Goldenberg et al., 1998) 
 
b) 
Risk Factor Referent Group OR 1Reference 
Maternal age ≥35 
years 
Maternal age 20-34 1.9 (Meis et al., 1995b) 
Parity ≥3 Parity = 1 1.8 (Meis et al., 1995b) 
Previous stillbirth No history of 
stillbirth 
3.3 (Meis et al., 1995b) 
Maternal smoking 
(≥10 cigarettes/day) 
No maternal 
smoking 
1.3 (Meis et al., 1995b) 
Vaginal bleeding Absence of vaginal 
bleeding 
2.0 (Meis et al., 1995b) 
Bacteriuria No bacteriuria 2.1 (Meis et al., 1995b) 
1
 
Goldenberg et al 1998 included 2,929 pregnancies collected by the National Institute of 
Child Health and Human Development Maternal Fetal Medicine Network and sPTB was 
defined as gestation <37 weeks and Meis et al 1995 included 26,205 pregnancies 
collected by the Cardiff Births Survey and sPTB was defined as gestation ≤257 days 
(36.7 weeks). 
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Diagnosis and treatment  
Clinical Diagnosis. Diagnosis of preterm labor  (PTL) is difficult because the symptoms, 
such as pelvic pressure, vaginal discharge, backache and cramps are hard to define 
(Creasy and Resnik, 2004). Diagnosis of PTL is made when persistent uterine 
contractions are followed by dilation of the cervix greater than 2 cm, greater than 50% 
effacement, or PROM (Von Der Pool, 1998). Digital examination of the cervix is not 
always accurate until significant dilation and effacement have occurred (Creasy and 
Resnik, 2004). Presence of four or more contractions per hour can also be used for 
diagnosis; however using these criteria alone is a poor predictor of PTL (Iams et al., 
1995). Therefore, diagnosing women who have symptoms of PTL but have a cervical 
dilation of <2 cm and/or have effacement <50% remains very difficult. 
 Other methods of PTL diagnosis include measurement of cervical length and 
molecular biomarkers such as corticotrophin-releasing hormone (CRH), fetal fibronectin, 
and cytokines. Both a cervical length of less than 25 mm and increased levels of CRH 
can independently be diagnostic measures of PTL (Vogel et al., 2005; Goldenberg et al., 
2005). However, results are inconsistent on the clinical effectiveness of these methods 
(Honest et al., 2003; Vogel et al., 2005). The most utilized biomarker for PTL is fetal 
fibronectin (fFN) (Von Der Pool, 1998). When found, it may indicate microruptures in 
the fetal membranes or disruption of the choriodecidual interface (Lockwood et al., 
1991). Cytokines can also be used as biochemical markers of PTL (Vogel et al., 2005).  
IL-6 was the best predictor of PTL in symptomatic women; however, due to the short 
half-life of cytokines, accurate testing is difficult (Vogel et al., 2005).   
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Treatment. There are currently many methods of treating PTL including administration 
of corticosteroids, tocolytic agents and antibiotics. The most commonly used treatment is 
tocolytic agents, such as magnesium sulfate, prostaglandin synthesis inhibitors, calcium 
channel blockers and beta-adrenergic agonists (Creasy and Resnik, 2004; Simhan and 
Caritis, 2007).  
Magnesium sulfate suppresses myometrial contractions and has minimal maternal 
and fetal side effects (Creasy and Resnik, 2004). The most common maternal side effects 
include headache, nausea, dizziness, dry mouth, lethargy and blurred vision (Hollander et 
al., 1987; Cox et al., 1990; Dirge et al., 1998).  
Prostaglandin synthesis inhibitors are the most commonly used tocolytic agents. 
They inhibit the cyclooxygenase enzyme, which is required for synthesis of prostaglandin 
G, a precursor of prostaglandins E and F, both of which are important in stimulating labor 
(Creasy and Resnik, 2004). Maternal side effects are uncommon; however, possible 
serious fetal side effects include pulmonary hypertension, intraventricular hemorrhage 
and closure of the utero ductus arteriosus, which allows oxygenated blood to be delivered 
from the placenta to the fetus (Creasy and Resnik, 2004). These side effects are unlikely 
if the treatment is only administered for a short duration (<48 hours) (Creasy and Resnik, 
2004).  
Calcium channel blockers act on voltage-dependent calcium channels to block the 
influx of calcium ions through the cell membrane and thus suppress contractions 
(Fleckenstein, 1977; McDonald et al., 1994). There are minimal maternal and fetal side 
effects, the most common of which are vasodilation, transient tachycardia and mild 
decrease in blood pressure (Ferguson et al., 1989).  
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Beta-adrenergic agonists suppress uterine contractions by inhibiting myosin light-
chain kinase; however, these are not commonly administered due to the high rate of 
serious cardiovascular and metabolic maternal side effects (Creasy and Resnik, 2004). 
Cardiovascular side effects include hypotension, cardiac arrhythmia, myocardial ischemia 
and pulmonary edema (Creasy and Resnik, 2004). The most common metabolic side 
effect is hyperglycemia (Creasy and Resnik, 2004).  
These treatment options have proven ineffective in reducing PTB prevalence; in 
fact, the prevalence of PTB has increased from 10.7% in 1992 to 12.8% in 2006 
(Hamilton et al., 2007). This may be due to the fact that most of these treatments are not 
effective in prolonging labor for more than 48-72 hours. Additionally, many of these 
treatments have harmful side effects for the mother and fetus after prolonged treatment 
(Creasy and Resnik, 2004; Simhan and Caritis, 2007). It is critical that a better 
understanding of the etiology of PTB is gained in order to develop better diagnostic and 
treatment options for those at risk of PTB. 
 
Biological pathways 
There are four main proposed pathways that lead to sPTB (Figure 2-2): 1) 
inflammation and infection,  2) activation of maternal or fetal hypothalamic pituitary-
adrenal axis, 3) decidual hemorrhage and 4) pathological uterine distension (Lockwood 
and Kuczynski, 2001). The individual factors involved in these pathways and how they 
affect sPTB are poorly understood.   
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Figure 2-2. Pathways of PTB. Adapted from Lockwood et al (2001) Paediatr. Perinat. 
Epidemiol. 2, 560-567. The four proposed PTB pathways include inflammation/infection, 
activation of the maternal fetal HPA axis, decidual hemorrhage and uterine distention. 
 
 
Inflammation/Infection Pathway. As discussed previously, infection accounts for about 
25% of all sPTBs (Vogel et al., 2005). The most common type of lower genital tract 
infection in adult women is BV, which is associated with adverse pregnancy outcomes 
such as sPTB and PPROM (Wadhwa et al., 2001). Infection occurs through four main 
pathways: 1) ascension from the vagina and cervix, 2) transmission from the placenta, 3) 
dissemination from the peritoneal cavity through the fallopian tubes and 4) introduction 
from amniocentesis, fetal blood sampling or chorionic villous sampling (Romero et al., 
2002). Infection can lead to PTB through several mechanisms (Goldenberg et al., 2000). 
Bacterial colonization of the chorion, amnion, placenta and decidua leads to an increase 
of cytokines and chemokines such as IL-1α, IL-1β, IL-6, IL-8, TNF-α and granulocyte 
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colony stimulating factor (GMCSF) (Goldenberg et al., 2000). This causes an increase of 
prostaglandin production that can trigger myometrial contractions. 
Hypothalamic-Pituitary-Adrenal (HPA) Axis Pathway.  During pregnancy the fetal-
placental-decidual component produces hormones, neuropeptides, growth factors and 
cytokines. Changes in concentrations of these proteins, particularly fetal adrenal 
dehydroepiandrosterone sulfate, causes the system to shift from progesterone-dominant to 
estrogen-dominant (Wadhwa et al., 2001). This shift causes the formation of gap 
junctions, expression of oxytocin receptors and the production of prostaglandins that 
induce labor (Wadhwa et al., 2001).   
The major factor that regulates HPA axis activity and response to stress is 
corticotropin-releasing hormone (CRH) (Vale et al., 1981; Challis et al., 1995). As 
pregnancy progresses, CRH increases and activates the pituitary-adrenal axis to drive 
cortisol secretion (Chrousos et al., 1998). CRH binding protein (CRH-BP) neutralizes 
most of the free CRH; however, in the third trimester, CRH-BP levels drastically decline 
resulting in an increase of CRH (Linton et al., 1993). Therefore, as mentioned above, 
placental secretion of CRH can be used to determine labor progression (McLean et al., 
1995). Maternal stress can interrupt this mechanism causing cortisol to be overproduced 
and this may result in sPTB (Challis et al., 1995; Lockwood and Kuczynski, 1999). CRH 
also increases prostaglandins and oxytocins, both of which induce contractions (Jones et 
al., 1989; Jones and Challis, 1990).   
Decidual Bleeding Pathway. Decidual hemorrhaging due to vaginal bleeding is 
associated with a three-fold increased relative risk for sPTB (Williams et al., 1991). This 
increases production of coagulation factors, such as factor 7 (F7) and factor 10 (F10) that 
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are important for the production of thrombin (F2) which is critical in clot formation. An 
overproduction of thrombin causes contractions and activates matrix metalloproteinases 
(MMPs) which lead to the degradation of the extracellular membrane (ECM). ECM 
degradation initiates changes in the cervix and rupture of the membranes which may 
result in PTB. 
Uterine Distension Pathway. Multifetal gestation or hydramnios cause an increase in 
uterine volume resulting in excessive stretching and uterine distension. Mechanical 
signals such as contraction-associated proteins (CAPs) including connexin-43, oxytocin 
receptor and prostaglandin F receptor originate from the fetal genome and regulate the 
growth and stimulation of the uterus (Creasy and Resnik, 2004). Excessive uterine 
distension induces CAP gene expression and myometrial activation (Creasy and Resnik, 
2004). This results in uterine contractions and PTB.   
 
Genetics  
There is evidence to suggest that sPTB has a genetic component. For example, 
mothers who were preterm or have a sister who delivered prematurely are at a higher risk 
for PTB compared to those with no history or family history of PTB (Carr-Hill and Hall, 
1985; Porter et al., 1997). Furthermore, history of previous PTB is one of the best 
predictors for PTB (Bakketeig et al., 1979; Carr-Hill and Hall, 1985; Porter et al., 1997). 
Twin studies estimate the heritability of sPTB at 20-40% (Treloar et al., 2000; Clausson 
et al., 2000). There has been an extensive amount of research in the last ten years 
examining genetic variants for association with PTB. Many studies have found 
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significant associations particularly in the complement coagulation (decidual 
hemorrhage) and inflammation/infection pathways (Table 2-5).  
 
Table 2-5. Significant genetic associations with PTB 
Gene  Gene Name Population Reference 
 Genes Involved In Coagulation 
F2 Coagulation factor II Fetal (Gopel et al., 1999) 
F5 Coagulation factor V Fetal (Gopel et al., 1999) 
 Maternal (Erhardt et al., 2000; Hao et al., 2004; 
Velez et al., 2008a) 
F7 Coagulation factor VII Fetal (Hartel et al., 2005) 
 Maternal (Hartel et al., 2005) 
MMP9 Matrix Metalloproteinase 9 Fetal (Ferrand et al., 2002) 
MTHFR 5,10-methylenetetrahydrofolate 
reductase 
Fetal (Chen et al., 2004b) 
MTRR Methionine synthase reductase Maternal (Engel et al., 2006) 
PAI1 Plasminogen activator inhibitor 
(SERPINE1) 
Fetal (Chen et al., 2007) 
PLAT Tissue plasminogen activator Maternal (Velez et al., 2008a) 
 Genes Involved In Inflammation/Infection 
IL-1β Interleukin 1, beta Fetal (Genc et al., 2002) 
IL-1R2 Interleukin 1 receptor, type II Maternal (Hao et al., 2004) 
IL-1RN Interleukin 1 receptor antagonist Fetal (Genc et al., 2002; Bessler et al., 2004) 
 Maternal (Murtha et al., 2006) 
IL-4 Interleukin 4 Fetal (Kalish et al., 2004) 
 Maternal (Annells et al., 2004; Kalish et al., 
2004) 
IL-6 Interleukin 6 Maternal (Simhan et al., 2003b; Hartel et al., 
2004) 
IL-6R Interleukin 6 receptor Maternal (Velez et al., 2007; Velez et al., 2008b) 
IL-10 Interleukin 10 Maternal (Annells et al., 2004) 
TLR2 Toll-like Receptor 2 Fetal (Krediet et al., 2007) 
TLR4 Toll-like Receptor 4 Fetal (Lorenz et al., 2002) 
TNF Tumor necrosis factor alpha Fetal (Aidoo et al., 2001; Menon et al., 
2006d) 
 Maternal (Roberts et al., 1999; Chen et al., 2003; 
Macones et al., 2004; Moore et al., 
2004; Amory et al., 2004; Annells et 
al., 2004; Engel et al., 2005) 
TNFRI Tumor necrosis factor receptor 
1A 
Maternal (Menon et al., 2006c; Menon et al., 
2006d) 
TNFRII Tumor necrosis factor receptor 
1B 
Maternal (Menon et al., 2006c; Menon et al., 
2006d) 
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Coagulation Factors. Variants in the coagulation genes F2, F5 and F7 are associated 
with PTB; a result that has been replicated (Table 2-5). In particular, the F5 Leiden 
mutation is found more often in infant (~16%) and mother (~18%) PTB cases compared 
to infant (~5%) and mother (~7%) controls (Gopel et al., 1999; Erhardt et al., 2000). F5 is 
important for conversion of prothrombin to thrombin, which is critical in blood clotting 
(Rosing and Tans, 1997a; Rosing and Tans, 1997b). Other factors such as PLAT, which 
is essential for the conversion of plasminogen to plasmin, is associated with PTB in EA 
(Velez et al., 2008a). Plasmin is a critical factor in the degradation of the ECM which can 
lead to PROM and PTB. Also, problems in the coagulation pathway may result in 
placental thrombosis, infarction or hypoperfusion; all of which can lead to PTB (Dizon-
Townson et al., 1997b).   
Homocysteine metabolism. During pregnancy, changes in the coagulation system occur 
that increase the risk of thromboembolic events, such as hyperhomocysteinaemia (HHC) 
(Gerhardt et al., 2000). HHC occurs when there is a disruption in homocysteine 
metabolism and is commonly caused by vitamin B12 or folate deficiency and mutations 
in the methylenetetrahydrofolate reductase (MTHFR) gene (Wang et al., 2001). HHC is 
associated with an increased risk of thromboembolism, coronary heart disease, pre-
eclampsia, recurrent miscarriage and placental abruption; all of which can lead to PTB 
(Wang et al., 2001). One study examining MTHFR C677T (rs1801133) in 250 Chinese 
PTB families and 250 controls found that fetal CT and TT genotypes were associated 
with PTB (OR 2.01, 95% CI 1.21-3.32 and OR 1.82, 95% CI 1.02-3.26, respectively) 
(Chen et al., 2004b). Another study examining 136 case and 573 control EA and AA 
maternal samples in total, found no association between MTHFR C677T and PTB (Engel 
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et al., 2006). However in this study, methionine synthase reductase (MTRR), an 
important factor in the conversion of homocysteine to methionine, was associated with an 
increased risk of PTB in EA (OR 2.0, 95% CI 1.1-3.6), but not in AA (Engel et al., 2006).  
Cytokines and Chemokines. A few studies have shown IL-1RN, IL-4, IL-6, IL-10 and 
TNF-α are associated with PTB in different populations; however, many of these studies 
have failed to replicate (Dizon-Townson et al., 1997a; Amory et al., 2001; Simhan et al., 
2003b; Amory et al., 2004; Bessler et al., 2004; Annells et al., 2004; Menon et al., 
2006c). The most studied cytokine mutation with PTB is TNF-α -308 (rs1800629). 
Several studies have associated TNF-α -308 with PTB and PPROM (Roberts et al., 1999; 
Moore et al., 2004). However, these results have not consistently replicated and a recent 
meta-analysis found no significant evidence for association between TNF-α -308 and 
PTB (Dizon-Townson et al., 1997a; Menon et al., 2006b). Additionally, TNF-α leads to a 
greater risk for chorioamnionitis, defined as inflammation of the membrane surrounding 
the fetus (Simhan et al., 2003c). There is evidence that the presence of both a 
polymorphism in TNF-α and BV can lead to increased risk for sPTB (Macones et al., 
2004).  
 
Strategies for Studying Complex Disorders 
 Genetic associations of BV and sPTB often fail to replicate. These diseases are 
complex and therefore it is probable that more than one genetic variant contributes to the 
mechanisms of these disorders. Additionally, many of these studies are constrained by 
poorly defined phenotypes. The studies on BV presented in the following chapters 
address these issues by examining intermediate phenotypes defined as cervical pro- and 
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anti-inflammatory cytokine concentrations. These intermediate phenotypes have more 
power to detect association with BV during pregnancy as well as provide a bigger picture 
of the genetics and immunology involved in the pathogenesis of BV. Also, variants in 
cytokine receptors along with the cytokine genes themselves are examined with each 
cervical cytokine concentration, to provide a broader understanding of the complex 
regulation of cervical immunity. To address issues involved in the intricacy of sPTB, a 
large candidate gene association study is performed. This allows for the examination of 
multiple genes involved in the four main PTB pathways. Also, approximately 1,300 
SNPs in this study overlap with a previous candidate gene association study of sPTB by 
Velez et al 2008a.  This allows for a detailed comparison of significant associations in 
these two studies. 
Another major problem contributing to the lack of replication of genetic 
association studies is ethnic heterogeneity. It is known that AA are at about a two times 
greater risk of BV and PTB compared to EA (Ness et al., 2003; Creasy and Resnik, 
2004). Also EA and AA have different patterns of genetic variation across the genome, 
particularly in genes involved in immune function such as IL-1, IL-4, IL-6, IL-8, IL-10, 
IL-13, TLR2 and TNF-α (Hoffmann et al., 2002; Rovin et al., 2002; Nakashima et al., 
2002; Pyo et al., 2003; Nguyen et al., 2004; Yim et al., 2004; Sakagami et al., 2004; Ness 
et al., 2004a; Tarazona-Santos and Tishkoff, 2005; Zabaleta et al., 2007; Velez et al., 
2007; Fujihara et al., 2007). Additionally, amniotic fluid levels of pro-inflammatory 
cytokines such as TNF-α differ between EA and AA (Menon et al., 2008b; Velez et al., 
2008c). However, few studies examining associations with BV and PTB account for 
ethnic heterogeneity. For the studies on BV, ethnic heterogeneity will be addressed by 
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analyzing AA and EA separately to allow for identification of differing mechanisms that 
may lead to vaginal colonization of harmful micro-organisms during pregnancy. The 
study sample on PTB is from Norway and is ethnically homogeneous; additionally, the 
cases and controls were carefully selected to ensure a well defined phenotype. Carefully 
designed studies may lead to a greater understanding of not only the genetic 
underpinnings of complex diseases but also the higher prevalence of BV and PTB 
observed in AA.  
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B.  Hypotheses and Specific Aims 
 
Hypothesis:   Genetic polymorphisms within biologically relevant pathways,  
including infection and neuroendocrine pathways, are associated with 
complex reproductive disorders such as BV and PTB.    
 
Specific Aim I: Identify cervical cytokine concentration and correlation differences 
by BV status and race. 
a. Identify cervical cytokine concentration differences by BV status and race. 
b. Identify cervical cytokine correlation differences by BV status and race. 
A nested case control analysis will be performed from a prospective cohort study 
conducted at Magee-Womens Hospital in Pittsburgh, PA to identify cervical cytokine 
concentrations and correlations associated with BV in EA and AA women, separately. 
Differences in cytokine concentrations and correlations by race will also be evaluated in 
BV+ and BV-
 
 women, separately. To determine differences in cytokine concentrations, 
two-sample t-tests or Kruskal-Wallis non-parametric tests will be used depending on 
normality of the cytokine concentrations. To determine cervical cytokine expression 
patterns, pair-wise correlations will be calculated with Spearman’s Rho. Differences in 
correlation coefficients will be identified using t-tests.  
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Specific Aim II:  Identify SNPs associated with cervical pro- and anti-inflammatory 
cytokine concentrations in the presence and absence of BV.   
a. Perform analysis of variance (ANOVA) in EA and AA separately using pro-
inflammatory cytokine concentrations with the corresponding genes and 
receptors.  
b. Perform ANOVA in EA and AA separately using anti-inflammatory cytokine 
concentrations with the corresponding genes and receptors. 
c. Perform ANOVA in EA and AA separately using pro- and anti-inflammatory 
cytokine concentrations with toll-like receptor genes. 
The Magee Womens cohort will be used to identify SNPs associated with cervical 
cytokine concentrations in EA and AA women, separately. BV status will be included in 
all ANOVA models. SNPs will be tested for deviations from Hardy-Weinberg 
equilibrium in the entire dataset.  
 
Specific Aim III:  Identify SNPs associated with spontaneous preterm birth (sPTB). 
a. Perform single locus association and haplotype analysis in maternal and fetal 
samples separately by testing SNPs in candidate genes for allele and genotype 
frequency differences between PTB cases and controls. 
b. Determine the effect size of significantly associated SNPs in a pooled sample of 
two independent EA populations. 
The Norwegian Mother and Child Cohort Study (MoBa) will be used to study the 
genetic associations of PTB. Approximately 160 genes biologically relevant to the 
pathways of PTB will be examined. Fisher’s exact test or chi-square tests for association 
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will be performed for mother and fetal genotypes, separately. Tests for deviations from 
HWE will be performed in cases and controls separately. Haplotype analysis using a 2, 3 
and 4 SNP sliding window will also be performed on all genes. Samples from the 
Centinneal study (Cenn) collected in Nashville, TN will be used to determine SNPs that 
have are associated in both studies. These SNPs will be tested for association with 
logistic regression in the Cenn and MoBa samples combined to determine the effect size. 
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CHAPTER III 
 
EXAMINING CERVICAL CYTOKINE CONCENTRATIONS AND 
CORRELATIONS BY BV STATUS AND RACE 
 
 
Overview parts A and B 
 BV is a serious vaginal disorder that affects AA more often than EA. This 
disparity cannot be explained by socio-economic variables alone and is likely, in part, 
due to differing inflammatory responses to harmful micro-organisms. To explore these 
differences, cytokine concentrations and correlation patterns are examined in Chapter III. 
Part A investigates differences in twenty-eight cervical cytokine, chemokine and growth 
factor concentrations by BV status and race. BV+ EA had significantly lower pro-
inflammatory levels of IP10 (p = 0.001) and MCP1 (p = 0.006) and BV+ AA had 
significantly higher pro-inflammatory levels of IL-1α (p < 0.001) compared to BV- 
women. BV- EA had significantly higher levels of IL-1α (p = 0.047), IL-6 (p = 0.010), 
IL-10 (p = 0.016) and PDGF-BB (p = 0.010) than AA; however, there were no significant 
concentration differences between BV+ 
Part B examines the coordinated regulation of the extensive network of cytokines, 
chemokines and growth factors involved in the immune response to BV. In EA there 
were significantly more correlations involving immuno-regulatory cytokines in BV
EA and AA women. 
- 
compared to BV+ women; conversely, for AA there were no differences in the correlation 
patterns between BV+ and BV- women. Overall, BV+ AA had a stronger correlated 
response compared to EA; alternatively, there were no differences between the races in 
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BV- 
 
women. These studies elucidated the immunological differences in response to BV, 
and demonstrated baseline differences as well as differences by race in the coordinated 
expression of inflammatory factors in the presence of BV. This may, at least partially, 
explain the disparity observed in the prevalence of this disorder. 
A. Cervical Cytokine Concentrations Differ by BV Status and Race 
 
Introduction 
BV is one of the most prevalent vaginal disorders in adult women, affecting 15-
20% of pregnant women (Eschenbach, 1993; Hillier et al., 1995; McGregor and French, 
2000; Cauci et al., 2002). AA women are at a 2 times greater risk for BV than EA, and 
this disparity remains after controlling for common risk factors, many of which occur 
more frequently in AA women (Koumans and Kendrick, 2001; Ness et al., 2003). 
Furthermore, the risk of PTB attributable to BV and vaginal inflammation is greater 
among AA than their EA counterparts (Hillier et al., 1995; Simhan et al., 2005b). The 
reasons for this racial disparity are unclear, and few studies have directly addressed this 
issue. 
Vaginal immunity and cervical cytokine expression are clearly important in the 
pathogenesis of BV. Higher vaginal concentrations of IL-1α, IL-1β and IL-6 have been 
observed in BV+ compared to BV- women (Platz-Christensen et al., 1993; Mattsby-
Baltzer et al., 1998; Cauci et al., 2003; Wasiela et al., 2005; St John E. et al., 2007). 
However, these results are not consistent and little is known about population differences 
with respect to lower genital tract immunity, particularly in the presence of BV. Our 
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purpose was to compare the cervical inflammatory milieu, as represented by a panel of 28 
cytokines, chemokines and growth factors, by both BV status and race. 
 
Materials and Methods 
 
 Subjects 
 A nested case control analysis was performed from a prospective cohort study 
conducted at Magee-Womens Hospital in Pittsburgh, PA. This study was approved by the 
University of Pittsburgh and Vanderbilt University Institutional Review Boards. All 
women provided demographic, medical, and clinical information through standardized, 
closed question interviews administered by research personnel.   
Inclusion criteria for the cohort study were singleton intrauterine gestation prior to 
13 weeks. Exclusion criteria included vaginal bleeding, fetal anomalies, known 
thrombophilias, pre-gestational diabetes mellitus, chronic hypertension requiring 
medication, current or planned cervical cerclage, immune compromise (HIV positive, use 
of systemic steroids within six months, use of post-transplant immunosuppressive 
medication), and autoimmune disease (inflammatory bowel disease, systemic lupus 
erythematosus, rheumatoid arthritis, scleroderma). These exclusions were developed 
prior to study enrollment because they are believed to associate with an altered immune 
response that could bias the associations we propose to examine.   
Additional exclusion criteria were chosen after enrollment to eliminate 
characteristics that could confound associations with cytokine concentrations. These 
exclusions included: presence of Trichomonas vaginalis, Neisseria gonorrhea and 
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Chlamydia trachomatis, antibiotic use three months prior to pregnancy and race other 
than self-identified EA or AA. Women with an intermediate BV score (Nugent score of 
4-6) were also excluded because of small numbers.    
 
 
Table 3-1. Socio-demographic characteristics 
 EA Women AA vs EA AA Women 
 BV BV- p value + BV BV- p value + p value 
Age, years 25.6 1 (5.2) 
24.7 
(5.3) 0.496 
26.3 
(6.4) 
25.8 
(5.0) 0.685 0.308 
Body Mass Index 26.4 1 (5.9) 
26.1 
(4.6) 0.797 
29.7 
(7.5) 
28.4 
(7.9) 0.444 0.008 
Gestational age at 
enrollment (weeks)
9.4 
1 (2.9) 
9.2 
(3.8) 0.839 
9.5 
(3.2) 
9.0 
(3.2) 0.485 0.978 
Cigarettes/day 3 
months prior to 
pregnancy
 
2 
 0.215   0.031 0.001 
None 20 (36.4) 
5 
(17.9)  
23 
(59.0) 
12 
(28.6)   
1-5 2 (3.6) 
2 
(7.1)  
5 
(12.8) 
9 
(21.4)   
6-10 15 (27.3) 
7 
(25.0)  
5 
(12.8) 
14 
(33.3)   
>10 18 (32.7) 
14 
(50.0)  
6 
(15.4) 
7 
(16.7)   
Cigarettes/day during 
pregnancy  2  0.145   0.138 0.038 
None 24 (43.6) 
6 
(21.4)  
24 
(61.5) 
17 
(40.5)   
1-5 12 (21.8) 
6 
(21.4)  
6 
(15.4) 
15 
(35.7)   
6-10 15 (27.3) 
11 
(39.3)  
6 
(15.4) 
8 
(19.1)   
>10 4 (7.3) 
5 
(17.9)  
3 
(7.7) 
2 
(4.8)   
1Mean is presented with standard deviation in parentheses and the p-value was calculated with t-tests 
2
 
Number of events is reported with percentage in parentheses and the p-value is calculated with Fisher 
exact tests 
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Demographic and clinical characteristics 
This study consisted of 164 women: 28 EA BV+, 42 AA BV+, 55 EA BV- and 39 
AA BV-. Socio-demographic differences by BV status and race are presented in Table 3-
1. There were no statistically significant differences between BV+ and BV- EA women; 
however, AA BV+
 
 women were more likely to have smoked prior to pregnancy (p = 
0.031). Overall, AA had a higher BMI (p = 0.008) and were less likely to smoke both 
prior to (p = 0.001) and after pregnancy (p = 0.038) than EA. 
 Microbiologic assessment 
Two vaginal swabs were collected for culture and identification of vaginal flora. 
BV was diagnosed by vaginal pH > 4.7 and a score of 7 through 10 from a Gram-stained 
vaginal smear interpreted using the Nugent method (Nugent et al., 1991). The 
identification of T. vaginalis was by culture using Diamonds media, incubated at 37o C in 
5% CO2
  
 for up to 5 days. Each day, microscopic identification by direct observation of 
motile forms was performed.  If the culture media was negative for five days, the results 
were considered negative. C. trachomatis and N. gonorrhoeae were identified using 
nucleic acid amplification tests and culture, respectively.   
 Cytokine measurements 
At a first trimester study visit (median gestation 6.5 weeks), in accordance with a 
standardized protocol, a pelvic examination was performed using a clean, non-lubricated 
speculum. Two Dacron swabs were placed in the cervix and left there for 10 seconds to 
achieve saturation for the assay of cytokines. These swabs were placed in a plastic tube 
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containing 4 ml of Purified Bovine Serum (final dilution of 1:5), and stored at -80°C until 
assayed. The sample was thawed at room temperature, placed in a spin-X centrifuge filter 
unit and centrifuged at 12,000 rpm for 20 minutes. 
The Luminex LabMAP and a Beadlyte analyte kit (Upstate, Charlottesville, 
Virginia) were used to assay the following 28 cytokines from a single aliquot of 50µL of 
specimen: EOTAXIN (chemokine CC motif ligand 11), GMCSF, interferon gamma 
(IFN-γ), IP10, interleukins (IL-) 1α, 1β, 2, 3, 4, 5, 6, 7, 8, 10, 12 subunit p40, 12 subunit 
p70, 13, 15, MCP1, platelet derived growth factor (PDGF-AA and PDGF-BB), fms-
related tyrosine kinase 3 (FLT3), macrophage inflammatory protein 1-alpha (MIP1α), 
regulated upon activation, normally T-expressed and presumably secreted (RANTES), 
TNF-α, vascular endothelial growth factor (VEGF), epidermal growth factor (EGF) and 
fibroblast growth factor 2 (FGF2). Multiplex-based platforms quantify cytokine 
concentrations in plasma with a high degree of agreement and correlation to ELISA, 
while providing improved sensitivity (Prabhakar et al., 2002; Pickering et al., 2002; 
Nelson et al., 2003; Biagini et al., 2004) 
These factors were chosen because they are early response cytokines and 
molecules important in the downstream cascade of inflammatory events. A monoclonal 
antibody specific for a cytokine is covalently linked to a fluorescent bead set that captures 
the cytokine. A complementary biotinylated monoclonal cytokine antibody then 
completes the immunological “sandwich” and the reaction is detected with streptavidin-
phycoerythrin. Each sample was frozen at -80°C after initial collection and was never 
thawed until this study. After thawing, multiplex assays were performed. These samples 
were previously analyzed in duplicate using ELISA for IL-1β, IL-6, and IL-8. We found 
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a very high degree of correlation between concentrations determined by ELISA and by 
multiplex assay (r2
The cervical fluid collection protocol used in this study has served as the 
validated methodology for several large multi-center trials (Carey et al., 1993; 
Goldenberg et al., 1996; Carey et al., 2000).  The inter-swab change in weight (pre vs 
post-collection) is ±1.2% and the inter-assay variation for cervical cytokines has been 
consistently <8% (Simhan et al., 2003a; Simhan et al., 2005a). Microbiologic and 
cytokine assays were performed in the Research Microbiology Laboratory at the Magee-
Womens Research Institute by lab technologists who were blinded to any clinical or 
identifying data from the study subjects. 
 = 0.95 to 0.97) for each of the cytokines.  
 
 Statistical analysis 
Statistical analyses were performed using Stata version 9 (StataCorp, 2007). 
Demographic and clinical differences between BV+ and BV- 
To examine the possibility of concentration differences between AA women and 
EA women, Mann-Whitney U tests were performed in BV
women were determined by 
Fisher’s exact test for dichotomous variables or t-tests for continuous variables. Shapiro-
Wilks tests were performed to evaluate the normality of each cytokine distribution. 
Mann-Whitney U tests were used to evaluate concentration differences by BV status for 
EA and AA separately. A total of 56 comparisons were made and false discovery rate 
(FDR) (Benjamini and Hochberg, 1995) was used to correct for multiple testing. A q 
value of 0.2 was used to determine the FDR threshold value. 
+ and BV- women, separately. 
The results of these 56 comparisons were also corrected for multiple tests with FDR. 
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Results 
 
 Differences in cytokine concentrations by BV status 
 In EA, IL-10 (medians 37.5 and 73.3 ng/mL), IP10 (medians 1807.8 and 3972.8 
ng/mL), MCP1 (medians of 348.0 and 859.0 ng/mL), MIP-1α (medians 417.3 and 833.2 
ng/mL), PDGF-AA (medians 499.1 and 1093.5 ng/mL) and PDGF-BB (1445.1 and 
2362.2 ng/mL) were decreased in BV+ compared to BV- women (Table 3-2a, Appendix 
Table 1). IL-1α was increased in BV+ EA women. Only IP10 and MCP1 were significant 
after correction for multiple testing. In AA, IL-1α (medians of 1165.2 and 558.4 ng/mL) 
and FLT3 (medians 353.5 and 245.0 ng/mL) concentrations were elevated among BV+ 
compared to BV- 
 
women; however, only IL-1α was significant after correction for 
multiple testing (Table 3-2b, Appendix Table 1).  
 
Cytokine concentrations by race 
EA BV- women had higher levels of IL-1α (medians of 904.9 and 558.4 ng/mL), 
IL-6 (3967.1 and 2162.2 ng/mL), IL-10 (medians of 73.3 and 43.0 ng/mL) and PDGF-BB 
(medians of 2362.2 and 1204.7 ng/mL) compared to AA BV- women (Table 3-3, 
Appendix Table 1). However, these results did not hold up to correction for multiple 
testing. There were no significant differences between races for BV+ women (Appendix 
Table 1). 
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Table 3-2. Significant cytokine differences between BV- and BV+
 
 women a) EA, b) 
AA 
a) 
Cytokine BV BV- nominal p  + 
IL-1α 904.9 
(166.0 – 11098.1) 
1973.1 
(82.4 – 25581.0) 
0.030 
IL-10 73.3 
(0.0** – 497.4) 
37.5 
(0.0** – 443.0) 
0.016 
IP10 3972.8 
(5.0 – 30181.9) 
1807.8 
(146.6 – 25000.0) 
0.001* 
MCP1 859.0 
(40.0 – 30631.9) 
348.0 
(48.0 – 22146.0) 
0.006* 
MIP-1 α 833.2 
(122.1 – 12604.3) 
417.3 
(97.0 – 15810.0) 
0.043 
PDGF-AA 1093.5 
(78.4 – 10122.0) 
499.1 
(99.3 – 10916.0) 
0.048 
PDGF-BB 2362.2 
(236.2 – 33201.0) 
1445.1 
(40.0 – 14663.7) 
0.015 
 
b) 
Cytokine BV BV- nominal p  + 
FLT3 245.0 
(12.0 – 1170.0) 
353.5 
(12.0 – 15139.1) 
0.046 
IL-1α 558.4 
(104.0 – 5554.6) 
1165.2 
(163.8 – 33876.5) 
<0.001* 
Median cytokine concentrations (ng/mL) and ranges in parentheses are presented for 
BV+ and BV-
* Result significant after correction for multiple testing using FDR (q=0.2) 
 women.  
** - Below sensitivity of laboratory assay.  
 
 
 
Table 3-3. Significant cytokine differences between BV-
Cytokine  
 EA and AA   
EA  AA p  
IL-1α 904.9 (166.0 – 11098.1) 
558.4 
(104.0 – 5554.6) 0.047 
IL-6 3967.1 (62.2 – 25000.0) 
2162.2 
(5.0 – 14744.0) 0.010 
IL-10 73.3 (0.0** – 497.4) 
43.0 
(1.3 – 391.0) 0.016 
PDGF-BB 2362.2 (236.2 – 33201.0) 
1204.7 
(12.0 – 9651.0) 0.010 
Median cytokine concentrations (ng/mL) and ranges in parentheses are presented for BV+ 
and BV-
* Result significant after correction for multiple testing using FDR (q=0.2) 
 women.  
** - Below sensitivity of laboratory assay.  
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 Cytokine concentrations excluding women with C. albicans 
A study examining cytokine output in vaginal epithelial cells found that in 
response to Candida albicans high levels of IL-1α are produced while there is little to no 
production of IL-6, IL-10 and MCP-1 (Steele and Fidel, Jr., 2002). After removing the 38 
individuals infected with C. albicans from our study, EA BV+ women still had 
significantly lower concentrations of IP10 (p = 0.003) compared to BV- women, and AA 
BV+ women still had significantly higher levels of IL-1α (p =0.002) than BV- women. 
Additionally, EA BV- women had significantly higher levels of IL-10, IL-12(p40) and 
PDGF-BB than AA BV- women. There were still no significant differences in cytokine 
concentrations between EA and AA BV+
 
 women.  
Discussion 
Our findings support the notion that the nature of the inflammatory milieu in the 
cervix is different between BV+ and BV- women. We have also identified several 
cytokines that differ by race in BV- but not BV+ women. Genc and colleagues have 
previously demonstrated that activation of the IL-1 system accompanies disruption of 
vaginal flora, particularly among women who go on to have a PTB (Genc et al., 2004c). 
Our data are in agreement with this concept; in AA, IL-1α concentrations were 
significantly higher in BV+ compared to BV-
Also in EA, a number of cervical cytokine concentrations including the anti-
inflammatory cytokine IL-10, pro-inflammatory chemokines IP10, MCP1 and MIP-1α, 
and growth factors PDGF-AA and PDGF-BB were found to be decreased in BV
 women, and this result was almost 
significant after FDR corrections in EA women.  
+ 
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compared to BV- 
In BV
women.  Low serum levels of IL-10 were associated with a greater risk 
of developing a variety of infections (Opal and DePalo, 2000). Additionally, it has been 
hypothesized that a decrease in concentrations of  pro-inflammatory cytokines in the 
lower genital tract may indicate an immune “hyporesponsiveness” that predisposes to 
subsequent ascending microbial invasion (Simhan et al., 2003a).  It is unclear whether 
lower levels of pro-inflammatory and anti-inflammatory cytokines and chemokines 
predispose to BV, or are caused by BV; however, reduced production of these critical 
factors may be a mechanism for the development and propagation of BV.   
- women, our data demonstrate lower cervical concentrations of IL-1α, IL-6, 
IL-10 and PDGF-BB in AA compared to EA women. Recent research examining the 
distribution of cytokine gene polymorphisms between EA and AA have found that these 
two populations differ significantly in allelic distribution at commonly assayed sites in 
IL-1α, IL-6 and IL-10 that could give rise to a differential inflammatory response (Ness 
et al., 2004a; Zabaleta et al., 2007). Therefore, this could alter the production of the 
cytokines, possibly explaining why lower levels of these cytokines were observed in AA 
compared to EA women. It is also recognized that EA and AA women have differing 
immune responses to infection (Myslobodsky, 2001; Hoffmann et al., 2002; Blake and 
Ridker, 2003; Ness, 2004). While we did not observe differing cytokine concentrations in 
BV+ women, it is possible that because EA women have higher levels of both pro- and 
anti-inflammatory cytokines they are less susceptible to infection with BV. This 
mechanism could help to explain why AA women are at a greater risk for developing BV 
compared to EA women even after accounting for socio-demographic risk factors. 
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However, our findings should be taken as exploratory as these results did not hold up 
after correcting for multiple tests. 
Additionally, a study examining cytokine output in vaginal epithelial cells found 
that in response to Candida albicans high levels of IL-1α are produced, while there is 
little to no production of IL-6, IL-10 and MCP-1 (Steele and Fidel, Jr., 2002). After 
removing women with C. albicans from our analysis we found that our results, in 
general, remained the same. This demonstrates that while C. albicans does affect the 
vaginal cytokine milieu, strong cytokine concentration differences between BV+ and BV- 
women still exist after accounting for infection with C. albicans. Also, it is important to 
note that after removing women with C. albicans infection the differences in cytokine 
levels between EA and AA BV- women were even stronger and remained significant 
after correction for multiple testing. However, these results should be interpreted with 
caution as the sample size is small (EA: 44 BV-, 24 BV+ and AA: 26 BV-, 32 BV+
It remains unclear based on our, or any other, data whether BV infection induces 
an altered cytokine response or if altered vaginal immunity predisposes an individual to 
BV. Future research will need to be conducted to determine this relationship. In 
conclusion we were able to demonstrate that BV
) and 
power may be limited to detect smaller effects.      
+ and BV- women differed in a number 
of cytokines that are related to inflammation and that these differences appear to be 
population specific. In addition, our data support the conclusion that cytokine levels are 
similar in AA and EA women in the presence of BV, but that there may be differences 
between these populations in the absence of BV.  If this is true, it would suggest that BV 
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either fosters or is fostered by a common set of cytokine and chemokine changes, 
regardless of race or ethnicity. 
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B. Patterns of Cervical Cytokine Concentrations Differ by BV Status and Race 
 
Introduction 
The study of inflammation in the setting of lower genital tract infection has 
focused on a handful of inflammatory molecules, most often considered individually. 
Studies in part A of this chapter identified individual cytokines such as IP10, MCP1 and 
IL-1α that differ by BV status (Ryckman et al., 2008d). However, investigating cytokines 
individually does not provide insight into their holistic function as members of a system 
or network, and it is probable that structured correlations among key cytokines, 
chemokines and growth factors that represent networked responses are more important in 
understanding both susceptibility and response to BV. The coordination of this 
expression remains unclear, particularly with respect to BV.  
Some studies have examined correlations among a few vaginal pro-inflammatory 
cytokine concentrations (IL-1α, IL-1β, IL-6 and IL-8) and found stronger correlations in 
BV+ compared to BV-
Additionally, it is well documented that AA and EA can exhibit different 
inflammatory responses to similar stimuli (Myslobodsky, 2001; Hoffmann et al., 2002; 
Blake and Ridker, 2003; Ness, 2004). In previous studies, described in part A, 28 
cytokine, chemokine and growth factor concentrations were evaluated for differences by 
BV status and race (Ryckman et al., 2008d). No statistically significant differences in 
cervical cytokine concentration between AA and EA BV
 women  (Cauci et al., 2003; Wasiela et al., 2005; Ryckman et al., 
2008c). These studies suggest that there is a strong correlated response to BV, 
particularly among pro-inflammatory cytokines.  
+ women were observed. 
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However, in BV- 
To more completely examine the network of cervical cytokine expression, we 
measured cervical levels of pro-inflammatory cytokines, immuno-regulatory cytokines 
and growth factors. We assessed the patterns of correlations among these immune factors 
by BV status. We also compared EA to AA to determine if the correlation patterns of 
cervical immune factors differed by race in women with healthy vaginal flora or in those 
with BV. 
women, IL-1α, IL-6, IL-10, and PDGF-BB concentrations were higher 
in EA compared to AA. This may be a plausible mechanism to explain why AA are at a 
greater risk for BV than EA even after adjusting for socio-demographic differences such 
as education and income (Ness et al., 2003). Additionally, it is possible that the 
interrelationships of the components of the cytokine network may differ by BV status or 
race. If this is true, then such a difference may contribute to the disparity observed in BV 
prevalence between AA and EA women.   
 
Materials and Methods 
 
Subjects 
 A detailed description of subject recruitment, socio-demographic characteristics 
and microbiological assessment can be found in Chapter III, part A. However, in this 
study, an additional AA BV+ woman was excluded due to a positive C. trachomatis 
culture at the second visit. Therefore, the total sample size was 83 EA (28 BV+ and 55 
BV-) and 80 AA (41 BV+ and 39 BV-
 
) women.  
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Cytokine characterization 
A complete description of cytokine measurement and assays are described in 
Chapter III, part A. The cytokines were classified based on the literature as follows: pro-
inflammatory (EOTAXIN, IL-1α, IL-1β, IL-6, IL-8, IP10, MIP1α, MCP1, RANTES and 
TNF-α), immuno-regulatory (IFN-γ, IL-2, IL-4, IL-5, IL-10, IL-12p40, IL-12p70, IL-13 
and IL-15) and growth factors (EGF, FGF2, FLT3, GMCSF, IL-3, IL-7, PDGF-AA, 
PDGF-BB and VEGF) (Stein, 1998; Parslow et al., 2001; Brunicardi and ed, 2005; 
Federman et al., 2007).   
 
Statistical analysis 
Spearman’s rank correlation was calculated to determine correlations for all pair-
wise combinations of the 28 cytokines, chemokines and growth factors using JMP-IN® 
(Sall et al., 2005). Overall correlation structure was assessed with two analyses: 1) testing 
for differences in the number of correlations present in each group and 2) testing for 
differences (heterogeneity) in correlation coefficients between each pair of cytokines 
among groups. The first method determines if the global pattern of cytokine correlations 
is different between BV statuses or races for any group of cytokines or for an individual 
cytokine. The second method examines individual cytokine pairs to determine exactly 
what cytokine correlations differ between groups.  
McNemar’s chi-square test was performed with Stata version 9 to determine if the 
number of correlations for each cytokine and group of cytokines differed by BV status or 
race (StataCorp, 2007). McNemar’s exact test was used if there were less than 5 
observations per group. McNemar’s test determines the dependence of categorical data 
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that are matched or paired. For this study, the categorical data is defined as the number of 
correlations that were significant in both groups, neither group, or one group but not the 
other. A p < 0.05 was considered significant.  
To test for heterogeneity of correlation coefficients between BV+ and BV-
 
 women 
and between ancestral groups, a t-test on the Fisher r-to-z transformations of the 
Spearman correlation coefficients was performed. This analysis is similar to previous 
work by both Ryckman et al. (2008c) and Velez et al (2008c).  
Correction for multiple testing 
The results for differences in the number of correlations between BV+ and BV-
 
 
women and between races were corrected for multiple testing separately, using FDR with 
a significance of 0.2 (Benjamini and Hochberg, 1995). Due to the large number of factors 
being studied, only the cytokines significant after FDR correction are presented in the 
results and discussion. The results for heterogeneity between correlation coefficients 
were not corrected for multiple testing due to the exploratory nature of this analysis.  
Results 
 
Significant correlations by race and BV status 
Three-hundred seventy eight correlations were examined for each of the following 
four groups: EA, BV+ and BV-; AA, BV+ and BV- (Appendix Table 2). In EA there were 
180 significant correlations in BV+ and 199 in BV- women (Appendix Figure 1a and b). 
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In AA, 225 correlations in BV+ and 206 correlations in BV-
 
 women were significant 
(Appendix Figure 1c and d).  
Correlation and heterogeneity patterns by BV status  
In EA, there were significantly more correlations involving at least one immuno-
regulatory cytokine in BV- than BV+ women (Table 3-4a). This is especially true for 
correlations with IL-4. Twenty-four correlations were heterogeneous between BV+ and 
BV- women and twenty of these are more correlated in BV+
In contrast, in AA there were no significant differences in correlation patterns 
between BV
 women (Figure 3-1a, 
Appendix Table 3). This heterogeneity was driven by correlations involving pro-
inflammatory cytokines, particularly MIP-1α. 
+ and BV- women for any functional group or individual cytokine (Table 3-
4b). Also only 13 out of 23 heterogeneous correlations between BV+ and BV- women 
were more correlated in BV+
 
 women (Figure 3-1b, Appendix Table 3). This 
heterogeneity was driven by correlations involving pro-inflammatory cytokines, 
particularly IL-1α that had eight heterogeneous correlations. 
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Table 3-4. Differences in the number of significant correlations between BV+ and 
BV-
a) 
 women a) EA, b) AA 
First  
Factor 
Second 
Factor 
P<0.05 In 
Both Groups 
P<0.05 In 
BV+
P<0.05 In 
 Only BV-
P>0.05 In 
Both Groups  Only 
1nominal 
p 
 Pooled Comparisons     
ALL ALL 128 52 71 127 0.10 
PI ALL 52 39 30 104 0.28 
IR ALL 79 19 44 65 <0.01* 
GF ALL 75 31 39 62 0.34 
 Individual 
 
    
PI PI 12 8 9 16 1.00 
PI IR 21 11 13 45 0.84 
PI GF 19 20 8 43 0.04 
IR IR 20 2 10 4 0.04 
IR GF 38 6 21 16 0.01* 
GF GF 18 5 10 3 0.30 
 Individual Cytokine Comparisons    
MIP-1α ALL 9 12 3 3 0.04 
IL-4 ALL 2 0 10 15 <0.01* 
PDGF-AA ALL 13 0 8 6 <0.01* 
VEGF ALL 2 12 2 11 <0.01* 
b) 
First  
Factor 
Second 
Factor 
P<0.05 In 
Both Groups 
P<0.05 In 
BV+
P<0.05 In 
 Only BV-
P>0.05 In 
Both Groups  Only 
1nominal 
p 
 Pooled Comparisons     
ALL ALL 159 66 47 106 0.09 
PI ALL 65 51 34 75 0.06 
IR ALL 100 31 19 57 0.12 
GF ALL 93 36 26 52 0.20 
 Individual 
 
    
PI PI 11 12 8 14 0.50 
PI IR 28 18 9 35 0.12 
PI GF 26 21 17 26 0.63 
IR IR 27 0 4 5 0.13 
IR GF 45 13 6 17 0.17 
GF GF 22 2 3 9 1.00 
 Individual Cytokine Comparisons    
RANTES ALL 8 12 3 4 0.04 
IL-12 (p40) ALL 9 6 0 12 0.03 
The first factor denotes the group (GF = Growth Factors, IR = Immuno-regulatory cytokines, PI = Pro-
inflammatory or ALL= All 28 cytokines) of one of the cytokines in the pairwise correlation. The second 
factor represents the group of the other cytokine in the pairwise correlation. For example the correlation 
between IL-1α and EOTAXIN would be counted in three groups in the above table: 1) ALL-ALL 2) PI -
ALL and 3) PI - PI. Each value represents the number of correlations that were either significant in both 
BV+ and BV-, significant in BV+ but not BV-, significant in BV- but not BV+ or not significant in BV+ and 
BV-
* Significant after correction for multiple testing using FDR (q=0.2) 
. The p-value tests for the differences between these groups.  
 1
 
P-value calculated with McNemar’s chi-square test 
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Figure 3-1: Significant heterogeneity between BV+ and BV-
GF = Growth Factors, IR = Immuno-regulatory cytokines, PI = Pro-inflammatory cytokines. Significant 
heterogeneity by BV status is represented by the presence of a line with the thickness of the line indicating 
the significance of heterogeneity defined by p-value < 0.05, not corrected for multiple testing. The type of 
line (solid (―) dotted (…), dashed (
 women a) EA, b) AA.  
_ _) or solid and dotted (_ ··_
 
)) indicates the direction of the 
heterogeneity. 
 
Correlation and heterogeneity patterns by race  
In BV+ women, AA had significantly more correlations compared to EA (Table 3-
5a). This was not due to any one set of factors but involves correlations with pro-
inflammatory cytokines, immuno-regulatory cytokines, and growth factors. Specifically, 
the pro-inflammatory cytokine RANTES, the immuno-regulatory cytokines IL-4, IL-5 
and IL-10 and the growth factors FGF2, FLT3 and PDGF-BB were driving this 
significance; however, only some immuno-regulatory cytokines were significant after 
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correction for multiple testing (Table 3-5a). Eleven out of seventeen correlations that 
showed heterogeneity between EA and AA were more correlated in EA compared to AA 
(Figure 3-2a, Appendix Table 3). However, this pattern does not appear to be driven by 
any particular group of cytokines. 
In contrast, the only significant difference observed between EA and AA in BV- 
 
women was between pro-inflammatory cytokines and growth factors; however, no 
individual cytokine drives this effect (Table 3-5b). The majority of heterogeneous 
correlations between EA and AA were more significant in AA than EA; but again, no 
particular group of cytokines drives this effect (Figure 3-2b, Appendix Table 3). 
Correlations excluding women with C. albicans 
Due to reports that cytokine production in vaginal epithelial cells is affected by 
the presence of C. albicans (Steele and Fidel, Jr., 2002) a secondary correlation structure 
analysis excluding 38 individuals with C. albicans was performed (EA: 24 BV+ and 44 
BV- AA: 31 BV+ and 26 BV-
 
). The results were generally very similar to the previous 
ones (data not shown). However, caution needs to be taken in the interpretation of these 
results as the sample size is small.  
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Table 3-5. Differences in the number of significant correlations between AA and EA 
a) BV+, b) BV
a) 
- 
First  
Factor 
Second 
Factor 
P<0.05 In 
Both Groups 
P<0.05 In 
BV+
P<0.05 In 
 Only BV-
P>0.05 In 
Both Groups  Only 
1nominal 
p 
 Pooled Comparisons     
ALL ALL 140 40 85 113 <0.01* 
PI ALL 68 23 48 86 <0.01* 
IR ALL 81 17 50 59 <0.01* 
GF ALL 81 25 48 53 0.01* 
 Individual 
 
    
PI PI 15 5 8 17 0.58 
PI IR 25 7 21 37 0.01* 
PI GF 28 11 19 32 0.20 
IR IR 19 3 8 6 0.23 
IR GF 37 7 21 16 0.01* 
GF GF 16 7 8 5 1.00 
 Individual Cytokine Comparisons    
RANTES ALL 9 2 11 5 0.02 
IL-4 ALL 1 1 10 15 0.01* 
IL-5 ALL 7 0 10 10 <0.01* 
IL-10 ALL 16 0 8 3 0.01* 
FGF2 ALL 14 1 8 4 0.04 
FLT3 ALL 9 3 12 3 0.04 
PDGF-BB ALL 13 1 8 5 0.04 
b) 
First 
Factor 
Second 
Factor 
P<0.05 In 
Both Groups 
P<0.05 In 
BV+
P<0.05 In 
 Only BV-
P>0.05 In 
Both Groups  Only 
1nominal 
p 
 Pooled Comparisons     
ALL ALL 154 45 52 127 0.54 
PI ALL 56 26 43 100 0.04 
IR ALL 100 23 19 65 0.54 
GF ALL 89 25 30 63 0.50 
 Individual 
 
    
PI PI 11 10 8 16 0.81 
PI IR 24 10 13 43 0.68 
PI GF 21 6 22 41 <0.01* 
IR IR 30 0 1 5 1.00 
IR GF 46 13 5 17 0.10 
GF GF 22 6 3 5 0.51 
 Individual Cytokine Comparisons    
PDGF-
 
ALL 11 10 2 4 0.04 
The first factor denotes the group (GF = Growth Factors, IR = Immuno-regulatory cytokines, PI = Pro-
inflammatory or ALL= All 28 cytokines) of one of the cytokines in the pairwise correlation. The second 
factor represents the group of the other cytokine in the pairwise correlation. For example the correlation 
between IL-1α and EOTAXIN would be counted in three groups in the above table: 1) ALL-ALL 2) PI -
ALL and 3) PI - PI. Each value represents the number of correlations that were either significant in both 
EA and AA, significant in EA but not AA, significant in AA but not EA or not significant in AA and EA. 
The p-value tests for the differences between these groups.  
* indicates significant after correction for multiple testing using FDR (q=0.2)1
 
P-value calculated with 
McNemar’s chi-square test 
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Figure 3-2. Significant heterogeneity between EA and AA a) BV+ women, B) BV-
GF = Growth Factors, IR = Immuno-regulatory cytokines, PI = Pro-inflammatory cytokines. Significant 
heterogeneity by races is represented by the presence of a line with the thickness of the line indicating the 
significance of heterogeneity defined by p-value < 0.05, not corrected for multiple testing. The type of line 
(solid (―) dotted (…), dashed (
 
women.  
_ _) or solid and dotted (_ ··_
 
)) indicates the direction of the heterogeneity.  
 
Discussion  
The response to infection requires a delicate balance between pro-inflammatory 
cytokines, immuno-regulatory cytokines and growth factors. It is likely that the 
expression of these factors is tightly coordinated, and this coordination can be detected 
using correlation analyses. Yet, few studies have examined networks of correlations with 
respect to BV. To fully evaluate the pattern of coordination in different groups of 
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cytokines, chemokines and growth factors, we determined if the number of significant 
correlations differs between BV+ and BV- women and between AA and EA women. 
Additionally, we examined individual correlation coefficients to determine if there was 
heterogeneity between BV+ and BV- 
In comparisons of BV
women or between EA and AA women.  
+ to BV- EA women, there were fewer correlations 
involving immuno-regulatory cytokines, specifically IL-4. It is important to note that in 
chapter III part A we did not find any significant differences in cervical concentrations 
between BV+ and BV- women for these immuno-regulatory cytokines (Ryckman et al., 
2008d). This indicates that while immuno-regulatory cytokine levels were not 
individually suppressed in BV+ women, the functional networks involving these 
cytokines was less prominent in BV+ than in BV- women. The absence of strong 
correlations among immuno-regulatory cytokines in BV+ women suggests that these 
cytokines are not being regulated in a coordinated fashion; if these cytokines, specifically 
IL-4, IL-10 and IL-13, are not being produced at sufficient levels, an overproduction of 
pro-inflammatory cytokines may occur, which has been observed in EA women with BV 
(Platz-Christensen et al., 1993; Sturm-Ramirez et al., 2000; Cauci et al., 2003; Ryckman 
et al., 2008c). This trend was not observed in AA; in fact, there were no significant 
differences in the number of correlations between BV+ and BV-
In EA, the number of significant correlations between BV
 women for any group of 
cytokines, indicating a disparity in the correlated response of cervical cytokines to 
infection between AA and EA. 
+ and BV- women 
differs only for immuno-regulatory cytokines and the differences in specific correlation 
coefficients was driven by pro-inflammatory cytokines, specifically MIP-1α. All of the 
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correlations with MIP-1α were more significant in BV+ compared with BV- women. In 
chapter III part A we found that in EA, cervical concentrations of several pro-
inflammatory cytokines, including MIP-1α, were lower in BV+ compared to BV-
In AA differences in specific correlation coefficients between BV
 women 
(Ryckman et al., 2008d). This suggests a hypo-responsiveness to infection that appears to 
be strongly coordinated. 
+ and BV- 
women were driven by the pro-inflammatory cytokine IL-1α. The majority of these were 
more significantly correlated in BV- compared with BV+ women. In chapter III part A, 
we found that in AA, cervical levels of IL-1α were elevated in BV+ compared to BV- 
women (Ryckman et al., 2008d). While there was an increase in cervical levels of IL-1α 
in BV+ women, this was not correlated with other cytokine levels, which is particularly 
interesting since IL-1 induces and is induced by several other cytokines and growth 
factors (Dinarello, 1996). It is possible that strong correlations were absent in BV+ 
women because the median cervical IL-1α levels were two times greater than levels in 
BV- 
As with all correlation analyses, it is unclear if this effect causes BV or is caused 
by BV. If one assumes that the baseline state is the absence of infection, it is reasonable 
to argue that the changes in correlation patterns that we observed are in fact the result of 
infections and not the cause of it as suggested by others (Cauci and Culhane, 2007).  
women and other cytokines do not vary to that same degree.  
It is evident that EA and AA have different immune responses to infection and 
have differing susceptibilities to BV (Myslobodsky, 2001; Hoffmann et al., 2002; Blake 
and Ridker, 2003; Ness, 2004); yet, few studies have focused on differences between 
these groups with respect to the cervical immune response to BV. The number of 
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significant correlations between EA and AA BV- women did not differ significantly in 
most cases. The one exception was that AA had more significant correlations between 
growth factors and pro-inflammatory cytokines compared with EA. In contrast, in BV+ 
women, AA had more significant correlations than EA for pro-inflammatory cytokines, 
immuno-regulatory cytokines and growth factors. In particular, the immuno-regulatory 
cytokines IL-4, IL-5 and IL-10 exhibit more significant correlations in AA than EA. In 
chapter III part A, IL-1α, IL-6, IL-10 and PDGF-BB were elevated in EA compared to 
AA BV- women (Ryckman et al., 2008d). In contrast, there were no cervical cytokine 
concentration differences between AA and EA BV+ women (Ryckman et al., 2008d). In 
BV+
Although several cytokine differences between groups were detected, studies in 
this chapter were limited by small sample sizes. The strongest cervical concentration 
difference between BV
 women, individual cytokine levels did not significantly differ between AA and EA, 
and the correlated response to local infection was stronger in AA. This hyper-responsive 
immunity, particularly involving immuno-regulatory cytokines, could be a plausible 
explanation for why AA with BV are at greater risk for developing adverse reproductive 
outcomes, such as PTB, than their EA counterparts.  
- and BV+ women was for IL-1α in AA and based on the log 
transformed means and standard deviations the power to detect this effect was 95.6% 
(calculated on Stata version 10). However, the power to detect a difference in IL-1β in 
EA, a cytokine consistently found at higher concentrations in BV+ EA women, was only 
35.2% and 114 individuals in each group would be needed reach 80% power. 
Addtionally, the differences by race in BV- women were not significant after correction 
for multiple testing; however, the power for the strongest association (IL-6) was only 
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42.1%. Also, there were no differences by race BV+
Few studies have examined the coordinated regulation of an extensive network of 
cytokines, chemokines and growth factors involved in the immune response to BV. Our 
results have identified key factors involved in the coordinated immune response to BV in 
EA and AA. These coordinated responses did not differ much between AA and EA BV
 women; however, for the most 
significant result (IL-12p70), the power to detect an effect was 18.2% and 233 
individuals in each group would be needed to achieve 80% power. This illustrates that 
our studies were underpowered to detect many effects that may have been missed, 
however, for the effects we did see there was either adequate power or the effect was 
strong enough to be detected regardless of power. 
- 
women; however, the coordinated regulation is very different between EA and AA BV+ 
women, an aspect very few studies have addressed. Based on our data, we hypothesize 
that the coordination of inflammatory factors in the cervix is important in understanding 
the immune response to BV, as well as differences between AA and EA women with 
respect to the host consequences of bacterial vaginosis during pregnancy.  
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CHAPTER IV 
 
GENETIC ASSOCIATIONS OF PRO- AND ANTI-INFLAMMATORY 
CERVICAL CYTOKINES 
 
 
Overview parts A, B and C 
Local innate immunity is critical in regulating the response to bacteria in the 
genital tract (Fidel, 2003; Russell et al., 2004). Several studies have demonstrated that 
elevated amniotic fluid concentrations of pro-inflammatory cytokines leads to a hyper-
responsive immunity that is associated with adverse birth outcomes such as PTB (Menon 
et al., 2007; Menon et al., 2008a; Menon et al., 2008b). Conversely, low concentrations 
of multiple cytokines create a hypo-responsiveness that predisposes women to infection 
and inflammation such as chorioamnionitis (Simhan et al., 2003). Studies in chapter III 
demonstrated that individual cytokines as well as cytokine networks differ by not only 
BV status but also race (Ryckman et al., 2008d). Additionally, several studies show 
polymorphisms in pro-inflammatory genes are associated with protein concentrations; 
however, only a few focus on vaginal, cervical or amniotic fluid cytokine expression 
(Genc et al., 2006; Rafiq et al., 2007; Velez et al., 2007).   
Chapter IV examines genetic associations with cervical anti-inflammatory and 
pro-inflammatory cytokines. In part A three anti-inflammatory cytokines (IL-4, IL-10 and 
IL-13) are examined for associations with SNPs in their respective genes and receptors. 
These associations are explored in the context of BV status and race. In EA, two SNPs in 
IL10RA (rs4936414 and rs2512143) were significantly associated with IL-10 
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concentration after correcting for multiple testing and adjusting for BV status. In AA, 
there were no significant results that held up to correction for multiple testing.  
Part B assesses the impact of genetic variation on cervical levels of IL-1α, IL-1β, 
IL-6, IL-8 and TNF-α and determines if this relationship is influenced by BV. In AA, but 
not EA, higher cervical levels of IL-1β, IL-8 and TNF-α were observed in BV+ women 
with a particular genotype in IL-1RAP (rs6765375), IL-8RA (rs1008562) and TNFR2 
(rs1201157), respectively. In EA, but not AA, cervical IL-6 concentrations were higher in 
BV+
Part C examines the impact of genetic variation in TLR genes on cervical 
concentrations of pro- and anti- inflammatory cytokines, and determines if this 
relationship is influenced by BV. In EA BV
 women with a particular genotype in IL-6R (rs4075015). However, none of these 
results held up to a global correction for multiple tests. 
- women, higher cervical concentrations of 
IL-1β were observed with a particular genotype in TLR4 (rs1554973), a result that 
remained significant after correction for multiple testing. Additionally, in EA, rs1927911 
and rs2149356 (TLR4) were associated with cervical IL-1β, IL-6 and TNF-α 
concentrations. Importantly, this effect is modified by BV status. For example, women 
with the CC genotype at rs1927911 or rs2149356 have higher cervical concentrations of 
IL-1β and IL-6 than women with the CT/TT or AA/AC genotypes, but only among BV-
 
 
women. However, this was not significant after correction for multiple testing. These 
studies demonstrate a significant relationship between cervical cytokine concentrations 
and cytokine receptor genes. Additionally, this relationship is affected by both BV status 
and race.  
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A. Genetic Associations of Cervical Anti-inflammatory Cytokines Differs by BV 
Status and Race 
 
 
Introduction 
The balance of pro- and anti-inflammatory components of the cervical immune 
system is critical in regulating the response to micro-organisms and infections of the 
lower genital tract. Anti-inflammatory cytokines are important in keeping inflammation 
in check; however, by attenuating the host immune response, one might speculate that 
these cytokines contribute to a state of “impaired” defense. Decreased concentrations of 
several pro-inflammatory cytokines in the lower genital tract, which may occur because 
of an increase in anti-inflammatory cytokines, indicate an immune “hyporesponsiveness” 
that increases the risk for subsequent ascending microbial invasion (Simhan et al., 
2003a).   
Previous studies in chapter III found fewer correlations involving immuno-
regulatory cytokines in EA BV+ compared to BV- women (Ryckman et al., 2008b). This 
may indicate a disruption in anti-inflammatory cytokines leading to impaired immunity. 
Additionally, there are likely to be a number of factors that influence or affect cervical 
immunity including demographic and environment exposures. The relationship between 
alterations in the vaginal ecology that occur with BV and disruption of the vaginal 
inflammatory milieu, which might lead to a predisposition for adverse pregnancy 
outcomes, is of particular interest. However, genetic contributors to this cervical 
immunity are poorly understood. This study examines the contribution of maternal 
genotype to the concentration of ILs-4, -10, and -13 in the cervix during the first trimester 
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of pregnancy. Also, the contribution of genotype in the context of BV status and race is 
examined. 
 
Material and Methods 
 
Subjects 
Cervical IL-4, IL-10 and IL-13 were examined in this study. A detailed 
description of subject recruitment, socio-demographic characteristics, microbiologic 
assessment and cytokine measurement is in Chapter III, part A.  
 
DNA genotyping  
A total of 72 SNPs in 6 genes were examined: IL-4 (8 SNPs), IL-4 receptor (IL-
4R, 27 SNPs), IL-10 (5 SNPs), IL-10 receptor alpha (IL-10RA, 11 SNPs), IL-10 receptor 
beta (IL-10RB, 15 SNPs) and IL-13 (6 SNPs) (Appendix Table 4). SNPs were selected 
based on their ability to tag surrounding variants in the Caucasian (CEPH) and Yoruban 
(YRI) populations of the HapMap database (http://www.hapmap.org). A minor allele 
frequency of 0.20 in CEPH and 0.07 in YRI and an r2 of 0.80 was used to determine 
tagSNPs. Genotyping was performed on the Illumina GoldenGate platform (Illumina, San 
Diego, CA). Genotyping efficiency was >95% for all SNPs and individuals analyzed. 
There were 64 EA (20 BV+, 44 BV-) and 52 AA (32 BV+, 20 BV-
 
) women with genotype 
information in this study.  
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Quality control 
A total of 5 SNPs in AA and 30 SNPs in EA were excluded from subsequent 
analyses due to low minor allele frequency such that one or more genotype/BV status 
groups contained fewer than 5 individuals, thus preventing the analysis of dominant, 
recessive or additive models. Therefore, 67 SNPs were analyzed in AA and 42 SNPs 
were analyzed in EA. Cytokine concentrations were assessed for normality with the 
Shapiro-Wilk test; however, none of the cytokines were normally distributed (p <0.01). 
Cytokine concentrations were transformed using the Box Cox method. 
 
Statistical analysis (Chapter IV part A, B and C)  
The relationship between each cytokine and its respective gene and receptors was 
analyzed with two-way analysis of variance (ANOVA). Analyses were stratified by race 
and included the interaction between BV status and SNP. The full model was: 
transformed cytokine concentration = µ + α(SNP) + β(BV status) + γ(BV status*SNP) + 
ε. Additive, dominant and recessive models were analyzed for all cytokine 
concentrations; however, models were excluded if there were fewer than 5 individuals in 
any genotype per BV status in the model. Only the best model (the model with the most 
significant p-value) was considered for subsequent analysis. Significant SNP or 
interaction effects (p < 5x10-3) were analyzed further with the Sidak test to determine 
which group (BV+ or BV-) was driving the significance. The Sidak test calculates p-
values that are corrected for multiple testing. Calculations were performed using Stata 
version 9 (StataCorp, College Station, TX). A total of 524 tests were performed and 
results were adjusted for this number of tests with FDR (q=0.2). This number included 
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tests for all evaluated genetic models, cytokine concentrations, both races and interaction 
and single SNP main effects. 
To determine if significant results were dependent on race, ANOVA was used to 
examine SNP and race main effects as well as a SNP and race interactions in BV+ and 
BV- 
 
women, separately. Allelic and genotypic distributions were compared between 
ethnic groups using Fisher’s exact tests. Also, using Powermarker software, HWE was 
calculated for each marker with Fisher’s exact tests (Liu and Muse, 2005). The analyses 
examining effects of race were not corrected for multiple testing. 
Cytokine associations excluding women with C. albicans  
To investigate if the presence of C. albicans affected these associations, the 
analyses were performed excluding individuals with C. albicans as described in part A of 
this chapter. There were negligible differences for the results that were statistically 
significant after correction for multiple testing (data not shown). 
 
Results 
 
Genetic associations with cytokine concentrations 
Among EA, 4 SNPs in IL10RA were associated with IL-10 concentration (Table 
4-1, Appendix Table 5). Two of these, rs2512143 and rs4936414, were significant after 
correction for multiple testing (p = 6x10-4 and p = 1x10-4, respectively). Women with the 
GG genotype at rs2512143 had significantly higher cervical IL-10 concentrations than 
women with the AA/AG genotypes (medians 79.7 ng/ml vs 43.0 ng/ml). Women with the 
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TT genotype at rs4936414 had significantly higher cervical IL-10 concentrations than 
women with the CC/CT genotypes (medians 86.2 ng/ml vs 39.8 ng/ml) (Figure 4-1). The 
effects were stronger in BV+ women (p = 0.045 for rs2512143 and p = 0.006 for 
rs4936414). The other two SNPs (rs2508445 and rs2229113) were not significant after 
correction for multiple testing (p = 0.002 for both), and BV status did not influence this 
effect. None of the interaction terms between genotype and BV status were significant for 
these models. All four of the SNPs in IL10RA were in strong LD with one another 
(Figure 4-1). Additionally, there were no SNPs in AA or in IL-4 or IL-13 genes for EA 
that were significantly (p<5x10-3
 
) associated with the concentration of these cytokines 
(Appendix Table 5).  
Ethnic heterogeneity and quality control 
The SNPs analyzed show large differences in their ethnic distribution (Appendix 
Table 4). Of 75 SNPs genotyped, 50 had significant differences in allele frequencies 
between ethnic groups, and, of those 50 SNPs, 32 were significant at p < 0.001. 
Similarly, 45 out of 75 SNPs had significant differences in genotype frequencies between 
ethnic groups, and, of those 45 SNPs, 28 were significant at p < 0.001. There were 3 
SNPs that deviated from HWE in AA, none of which had p < 0.01. In EA, 5 SNPs 
deviated from HWE, only one of which had a p < 0.01.  
To determine if significant associations with cytokine concentration were affected 
by race, race main effects and race/SNP interactions were examined with each cytokine 
in BV+ and BV- women separately. However, these results were not corrected for 
multiple testing. In BV+ women there were significant race/SNP interactions at 
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rs4936414 (p = 0.03) and rs2508445 (p = 0.03) with IL-10 concentrations. In BV- women 
there was a significant race main effect at rs2508445 (p = 0.04) with IL-10 
concentrations.  
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Table 4-1. Significant associations between SNPs in IL-10RA and cervical IL-10 concentrations in EA 
 
 Model 
(Genotype 1 vs 2) 
nominal p-values for ANOVA model 1Genotype 1 vs 2 2BV+ vs BV- 
RS# Model SNP BV Intxn BV BV+ Genotype 1 - Genotype 2 
rs2229113 AA/AG vs GG 0.014 0.002 0.509 0.228 0.052 0.357 1.000 0.604 
rs2508445 GG vs GT/TT 0.014 0.002 0.509 0.228 0.052 0.357 0.717 0.153 
rs2512143 AA/AG vs GG 0.005 6x10-4 0.428 * 0.364 0.045 0.103 0.693 1.000 
rs4936414 CC/CT vs TT 8x10-4 1x10* -4 0.688 * 0.138 0.006 0.085 0.529 0.983 
1p-values for pairwise comparisons between the two genotype groups in BV+ and BV- women 
2p-values for pairwise comparisons between BV+ and BV-
* significant after correction for multiple testing using FDR (q = 0.2) 
 women in each genotype group 
 
  
Figure 4-1 Significant associations between IL-10RA and cervical IL-10 concentrations Association between IL-10RA at rs4936414 with 
cervical IL-10 concentration is depicted (left graph). LD pattern in IL-10RA (right graph). SNPs boxed in red represent significant associations after correction 
for multiple testing. SNPs boxed in blue represent associations that were not significant after correction for multiple testing. LD is measured as D′. All r2 values 
were reflective of  D′ (r2 > 0.84). 
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Discussion 
Our data demonstrate a significant relationship between cervical concentrations of 
IL-10 and common polymorphic variation in the gene that encodes for this cytokine 
receptor (IL-10RA), particularly in EA. Importantly, the contribution of genotype to IL-
10 concentration is significant, even when considered in the context of BV. These data 
are the first report of maternal genotype exerting an influence on cervical immunity 
during pregnancy. 
There is previous literature supporting a contribution of genetic variation to the 
production of inflammatory molecules, including IL-10. Recently, it was found that 
peritoneal fluid concentrations of IL-10 among women with endometriosis differed by 
IL-10 genotype (Zhang et al., 2007).  Also, placental IL-10 mRNA and protein 
expression varies by IL-10 -1082 (rs1800896) polymorphism status (Makris et al., 2006). 
Genetic regulation of IL-10 may also be linked with disorders of infection-mediated or 
inflammatory nature. Maternal carriage of the IL-10 -1082 G allele in the presence of 
chorioamnionitis was associated with early sPTB (Kerk et al., 2006). Our work adds to 
the extant literature by evaluating the cervical inflammatory milieu during pregnancy and 
by more broadly considering the genes that influence the production and function of IL-
10 along with the two other major anti-inflammatory cytokines.  
Of the four SNPs in IL-10RA associated with cervical IL-10 concentration, one is 
located in the promoter (rs4936414), one in an intron (rs2512143), another is the coding 
SNP for amino acid 351 (R→G) (rs2229113), and the last SNP (rs2508445) is located in 
the 3’ UTR. These SNPs were in strong LD with one another, particularly the coding 
SNP (rs2229113) that is in strong LD (D’ = 1, r2 > 0.84) with the other three associated 
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SNPs. Therefore, it is possible that these changes, in particular rs2229113, are directly 
involved in affecting IL-10 concentration. Rs2229113 is a nonsynonomous missense 
mutation where an arginine is converted to glycine. Arginine is a polar amino acid with a 
positive (basic charge), whereas glycine is a nonpolar amino acid. This mutation may be 
functional; however, there is no known research on this particular mutation to date.  
Additionally, all of these SNPs, except rs2508445, differ significantly in either 
genotype or allele frequencies between AA and EA. The LD patterns are also very 
different between the Caucasian and Yoruban Hapmap samples. There were significant 
race/SNP interactions with IL-10 concentration in BV+
It is interesting to note that, in our study, the polymorphisms most strongly related 
to IL-10 concentration are in the genes encoding the IL-10 receptor, not the IL-10 gene 
itself. To more fully appreciate the genetic regulation of the expression and function of 
cytokines, it is important to consider not only the gene encoding that cytokine, but also 
those that encode for critical receptors or cofactors. While such an approach increases 
analytic complexity, it may provide more accurate insight into these biological processes. 
 women at rs4936414 and 
rs2508445. These associations may explain racial differences observed not only in the 
prevalence of conditions such as BV, but also in cervical cytokine differences observed in 
chapter III.  
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B. Genetic Associations of Cervical Pro-inflammatory Cytokines Differ by BV 
Status and Race 
 
 
Introduction 
Pro-inflammatory cytokines are important mediators of the inflammatory 
response and are critical factors in cell-mediated immunity, which constitutes the main 
defense against invading pathogens. Previous studies, described in part A, demonstrate 
that polymorphisms in receptor genes were associated with cervical anti-inflammatory 
cytokine concentrations, and this effect remained after adjusting for the presence of BV 
(Simhan et al., 2008). However, while several studies have found associations between 
genetic factors, pro-inflammatory serum cytokine levels and cytokine expression levels, 
few have focused on pro-inflammatory cervical immunity (Reuss et al., 2002; McDaniel 
et al., 2003; Rafiq et al., 2007). For example, vaginal IL-1β concentrations are 
consistently increased in women with BV, while IL-1α and IL-8 are sometimes increased 
in women with BV. Furthermore, IL-6 and TNF-α concentrations are rarely different 
between women with and without BV (Platz-Christensen et al., 1993; Imseis et al., 1997; 
Mattsby-Baltzer et al., 1998; Sturm-Ramirez et al., 2000; Cauci et al., 2003; Alvarez-
Olmos et al., 2004; Wasiela et al., 2005; Basso et al., 2005; Hedges et al., 2006; Ryckman 
et al., 2008c). Additionally, several genetic polymorphisms, particularly those in IL-1β, 
IL-6 and IL-8, are associated with BV (Genc et al., 2004a; Goepfert et al., 2005; Cauci et 
al., 2007). However, few studies have examined the connection between genetic 
polymorphisms and cervical cytokine concentrations with respect to BV. Additionally, it 
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is unclear if the genetic regulation of cervical cytokine concentrations is impacted by the 
presence of BV infection. 
AA are at a 2 times greater risk for developing BV than EA, even after controlling 
for socio-demographic variables such as education and income (Ness et al., 2003). 
Additionally, AA and EA have differing immune responses to infection as well as genetic 
differences in immunity-related factors (Myslobodsky, 2001; Hoffmann et al., 2002; 
Blake and Ridker, 2003; Ness, 2004). Few studies have examined the differences 
between these groups with respect to the genetic regulation of cervical immunity, 
particularly in the presence of BV. 
In this investigation, we determined if SNPs in pro-inflammatory genes and 
receptors were associated with pro-inflammatory cervical concentrations of IL-1α, IL-1β, 
IL-6, IL-8 and TNF-α. Additionally we determined if these associations were affected by 
BV status and race.  
 
Material and Methods 
 
Subjects 
Cervical IL-1α, IL-1β, IL-6, IL-8 and TNF-α were examined in this study. A 
detailed description of subject recruitment, socio-demographic characteristics, 
microbiologic assessment and cytokine measurement is in Chapter III, part A.  
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DNA genotyping  
A total of 200 SNPs in 13 genes were examined: IL-1α (3 SNPs), IL-1β (7 SNPs), 
IL-1R1 (16 SNPs), IL-1R2 (23 SNPs), IL-1RN (14 SNPs), IL-1RAP (65 SNPs), IL-6 (8 
SNPs), IL-6R (22 SNPs), IL-8 (3 SNPs), IL-8RA (4 SNPs), TNF-α (6 SNPs), TNFR1 (10 
SNPs) and TNFR2 (19 SNPs) (Appendix Table 6). A description of TagSNP selection 
and genotyping is provided in part A of this chapter.  
 
Quality control 
A total of 58 SNPs in AA and 51 SNPs in EA were excluded from subsequent 
analyses due to low minor allele frequency such that one or more genotype/BV status 
groups contained fewer than 5 individuals, thus preventing the analysis of dominant, 
recessive and additive models. Therefore, 142 SNPs in AA and 149 SNPs in EA 
remained for analysis. Cytokine concentrations were assessed for normality with the 
Shapiro-Wilk test; however, none of the cytokines were normally distributed (p < 0.01). 
Cytokine concentrations were transformed with natural log and analyzed with ANOVA 
and Sidak tests. IL-8 and TNF-α  were not normally distributed after transformation with 
the natural log or Box Cox methods; therefore, non-parametric tests including Kruskal-
Wallis and the Mann-Whitney U test were used to analyze these cytokines. Further 
details on the statistical methods are discussed in part A of this chapter. 
 
Correction for multiple testing 
A total of 996 tests were performed and results were adjusted for this number of 
tests with FDR (q=0.2). This number included tests for all evaluated genetic models, 
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cytokine concentrations, both races and interaction and single SNP main effects. 
However, using this method, there were no significant results after correction. Therefore, 
due to the exploratory nature of this study, corrections for multiple testing were 
performed individually for each race, cytokine and test (either SNP or interaction), using 
FDR (q = 0.2). 
 
Cytokine associations excluding women with C. albicans  
To investigate if the presence of C. albicans affected these associations, the 
analyses were performed excluding individuals with C. albicans. There were negligible 
differences for the results that were statistically significant after correction for multiple 
testing (data not shown). 
 
Results 
 
Genetic associations with cytokine concentrations 
In AA women, 2 SNPs (rs6765375 and rs1469007) in IL-1RAP had significant 
BV status/SNP interactions with cervical IL-1β concentrations (p = 0.003 and 0.004, 
respectively) (Table 4-2a, Appendix Table 7). These SNPs were in LD with one another 
(D′ = 0.73, r2 = 0.18). BV- women with the AA/AC genotypes at rs6765375 had 
significantly lower cervical IL-1β levels than BV- women with the CC genotype (medians 
17.5 ng/ml vs 165.7 ng/ml, p = 0.042) (Figure 4-2). Additionally, BV- women with the 
AA/AC genotypes had significantly lower cervical IL-1β levels compared to BV+ women 
with the same genotypes (medians 17.5 ng/ml vs 264.3 ng/ml, p = 0.013). At rs1469007, 
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BV+ women with the GT/TT genotypes had significantly higher IL-1β than BV+
 
 women 
with the GG genotype (medians 233.2 ng/ml vs 57.5 ng/ml, p = 0.043). None of the 
above results were significant after correction for multiple testing with FDR (q = 0.2). 
 
 
 
Figure 4-2. Transformed concentration of IL-1β by rs6765375 (IL-1RAP) 
genotype in AA 
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Table 4-2. Significant associations between SNPs and cervical cytokine concentrations a) AA, b) EA 
 
a) 
   Model 
(Genotype 1 vs 2) 
nominal p-values for ANOVA model 1Genotype 1 vs 2 2BV+ vs BV- 
Cytokine Gene RS# Model SNP BV Intxn BV BV+ Genotype 1 - Genotype 2 
IL-1β IL-1RAP rs1469007 GG vs GT/TT 0.014 0.915  0.639 0.004 0.204 0.186 0.275 0.043 
IL-1β IL-1RAP rs6765375 AA/AC vs CC 0.009 0.249  0.197 0.003 0.540 0.042 0.013 0.744 
IL-8 IL-8RA 3 rs1008562 CC vs CG/GG - - - 0.012* 0.003 0.934 1.000 0.009 
IL-8 IL-8RA 3 rs1008563 CC vs CT/TT - - - 0.047* 0.077 0.262 0.022 0.354 
TNF-α TNFR2 3 rs1201157 CC vs CT/TT - - - 0.006* 0.007 0.091 0.105 0.003 
 
b) 
   Model 
(Genotype 1 vs 2) 
nominal p-values for ANOVA model 1Genotype 1 vs 2 2BV+ vs BV- 
Cytokine Gene RS# Model SNP BV Intxn BV BV+ Genotype 1 - Genotype 2 
IL-6 IL-6R rs4075015 AA/AT vs TT 0.029 0.048 0.083  0.004* 0.033 0.923 0.874 0.033 
1p-values for pairwise comparisons between the two genotype groups in BV+ and BV- women 
2p-values for pairwise comparisons between BV+ and BV- women in each genotype group 
3
* significant after correction for multiple testing using FDR (q = 0.2) 
indicates Kruskal-Wallis test was performed, therefore only the interaction p-value is calculated 
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In AA women 2 SNPs (rs1008562 and rs1008563) in IL-8RA had significant 
BV/SNP interactions with cervical IL-8 levels (p = 0.012 and 0.047, respectively) (Table 
4-2a, Appendix Table 7). These SNPs were in strong LD with one another (D′ = 1.0, r2 = 
0.31). These results were significant after correction for multiple testing. BV+ women 
with the CG/GG genotypes at rs1008562 had significantly higher cervical IL-8 levels 
than BV+ women with the CC genotype (medians 25000.0 ng/ml vs 7884.7 ng/ml, p = 
0.003) (Figure 4-3). Additionally, BV+ women with the CG/GG genotypes had 
significantly higher cervical IL-8 levels than BV- women with the same genotypes 
(medians 25000.0 ng/ml vs 5623.3 ng/ml, p = 0.009). At rs1008563, BV+ women with 
the CT/TT genotypes had significantly higher IL-8 levels than BV-
 
 women with the same 
genotype (medians 18514.6 ng/ml vs 9959.3 ng/ml, p = 0.022).  
rs1008562
BV positiveBV negative
CC CG/GG CC CG/GG
IL
-8
p = 9x10-3
p = 3x10-3
rs1008562
 
Figure 4-3. Median IL-8 concentrations by rs1008562 (IL-8RA) genotype in 
AA 
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One SNP (rs1201157) in TNFR2 had a significant BV/SNP interaction with TNF-
α concentrations in AA women (p = 0.006) (Table 4-2a, Appendix Table 7). This result 
was significant after correction for multiple testing. BV+ women with the CT/TT 
genotypes had significantly higher TNF-α cervical levels than those with the CC 
genotype (medians 48.5 ng/ml vs 5.0 ng/ml, p = 0.007) (Figure 4-4). Additionally, BV+ 
women with the CT/TT genotypes had significantly higher TNF-α cervical levels than 
BV-
 
 women with the same genotypes (medians 48.5 ng/ml vs 5.0 ng/ml, p = 0.003).  
 
Figure 4-4. Median TNF-α concentrations by rs1201157 (TNFR2) genotype 
in AA 
 
 
In EA women, one SNP (rs4075015) in IL-6R had a significant BV/SNP 
interaction with cervical IL-6 concentrations (p = 0.004) (Table 4-2b, Appendix Table 7). 
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This result was significant after correction for multiple testing. BV+ women with the TT 
genotype at rs4075015 had significantly lower cervical IL-6 concentrations than BV+ 
women with the AA/AT genotypes (medians 147.0 ng/ml vs 2151.3 ng/ml, p = 0.033) 
(Figure 4-5). Additionally, BV+ women with the TT genotype had significantly lower 
cervical IL-6 concentrations than BV-
 
 women with the same genotype (medians 147.0 
ng/ml vs 3444.5 ng/ml, p = 0.033).  
 
rs4075015
p = 0.03
p = 0.03
BV positiveBV negative
 
Figure 4-5. Transformed concentration of IL-6 by rs4075015 (IL-6R) 
genotype in EA 
 
 
Ethnic heterogeneity and quality control 
The SNPs analyzed show large differences in their ethnic distribution (Appendix 
Table 6). Of 200 SNPs genotyped, 125 had significant differences in allele frequencies 
between ethnic groups, and, of these, 75 SNPs were significant at p < 0.001. Similarly, 
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120 out of 200 SNPs had significant differences in genotype frequencies between ethnic 
groups, and, of these, 62 were significant at p < 0.001. There were 10 SNPs that deviated 
from HWE in AA, only 3 of which have p < 0.01. In EA, 14 SNPs deviated from HWE, 
only 3 of which had p < 0.01.  
To determine if significant associations with cytokine concentration were affected 
by race, race main effects and race/SNP interactions were examined with each cytokine 
in BV+ women and BV- women, separately (Table 4-3). In BV+ women, there were 
significant race main effects, race/SNP interactions or both at rs1469007 for IL-1β 
concentrations, rs1008562 and rs1008563 for IL-8, rs1201157 for TNF-α and rs4075015 
for IL-6. However, in BV-
 
 women, none of these associations were significant.  
Table 4-3. Race main affects and SNP/race interaction p-values in BV+ and BV-
 
 
women a) AA, b) EA 
a) 
    BV+ BV (p-values) - (p-values) 
Cytokine Gene RS# Model race intxn race intxn 
IL-8 IL-8RA rs1008562 CC vs CG/GG - 0.003 - 0.837 
IL-8 IL-8RA rs1008563 CC vs CT/TT - 0.007 - 0.262 
TNF-α TNFR2 rs1201157 CC vs CT/TT - 0.047 - 0.121 
IL-1β IL-1RAP rs6765375 AA/AC vs CC 0.106 0.879 0.068 0.598 
IL-1β IL-1RAP rs1469007 GG vs GT/TT 0.023 0.497 0.183 0.752 
IL-1β IL-1RAP rs9821002 AA/AC vs CC 0.258 0.726 0.055 0.575 
 
b) 
    BV+ BV (p-values) - (p-values) 
Cytokine Gene RS# Model race intxn race intxn 
IL-6 IL-6R rs4075015 AA/AT vs TT <0.001 0.003 0.746 0.170 
* significant after correction for multiple testing 
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Discussion 
It remains unclear as to why some women with BV experience adverse pregnancy 
outcomes, such as PTB, while others do not. Several studies have observed higher serum, 
amniotic fluid or vaginal concentrations of IL-1β, IL-6, IL-8 and TNF-α in women with 
infection or in those experiencing PTB (Romero et al., 1990; El-Bastawissi et al., 2000; 
Velez et al., 2007; Menon et al., 2008a; Ryckman et al., 2008c; Ryckman et al., 2008d). 
Additionally, several studies have observed that genetic polymorphisms in pro-
inflammatory genes were associated with BV and PTB; however, few of these studies 
have assessed the impact of genetic variation in these pro-inflammatory genes or their 
receptors on vaginal cytokine levels (Macones et al., 2004; Engel et al., 2005; Wang et 
al., 2006). In this study we examined genetic polymorphisms in IL-1α, IL-1β, IL-6, IL-8 
and TNF-α and their receptors for association with cervical cytokine concentrations and 
determined if BV status interacted with these polymorphisms to affect cytokine levels. 
One study demonstrated that amniotic fluid levels of IL-1β were elevated in AA 
but not EA women who delivered prematurely (Menon et al, 2007). In our study, two 
intronic SNPs in IL-1AP were associated with higher cervical IL-1β concentrations in 
AA BV+ women with a particular genotype compared to BV- women with the same 
genotype. Binding of IL-1RAP is necessary for signal transduction of IL-1β. These SNPs 
were in moderate LD with one another (D′ = 0.73, r2 = 0.18) in our data. While EA and 
AA women differed significantly in allele and genotype frequencies at rs6765375, there 
were no race main effects or race/SNP interactions with IL-1β levels in BV+ or BV- 
women. This indicates that although IL-1RAP may be important in the regulation of 
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cervical IL-1β levels, these SNPs do not necessarily help to explain the ethnic disparity 
observed in BV.  
Furthermore, in AA BV+ women, two SNPs (rs1008563 and rs1008562) located 
in the 3’UTR of IL-8RA and one intronic SNP (rs1201157) in TNFR2 were associated 
with elevated IL-8 and TNF-α levels, respectively. In the Hapmap Yoruban (YRI) 
samples, rs1201157 was in strong LD (D′ = 1.0, r2 = 0.09) with a synonymous SNP at 
amino acid position 56, which was not genotyped in our population. While the allele and 
genotype frequencies of these SNPs did not differ significantly between EA and AA, 
there were significant race/SNP interactions in BV+, but not BV-
Cervical and vaginal levels of IL-6 are not consistently higher in women with BV; 
however, elevated cervical and amniotic fluid levels of IL-6 are frequently observed in 
women with microbial invasion of the intra-amniotic cavity who have also delivered 
prematurely (Romero et al., 1990; El-Bastawissi et al., 2000). In addition, a SNP in IL-6 
(rs1800797) was associated with elevated IL-6 concentrations in EA, but not AA, women 
who delivered prematurely. This effect was primarily driven by microbial invasion of the 
amniotic cavity (Velez et al., 2007). While we did not replicate this finding with cervical 
concentrations of IL-6, we did find that in BV
, women. These results 
indicate that polymorphisms in receptor genes can be extremely important in the 
regulation of pro-inflammatory cervical cytokine concentrations and these associations 
were affected by both BV status and race.    
+ women the TT genotype at rs4075015 in 
IL-6R was associated with lower IL-6 concentrations compared to the AA/AT genotype 
and BV- women with the TT genotype. While the allele and genotype frequencies of 
these SNPs did not differ significantly between EA and AA, there were significant 
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race/SNP interactions in BV+, but not BV-
Studies in chapter III part B, which examined cervical cytokine correlations in 
AA and EA BV
, women. These results indicate an important 
underlying mechanism in the genetic control of cervical IL-6 concentrations which may 
be race specific.    
+ and BV- women, found that AA had a very strong correlated cytokine 
network in women with BV but not in those without the condition (Ryckman et al., 
2008b). Our study supports this finding in showing that genetic associations with pro-
inflammatory cytokine concentrations were more prominent in AA and race/SNP 
interactions were not present in BV-
 
 women. It is important to note that all of the 
associations observed in this study were with receptor genes or co-factors and not with 
the cytokine genes themselves. This result emphasizes the importance of not only 
examining genes that encode cytokines but also those that encode for critical receptors or 
cofactors. This approach, while analytically complex, will provide greater insight into the 
biological processes involved in cytokine regulation and the mechanism of BV as well as 
PTB.  
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C. Genetic Association of Cervical Pro- and Anti-inflammatory Cytokines by Toll-
like Receptors 
 
 
Introduction 
Previous studies, described in parts A and B of this chapter, demonstrated that 
genetic polymorphisms in receptor genes are associated with IL-6 and IL-10 levels in EA 
but not AA; while polymorphisms in receptor genes are associated with levels of IL-8 
and TNF-α in AA but not EA (Simhan et al., 2008). Many of these effects were 
influenced by BV status. It is probable that other genes or receptors, not examined in the 
previous studies, are also associated with these cervical cytokine levels. Examining these 
genes may help to elucidate the differing mechanisms of cervical cytokine regulation 
observed between AA and EA.  
TLRs are important components of the innate immune system and are essential in 
recognizing bacterial micro-organisms and initiating the appropriate immune response 
(Janssens et al., 2003; O'Connell et al., 2005). In particular, TLR2 and TLR4 have been 
characterized in the female reproductive tract and in decidual cells at the maternal-fetal 
interface (Fazeli et al., 2005; Canavan et al., 2007). Therefore, these genes may be 
important in the regulation of cervical immunity. However, little research has examined 
the genetic regulation of these cytokines in the cervical milieu.  
Additionally, it is likely that TLRs are involved in the pathogenesis and response 
to BV. BV is characterized by a mixture of gram-positive and gram-negative bacteria; 
TLR2 recognizes gram-positive bacteria, while TLR4 recognizes gram-negative bacteria. 
Therefore, these genes are plausible candidates to study in relation to BV. Genetic 
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polymorphisms in TLR genes may affect downstream factors such as pro- and anti- 
inflammatory cytokines depending on the presence of BV. A previous study identified a 
variant in TLR4 associated with BV-related bacteria and increased concentrations of 
vaginal IL-1β. Identifying factors that may lead to an altered immune response to various 
bacteria is important for elucidating the risk for not only BV, but also for adverse 
pregnancy outcomes such as PTB.  
To determine if cervical cytokines are associated with common variation in TLRs, 
five anti-inflammatory cytokines (IL-4, -10, IL-12(p40), IL-12(p70) and -13) and six pro-
inflammatory cytokines (IL-1α, -1β, -6, -8, IP10 and TNF- α) in AA and EA women were 
examined for associations with polymorphisms in TLR2 and TLR4. Associations were 
also examined for the interaction between these polymorphisms and BV.  
 
Material and Methods 
 
Subjects 
Cervical levels of IL-1α, IL-1β, IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, IL-
13 and IP10 were examined in this study. A detailed description of subject recruitment, 
socio-demographic characteristics, microbiologic assessment and cytokine measurement 
is in Chapter III, part A.  
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DNA genotyping 
Four SNPs in TLR2 and thirteen SNPs in TLR4 were examined with all eleven 
cytokine concentrations for this analysis (Appendix Table 8). Details on TagSNP 
selection and genotyping are provided in part A of this chapter. 
 
Quality control 
A total of 4 SNPs in AA and 9 SNPs in EA were excluded from subsequent 
analyses due to low minor allele frequency such that one or more genotype/BV status 
groups contained fewer than 5 individuals, thus preventing the analysis of dominant, 
recessive and additive models. Therefore, 13 SNPs in AA and 8 SNPs in EA were 
included in the analysis. Levels of IL-1α, IL-1β, IL-6, IL-10 and IL-12p70 were normally 
distributed (Shapiro Wilk p > 0.01) after transformation with natural log and were 
analyzed with ANOVA. Levels of IP10, IL-12p40 and IL-13 were normally distributed 
after implementing the Box Cox transformation and were analyzed with ANOVA. IL-4, 
IL-8 and TNF-α were not normally distributed after transformation by natural log or Box 
Cox; therefore, the Kruskal-Wallis non-parametric test was used to evaluate these 
cytokines. Details on the statistical analyses are discussed in part A of this chapter. 
 
Correction for multiple testing 
A total of 433 tests were performed and results were adjusted for this number of 
tests with FDR (q=0.2). This number included tests for all evaluated genetic models, 
cytokine concentrations, both races and interaction and single SNP main effects. 
 
82 
Cytokine associations excluding women with C. albicans  
To investigate if the presence of C. albicans affects these associations, the 
analyses were performed excluding individuals with C. albicans. There were negligible 
differences for the results that were statistically significant after correction for multiple 
testing (data not shown). 
 
Results 
 
Genetic associations with cytokine concentrations 
After correction for multiple testing, one SNP in TLR4 (rs1554973) was 
associated with IL-1β concentrations (p = 4x10-4) in EA women (Table 4-4, Appendix 
Table 9). Women with the TT genotype had significantly higher IL-1β concentrations 
than women with the CC/CT genotypes (medians 296.2 ng/mL vs 62.0 ng/mL). There 
was no significant interaction between BV status and genotype; however, the SNP 
association was stronger in BV- women (Figure 4-6). For example, BV- women with the 
TT genotype had significantly higher concentrations of IL-1β than those with the CC/CT 
genotype (medians 238.7 ng/mL vs 52.8 ng/mL, p = 0.003), while cervical IL-1β 
concentrations did not differ by genotype in BV+
 
 women. There were no significant SNP 
associations after correction for multiple testing in AA women.  
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p = 3x10-3 p = 0.20
rs1554973
 
Figure 4-6. Transformed concentration of IL-1β by rs1554973 (TLR4) 
genotype in EA 
 
 
 Although not significant after initial correction for multiple testing with FDR, 
rs1927911 and rs2149356, both in TLR4, were the only polymorphisms associated with 
five or more cytokine levels in EA women (Table 4-4). These SNPs were in strong LD 
with one another (D′ = 1.0, r2 = 0.82) as well as with rs1554973 (D′ > 0.78, r2 > 0.46). At 
rs1927911, BV- women with the CT/TT genotype had significantly lower cervical 
concentrations of IL-1β and IL-6 than those with the CC genotype (IL-1β: medians 73.6 
ng/mL vs 215.0 ng/mL; IL-6: medians 1190.9 ng/mL vs 4120.0 ng/mL) (Figure 4-7a and 
b). In BV+ women with the CT/TT genotypes, TNF-α concentration was significantly 
higher than in women with the CC genotype (medians 5.0 ng/mL vs 28.5 ng/mL) (Figure 
4-7c). At rs2149356, BV- women with the AA/AC genotypes had significantly lower 
cervical concentrations of IL-6 than those with the CC genotype (medians 1095.0 ng/ml 
vs 4778.0 ng/mL). In BV+ women with the AA/AC genotypes, TNF-α concentration was 
84 
significantly higher than in women with the CC genotype (medians 5.0 ng/mL vs 43.0 
ng/mL). There were no SNPs in AA women significantly (p < 5x10-3
      
) associated with 
any single cytokines or more than two cervical cytokine concentrations (Appendix Table 
9).  
 
a)                                                                       b) 
c) 
 
 
 
Figure 4-7. Genetic associations of rs2149356 (TLR4) genotype with multiple 
cervical cytokines in EA a) IL-1β, b) IL-6, c) TNF-α 
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Table 4-4. Significant associations between SNPs in TLR4 and cervical cytokine concentrations in EA  
 
  Model 
(Genotype 1 vs 2) 
nominal p-values for ANOVA model 1Genotype 1 vs 2 2BV+ vs BV- 
RS# Cytokine Model SNP BV Intxn BV BV+ Genotype 1 - Genotype 2 
rs1554973 IL-1β CC/CT vs TT 2x10-4 4x10* -4 0.090 * 0.940 0.198 0.003 0.874 0.557 
rs1927911 IL-1β CC vs CT/TT 0.006 0.013 0.028 0.664 0.742 0.056 0.649 0.420 
 IL-6 CC vs CT/TT 0.023 0.018 0.648 0.470 0.897 0.026 0.944 1.000 
 IL-12p40 CC vs CT/TT 0.205 0.045 0.770 0.752 0.663 0.515 0.997 1.000 
 IL-12p70 CC vs CT/TT 0.117 0.016 0.781 0.297 0.213 0.743 0.992 0.947 
 TNF-α CC vs CT/TT 3 - - - 0.048 0.019 0.192 0.634 0.099 
rs2149356 IL-1β AA/AC vs CC 8x10 0.004 -4 0.027 0.352 0.777 0.005 0.180 0.910 
 IL-6 AA/AC vs CC 0.005 0.009 0.559 0.280 0.924 0.004 1.000 0.818 
 IL-10 AA/AC vs CC 0.113 0.033 0.269 0.133 0.164 0.992 0.386 1.000 
 IL-12p40 AA/AC vs CC 0.193 0.040 0.762 0.690 0.600 0.538 1.000 0.996 
 IL-12p70 AA/AC vs CC 0.071 0.009 0.848 0.316 0.164 0.551 0.958 0.992 
 TNF-α AA/AC vs CC 3 - - - 0.038 0.008 0.545 0.038 0.315 
1p-values for pairwise comparisons between the two genotype groups in BV+ and BV- women 
2p-values for pairwise comparisons between BV+ and BV- women in each genotype group 
3
* significant after correction for multiple testing using FDR (q = 0.2) 
indicates Kruskal-Wallis test was performed, therefore only the interaction p-value is calculated 
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Ethnic heterogeneity and quality control  
The SNPs analyzed show large differences in their ethnic distribution (Appendix 
Table 8). All of the SNPs in TLR2 and TLR4 had significant differences in either allele 
or genotype frequencies between ethnic groups. Of these, 3 SNPs in TLR2 and 8 SNPs in 
TLR4 had significant allelic or genotypic (p < 0.001) differences between the two groups. 
There were 2 SNPs that deviated from HWE in EA, neither of which had p < 0.01. In AA 
women there were no SNPs that deviated from HWE at p < 0.05.  
To determine if significant associations with cytokine concentration were affected 
by race, race main effects and race/SNP interactions were examined with each cytokine 
in BV+ women and BV- women, separately. At rs1469007 there was a significant race 
main effect and race/SNP interaction with IL-1β concentrations in BV- women (p = 0.04 
and p = 0.003, respectively); however, these effects were not significant in BV+ women.   
Additionally, in BV- women, for both rs1927911 and rs2149356, there were significant 
race main effects (p = 0.03 and p = 0.009, respectively) and race/SNP interactions (p = 
0.01 and p = 0.002, respectively) with cervical IL-1β concentration, whereas in BV+ 
women, these associations were not significant. Also in BV- women, there were 
significant race effects with IL-6 (p = 0.047) and significant interaction effects with TNF-
α (p = 0.025) at rs2149358; these effects were not present in BV+
 
 women. However, 
these associations were only marginally significant for rs1927911 (p = 0.078 for IL-6 and 
0.058 for TNF-α).  
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Discussion 
Previous studies in this chapter identified variants in IL-1RAP, IL-8RA and 
TNFR2 associated with cervical pro-inflammatory IL-1β, IL-8 and TNF-α concentrations 
in AA but not EA. In EA, SNPs in IL10RA were associated with cervical anti-
inflammatory IL-10 concentrations (Simhan et al., 2008). Additionally, in EA, a SNP in 
IL-6R was associated with IL-6 concentrations, which is classically defined as a pro-
inflammatory cytokine but exhibits many anti-inflammatory properties. This suggests 
that, particularly in EA, associations with pro-inflammatory cytokines involve genes not 
previously examined. We therefore examined genetic polymorphisms in TLR2 and TLR4 
for associations with both cervical pro- and anti-inflammatory cytokines and the 
associations were also examined in the context of BV and race.  
Previously, a polymorphism in TLR4 (rs4986790) was found to be associated 
with an increase in vaginal pH, G. vaginalis, anaerobic gram-negative rods, Prevotella, 
Bacteroides and Porphyromonas (Genc et al., 2004). Additionally, women with the AA 
genotype at rs4986790 and colonization of G. vaginalis and/or gram-negative rods had 
significantly higher vaginal IL-1β concentrations than women with the AG/GG genotype 
(Genc et al., 2004). While this SNP was not genotyped in our data, in the Caucasian 
samples from the Hapmap it is in strong LD with rs1554973 (D′ = 1.0, r2 = 0.13), which 
is located in the 3’UTR of TLR4 and significantly associates with cervical IL-1β 
concentrations in BV- women. A similar trend in BV+ women, albeit not significant after 
correction for multiple testing, was observed where the TT genotype was associated with 
higher cervical IL-1β concentrations than the AG/GG genotypes. This suggests that either 
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one of these SNPs is the causative variant associated with cervical IL-1β concentrations 
or these SNPs are in LD with the causative variant.  
Additionally, we found several SNPs in TLR4 that were associated with multiple 
pro-inflammatory cytokine concentrations in EA but not AA. This indicates that in EA, 
TLR4 may be a key master regulator for cervical pro-inflammatory cytokine production. 
TLR4 generally favors the production of pro-inflammatory cytokines, and 
polymorphisms in this gene have been associated with several pro-inflammatory cytokine 
levels, including vaginal IL-1β.  
We have demonstrated that TLR4 is an important regulator of cervical pro-
inflammatory concentrations and that this regulation differs not only by BV status but 
also between AA and EA. We have identified factors that may predispose EA women to a 
cervical milieu characterized by an increased concentration of several pro-inflammatory 
cytokines. Additionally, we have identified associations in TLR genes that give greater 
insight into the biological processes involved in cytokine regulation, the mechanism of 
BV, and possibly racial disparity in clinical phenotypes such as PTB.  
 BV is a complex disorder and there are likely many genetic factors involved in 
cervical immunity. Studies in this chapter were focused on candidate genes and therefore 
limited in the ability to detect a wide range of factors that may previously have not been 
examined in association with cervical immunity and BV. Additionally, our studies 
consisted of small sample sizes and had limited power to detect small effect sizes as well 
as examine gene-gene interactions. However, few studies have examined genetic variants 
in relation to BV and these studies lend insight to some of the biological underpinnings 
involved in not only disease susceptibility but also cervical immunity. 
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CHAPTER V 
 
GENETIC ANALYSIS OF PRETERM BIRTH 
 
Overview parts A and B 
PTB (gestational age <37 weeks) is a major public health problem in modern 
perinatal medicine and accounts for 75% of perinatal mortality and 50% of perinatal 
morbidity. PTB is a common condition and in some parts of the world, e.g. the US, more 
than 10% of pregnancies end preterm. PTB is related to long term respiratory problems 
and neurological morbidity. The majority of PTB (~75%) is not indicated by the presence 
of pregnancy complications such as preeclampsia or IUGR. sPTB can result from 
spontaneous contractions caused by infection, PPROM and unknown causes (Morken et 
al 2005). Based on human and animal studies, four main pathways have been 
hypothesized to lead to PTB: 1) activation of maternal or fetal hypothalamic pituitary-
adrenal axis, 2) inflammation/infection, 3) decidual hemorrhage, and 4) uterine distension 
(Lockwood and Kuczynski, 2001). These pathways converge on a final terminal pathway 
where uterotonins, proteases and prostaglandins are released, leading to contractions, 
rupture of the membranes and eventually PTB. The individual factors involved in these 
putative PTB pathways and how they affect pregnancy length and outcome are poorly 
understood. 
Chapter V examines maternal and fetal genetic associations with PTB in a 
Norwegian cohort. In part A, single locus associations with PTB are examined in an 
extensive candidate gene study encompassing approximately 160 genes involved in the 
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proposed PTB pathways. These studies indicate that the strongest single locus maternal 
and fetal associations are involved in the following pathways: extracellular matrix 
strength (COL1A2), inflammation and infection (IL1RAP and IL4R), complement and 
coagulation (TFPI), homocysteine metabolism (MTHFR), activation of the HPA axis 
(CRH) and serotonin transport (SLC6A4). In fetal samples, the most significant single 
locus association is an additive model with a SNP in the tissue factor pathway inhibitor 
(TFPI) gene (OR = 2.46, 95% CI = 1.57-3.86, p = 8x10-5
Part B compares the associations found in a previous study by Velez et al., 2008 
to the results from Norway to identify associations that demonstrate significance in both 
studies and to estimate effect sizes. The data are analyzed together to increase sample 
size and to quantify the effects of SNPs that were significant in both studies. The majority 
of significant maternal and fetal associations in the pooled sample are involved in ECM 
degradation (COL1A2), prostaglandin synthesis (PTGER3) and complement/coagulation 
(PLAT and PON1). The most significant result in maternal pooled samples is a SNP in 
the prostaglandin E receptor 3 gene (PTGER3) (genotypic p = 2x10
). The most significant single 
locus association in maternal samples is a SNP in COL1A2, where the AG/GG genotypes 
are protective against PTB when compared to the AA genotype (OR = 0.31, 95% CI = 
0.15-0.64, p = 0.001).  
-4). The most 
significant result in fetal pooled samples is in the paraoxonase 1 gene (PON1) (genotypic 
p = 8x10-4
 
). These studies identify single locus polymorphisms associated with PTB in 
two independent EA populations. 
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A. Maternal and Fetal Single Locus Associations with PTB 
 
Introduction 
PTB, defined as gestation less than 37 weeks, is one of the largest unsolved 
obstetrical problems worldwide. For example, in the US alone, more than 12% of the 
approximately five million births each year are preterm, accounting for more than $26 
billion per year in excess health care costs  (Martin et al., 2005; Anonymous, 2006). 
Preterm-related conditions are responsible for as much as 75% of perinatal mortality and 
a disproportionately large percentage of infant morbidities  (McCormick, 1985; Hack and 
Fanaroff, 1999; Raju et al., 2006; MacDorman et al., 2008). The majority of PTB (~75%) 
results from spontaneous contractions caused by infection, PPROM and unknown causes 
(Morken et al., 2005). Based on human and animal studies, four main pathways have 
been hypothesized to lead to PTB: 1) activation of maternal or fetal hypothalamic 
pituitary-adrenal axis, 2) inflammation/infection, 3) decidual hemorrhage, and 4) uterine 
distension (Lockwood and Kuczynski, 2001). These pathways converge on a final 
terminal pathway where uterotonins, proteases and prostaglandins are released, leading to 
contractions, rupture of the membranes and eventually PTB. The individual factors 
involved in these putative PTB pathways and how they affect pregnancy length and 
outcome are poorly understood. 
Among the types of risk factors that have been hypothesized to lead to PTB, there 
is increasing evidence that PTB has a significant genetic component. First, family history 
of PTB and previous PTB are among the largest known risk factors for PTB (Bakketeig 
et al., 1979; Carr-Hill and Hall, 1985; Porter et al., 1997; Esplin et al., 2008). Second, 
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twin studies estimate the heritability of PTB at 20-40% (Treloar et al., 2000; Clausson et 
al., 2000). In addition, there is substantial evidence to suggest geographic ancestry is 
associated with risk for PTB; therefore, it is presumable that genetic differences affect 
risk (Menon et al., 2006d; Menon et al., 2007; Menon et al., 2008a). Finally, in the last 
ten years many studies have found significant genetic associations with PTB, particularly 
with genes in the inflammation/infection pathway (Varner and Esplin, 2005; Menon et 
al., 2006a; Pennell et al., 2007). However, often these studies fail to replicate (Menon et 
al., 2006b). Therefore, to demonstrate true genetic effects, multiple studies of carefully 
defined cohorts are required. Due to the large number of false positive results that are 
generated in association studies, true associations and findings of biological significance 
will only be identified when well-defined studies that are consistently replicated in 
independent populations are performed. To elucidate the genetic etiology of PTB, 
approximately 160 candidate genes were investigated for single locus and haplotypic 
associations with PTB.   
 
Materials and Methods 
 
Subjects 
The Norwegian Mother and Child Cohort (MoBa) is a Norwegian national 
pregnancy study that provides opportunities to explore the causes of complex 
phenomena. The main objective of this cohort is to develop a long term resource to test 
hypotheses relating to pregnancy outcomes and childhood health. Epidemiological data 
and biological material were collected from 100,000 pregnancies during the period of 
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1999-2008 by the Norwegian Institute of Public Health. The target population consisted 
of all pregnant women in Norway. Women were invited to participate during their routine 
ultrasound scan at gestational week 17-18. All hospitals and maternity units with more 
than 100 deliveries annually were invited to participate, and 50 of 52 such units 
participated. The total participation rate was 42.7% (Magnus et al., 2006). The MoBa 
study collected data from three questionnaires focused on nutrition, overall health status, 
and child outcome. In addition to the questionnaire variables, data were added from the 
Medical Birth Registry of Norway (MBRN). The MoBa study has been described in 
detail elsewhere (Magnus et al., 2006). The present study used samples derived from a 
subset of the MoBa cohort available at its outset (53,711 pregnancies).  
Data from the MBRN on gestational age, type of delivery onset, intrauterine fetal 
death (IUFD), congenital malformations and plurality were used in this study. Gestational 
age was determined based on expected date of parturition according to ultrasound and/or 
the date of last menstrual period. Ultrasound was the main method of determining 
gestational age as most pregnancies in Norway are dated by ultrasound. Type of delivery 
onset was recorded as spontaneous labor, induced labor, or prelabor caesarean section. 
The two latter groups were regarded as iatrogenic preterm deliveries and were excluded 
from our study. IUFD and plurality were also registered in the MBRN, making it possible 
to identify and exclude these cases. Congenital malformations, registered as ICD-10 
codes in the MBRN were excluded. These definitions have been previously described 
(Morken et al., 2005). 
The cases in this study were defined as singletons with spontaneous onset of PTB 
between 22 gestational weeks and 0 out of 7 days (220/7) and 370/7 gestational weeks in 
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women aged 20 – 35 years. This age range was chosen to ensure that women at high risk 
for PTB due to age (young women less than 20 years and older women greater than 35 
years) were not included in the study. The exclusion criteria were pre-existing medical 
conditions such as diabetes, hypertension, autoimmune diseases, inflammatory bowel 
diseases, systemic lupus erythematosus, rheumatoid arthritis, scleroderma or any 
immune-compromised condition. Women were also excluded if they had pregnancy 
complications such as preeclampsia, hypertension, diabetes, small for gestational age 
(according to intrauterine growth curves), abruption of the placenta, placenta previa, 
cervical cerclage or fetal malformations. The controls were selected according to the 
same criteria as above except for spontaneous onset of term delivery with gestational age 
between 390/7 and 406/7 
 
weeks. The Ethics Committee of the southern healthcare region of 
Norway approved the MoBa study. There were 214 case mother-baby-father trios that 
will be further examined in an independent family analysis and 220 control mother-baby 
pairs selected for this study. 
DNA genotyping and quality control 
A total of 1,536 tag SNPs were selected from 167 PTB candidate genes 
(Appendix Table 10). SNPs were selected based on their ability to tag surrounding 
variants in the Caucasian (CEPH) and Yoruban (YRI) populations of the HapMap 
database (http://www.hapmap.org). A minor allele frequency of 0.07 in CEPH and 0.20 
in YRI and an r2 of 0.80 was used to determine tagSNPs. Genotyping was performed on 
the Illumina GoldenGate Assay system. 1,430 SNPs had genotyping efficiency greater 
than 95% and were used for subsequent analyses. 
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Demographic and clinical characteristics 
Both maternal and fetal samples were excluded at onset if the last menstrual 
period and birthweight were not consistent with case-control status. Additionally, 
families (mother-baby-father case trios and mother-baby controls) were excluded if 
greater than 0.01% of the SNPs had Mendelian errors. This was done to ensure high 
quality genotyping efficiency. Additionally, individuals were excluded for low 
genotyping efficiency (<95%). The final sample size included 419 fetal samples (203 
cases, 216 controls) and 424 maternal samples (207 cases, 217 controls).  
Clinical differences between cases and controls are presented in Table 5-1. There 
were no statistically significant differences between cases and controls for APGAR score 
at 1 minute or 5 minutes, maternal age or smoking; however, as expected, cases had 
babies with lower birthweight and gestational age (p <0.001 for both).  Additionally, 
cases and controls significantly differed in parity (p <0.001). 
 
Table 5-1. Clinical characteristics  
Variable 1 Controls (n=217) Cases (n=207) 2p 
Parity  0 [0-4] 1 [0-4] <0.001 
Gestational Age (days) 253 [182-258] 280 [273-286] <0.001 
Birthweight (grams) 2810 [950-4000] 3650 [2610-4970] <0.001 
APGAR at 1 minute (% <7) 16 (8%) 12 (6%) 0.355 
APGAR at 5 minutes (% <7) 3   (1%) 5   (2%) 0.522 
Maternal Age (yrs) 29 [20-34] 30 [21-34] 0.203 
Smoking (%) 22 (12%) 21 (11%) 0.770 
     Medians are reported with the range in brackets 
1Cases are defined as < 37 weeks gestation compared with the women delivering at term between 39-40 
weeks (controls).  
2P-values are calculated by Mann Whitney U- test for continuous variables and chi-square test or 
Fisher's exact test for dichotomous variables.
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Statistical analysis 
Chi-square tests were used to examine differences between cases and controls for 
APGAR at 1 minute (<7 versus ≥7), APGAR at 5 minutes (<7 versus ≥7) and smoking 
(non-smokers versus smokers).  Parity (number of times a woman has given birth defined 
by birth registry), gestational age (days), birthweight (grams) and maternal age were 
tested for normality using Shapiro-Wilks tests. None of these variables were normally 
distributed therefore, these variables were analyzed with nonparametric Mann-Whitney 
two-sample ranksum tests. Stata version 10 statistical software was used for all analyses.  
Gene names, marker positions (base pair – bp) and marker function were 
identified using the SNPper database (http://snpper.chip.org). Allele and genotype 
differences between cases and controls, deviations in HWE and inbreeding coefficients 
were calculated with PLINK (http://pngu.mgh.harvard.edu/purcell/plink/), the Whole-
genome Association Study Pipeline (WASP) and Powermarker software programs 
(http://chgr.mc.vanderbilt.edu/wasp/) (Liu and Muse, 2005; Purcell et al., 2007). 
Statistical significance for these analyses was determined using chi-square tests or 
Fisher’s exact tests (if there were less than five individuals for any allele or genotype). 
These results were corroborated using a prevalence based association test (PRAT) 
(Ryckman et al., 2008a). This test calculates a global allele frequency based on the 
prevalence of the disease in order to calculate expected frequencies of each genotype in 
cases and controls separately, and a permutation test is used to determine the 
significance. The global allele frequency was determined using a prevalence of 5%. 
Using prevalences of 10% and 20% yielded similar results (data not shown). FDR (q = 
0.2) was used to correct for multiple testing in maternal and fetal samples, separately.  
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 Significant (p < 5x10-3) allelic or genotypic associations were followed up with 
additive, dominant and recessive models, using logistic regression. This cutoff, although 
arbitrary, was used to reduce Type I error but still maintain a large enough set of findings 
for follow-up analyses, hence also reducing Type II error. Significant (p < 0.05) logistic 
regression models were adjusted for parity because this was the only risk factor that was 
significantly different between cases and controls.  These analyses were performed with 
Stata version 10. Haplotype analysis using a 2, 3 or 4 marker sliding window was 
performed in genes with significant (p < 5x10-3
 
) allelic or genotypic associations using 
Unphased (Dudbridge, 2008). This software uses a quasi-Newton algorithm to maximize 
the likelihood of each haplotype when an individual’s phase is unknown. The overall test 
of association is a likelihood ratio test based on the null hypothesis that all of the 
haplotypes have equal odds ratios. Graphical representation of significant results and 
haplotypes was performed with Haploview (Barrett et al., 2005). 
Results 
 
Maternal single locus association 
 There were 125 significant allelic and/or genotypic single locus results out of 
1430 SNPs analyzed. Eleven SNPs from ten different genes were significantly associated 
with PTB at allelic or genotypic p < 5x10-3 (Figure 5-1, Table 5-2 and Appendix Table 
11). None of these results were significant after correction for multiple testing with FDR. 
Of the top 11 SNPs, 5 deviated from HWE, 2 of which were in cases (PGRMC2 
rs11726595, p = 0.004; TFPI rs3213739, p = 0.01) and 3 in controls (CBS rs6586282, p = 
98 
0.008; F7 rs1475931, p = 0.002; PON1 rs854569, p = 1.7x10-5
These associations were corroborated using the method PRAT (Table 5-2). All of 
the PRAT results were significant in cases but not controls or controls but not cases with 
the exception of COL1A2 rs2472 which was significant in both cases and controls. As 
demonstrated previously (Ryckman et al. 2008a), significance in either cases or controls 
or both, indicates an association with PTB.  
). For all 5 SNPs, the 
inbreeding coefficients in cases and controls were in opposite directions, indicating that 
deviations were not likely caused by genotyping error, since cases and controls were 
randomly placed on each plate for genotyping.  
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Table 5-2. Maternal single locus association results a) allelic and genotypic association b) logistic regression adjusting for parity 
a) 
Gene Gene Name SNP rs# Role Allele 
Case 
Freq. 
Control 
Freq. 
Case v Control p 
Allele       Genotype 
PRAT p 
Case       Control 
CBS Cystathionine beta-synthase rs6586282 Intron A 0.18 0.152 0.22 4.7x10-3 0.19 1x10-3 
COL1A2 Collagen Type 1, alpha-2 rs2472 Intron G 0.03 0.07 1.6x10-3 1.2x10-3 0.01 <1x10-3 
CRHR2 
Corticotropin-releasing hormone 
receptor 2 rs4722999 Intron G 0.35 0.44 5.0x10-3 0.02 6x10-3 0.67 
F7 Coagulation factor 7 rs1475931 Intron A 0.20 0.222 0.46 2.3x10-3 0.37 <1x10-3 
IL1RAP 
Interleukin 1 receptor accessory 
protein 
rs7628333 Intron A 0.22 0.32 1.8x10-3 4.7x10-3 4x10-3 0.16 
rs3821744 Intron A 0.28 0.37 4.7x10-3 0.01 0.01 0.49 
IL1RN Interleukin 1 receptor antagonist rs315920 Promoter A 0.15 0.23 4.9x10-3 0.01 0.01 0.47 
PGRMC2 
Progesterone receptor membrane 
component 2 rs11726595 Downstream G 0.231 0.19 0.11 4.7x10-3 4x10-3 0.51 
PON1 Paraoxonase 1 rs854569 Intron A 0.17 0.232 0.04 4.4x10-3 0.69 1x10-3 
TFPI Tissue factor pathway inhibitor rs3213739 Intron A 0.38 0.46 1 0.03 2.4x10 8x10-3 0.11 -3 
TREM1 
Triggering receptor expressed on 
myeloid cells 1 rs4711668 Intron A 0.36 0.27 2.9x10 9.0x10-3 7x10-3 0.24 -3 
1cases deviated from HWE at rs11726595 (p = 0.004) and rs3213739 (p = 0.01) 
2controls deviated from HWE at rs6586282 (p = 0.008), rs1475931 (p = 0.002) and rs854569 (p = 1.7x10-5
b) 
) 
Gene SNP rs# Model OR 95% CI Model p Adjusted Model p1 
CBS rs6586282 Additive 0.79 0.54-1.14 0.209 0.215 
COL1A2 rs2472 AAvsAG/GG 0.32 0.16-0.66 0.002 0.002 
CRHR2 rs4722999 Additive 0.67 0.51-0.89 0.006 0.007 
F7 rs1475931 AAvsAC/CC 0.23 0.06-0.82 0.023 0.008 
IL1RAP rs7628333 AA/AGvsGG 1.88 1.28-2.77 0.001 0.003 rs3821744 Additive 1.58 1.16-2.14 0.004 0.006 
IL1RN rs315920 AA/AGvsGG 1.83 1.22-2.75 0.004 0.004 
PGRMC2 rs11726595 AAvsAG/GG 1.64 1.11-2.44 0.013 0.016 
PON1 rs854569 AA/ACvsCC 1.68 1.13-2.50 0.010 0.008 
TFPI rs3213739 AA/ACvsCC 1.94 1.29-2.92 0.001 0.001 
TREM1 rs4711668 AA/AGvsGG 0.55 0.37-0.81 0.002 0.002 
1 Models adjusted for parity  
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a) 
 
 
b) 
 
Figure 5-1. Maternal single locus association results. Each point on the graph 
represents an association test either allelic (a) or genotypic (b). The x axis is SNP position 
in chromosomal order and the y axis is the inverse negative log of the p-value. Significant 
associations are highlighted in genes with at least one association at p < 0.005.  
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Fetal single locus association 
 There were 142 significant allelic and/or genotypic single locus results out of 
1,430 SNPs. Eighteen SNPs from ten different genes were significantly associated with 
PTB at allelic or genotypic p < 5x10-3 
These results were further corroborated using PRAT (Table 5-3a). All of the 
PRAT results were significant in cases but not controls or controls but not cases with the 
exception of G8 protein (C6orf48) rs2471980, COL1A2 rs420257, CRH rs6472257 and 
11-beta-hydroxysteroid dehydrogenase, type 1 (HSD11B1) rs3753519, which were 
significant in both cases and controls, indicating association (Ryckman et al 2008).  
(Figure 5-2, Table 5-3 and Appendix Table 11). 
Only rs6434222 in TFPI was significant after correction for multiple testing with FDR. 
Of the top 18 SNPs, 3 deviated from HWE, one of which deviated in cases (HSD17B7 
rs4656381, p = 0.01) and two in controls (C6orf48 rs2471980, p = 0.03; HSD11B1 
rs3753519, p = 0.01). For the SNPs that deviated from HWE the inbreeding coefficients 
in cases and controls were in opposite directions; this is similar to what was observed in 
the maternal data, indicating that deviations are not likely caused by genotyping error.  
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Table 5-3. Fetal single locus association results a) allelic and genotypic association b) logistic regression adjusting for parity 
a) 
Gene Gene Name SNP rs# Role Allele 
Case 
Freq. 
Control 
Freq. 
Case vs Control p PRAT p 
Allele Genotype Case Control 
C6orf48 c6 open reading frame 48 rs2471980 Promoter G 0.28 0.36 0.02 2 3.8x10 0.03 -3 0.02 
COL1A2 Collagen, type 1 alpha-2 rs420257 Intron G 0.24 0.34 1.4x10 9.6x10
-3 1x10-4 0.03 -3 
rs441051 Intron A 0.17 0.25 2.8x10 0.01 -3 5x10 0.54 -3 
CRH Corticotropin-releasing hormone rs6472257 Promoter A 0.09 0.14 0.02 4.2x10 0.03 
-3 0.02 
HSD11B1 11-beta-hydroxysteroid dehydrogenase, type 1 rs3753519 Intron A 0.09 0.15 0.01 
2 1.5x10 0.03 -3 <1x10-3 
HSD17B7 17-Beta-hydroxysteroid dehydrogenase 7 rs4656381 Intron A 0.35 0.28 
1 0.03 2.9x10 1x10-3 0.09 -3 
IL4R Interleukin 4 receptor rs2239347 Intron C 0.52 0.41 1.4x10 3.8x10-3 1x10-3 0.69 -3 
MTHFR Methylenetetrahydrofolate reductase 
rs1994798 Intron G 0.37 0.47 3.9x10 0.01 -3 4x10 0.48 -3 
rs9651118 Intron G 0.31 0.21 2.5x10 8.7x10-3 2x10-3 0.39 -3 
PON1 Paraoxonase 1 rs854548 Downstream A 0.20 0.29 2.5x10 9.6x10
-3 0.01 -3 0.77 
rs854552 3′ UTR G 0.21 0.30 1.8x10 6.0x10-3 3x10-3 0.62 -3 
SLC6A4 Solute carrier family 6 rs4251417 Intron A 0.07 0.14 8.0x10 2.7x10-4 0.01 -3 0.76 
TFPI Tissue factor pathway inhibitor 
rs12693471 Downstream G 0.26 0.36 4.0x10 0.01 -3 1x10 0.67 -3 
rs3213739 Intron A 0.38 0.48 4.4x10 0.01 -3 2x10 0.68 -3 
rs6434222 Intron T 0.17 0.08 *5.8x10 *1.0x10-5 <1x10-4 0.57 -3 
rs7586970 Intron G 0.26 0.36 3.7x10 0.01 -3 1x10 0.63 -3 
rs8176508 Intron A 0.41 0.32 3.7x10 0.01 -3 2x10 0.34 -3 
rs8176541 Intron A 0.26 0.36 4.3x10 0.01 -3 1x10 0.65 -3 
1cases deviated from HWE at rs4656381 (p = 0.01)  
2
*significant after correction for multiple testing using FDR (q = 0.20)  
controls deviated from HWE at rs2471980 (p = 0.03) and rs3753519 (p = 0.01) 
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b) 
Gene SNP rs# Model OR 95% CI Model p Adjusted 
Model p1 
C6orf48 rs2471980 CC/CGvsGG 0.32 0.16-0.65 0.001 0.002 
COL1A2 rs420257 AAvsAG/GG 0.48 0.32-0.71 2.24x10 1.65x10-4 -4 
rs441051 Additive 1.68 1.19-2.37 0.003 0.004 
CRH rs6472257 AA/AGvsGG 1.91 1.19-3.07 0.007 0.003 
HSD11B1 rs3753519 AA/AGvsGG 1.98 1.24-3.15 0.004 0.004 
HSD17B7 rs4656381 AAvsAG/GG 0.33 0.17-0.64 0.001 0.003 
IL4R rs2239347 Additive 1.58 1.19-2.09 0.001 0.003 
MTHFR rs1994798 Additive 0.67 0.50-0.88 0.004 0.003 
rs9651118 Additive 1.65 1.20-2.29 0.002 0.002 
PON1 rs854548 AA/AGvsGG 1.83 1.24-2.71 0.003 0.002 
rs854552 AAvsAG/GG 0.53 0.36-0.79 0.002 8.77x10
SLC6A4 
-4 
rs4251417 Additive 2.16 1.35-3.44 0.001 0.001 
TFPI 
rs12693471 Additive 0.63 0.47-0.86 0.004 0.004 
rs3213739 Additive 1.54 1.15-2.05 0.003 0.004 
rs6434222 Additive 2.49 1.59-3.91 7.02x10 7.72x10-5 
rs7586970 
-5 
Additive 0.63 0.46-0.86 0.003 0.003 
rs8176508 AA/ATvsTT 0.55 0.37-0.82 0.003 0.003 
rs8176541 Additive 1.57 1.16-2.14 0.004 0.004 
1 Models adjusted for parity 
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Figure 5-2. Fetal single locus association results.  Each point on the graph represents an 
association test either allelic (a) or genotypic (b). The x axis is SNP position in 
chromosomal order and the y axis is the inverse negative log of the p-value. Significant 
associations are highlighted in genes with at least one association at p < 0.005.  
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COL1A2 
Thirty-four SNPs in COL1A2 were examined for association with PTB in 
maternal and fetal samples and ten of these associated with PTB (Figure 5-3a and 
Appendix Table 10). Seven SNPs were associated with PTB only in fetal samples, one 
SNP was associated only in maternal samples and two SNPs were associated in both 
maternal and fetal samples. The most significant maternal single locus result was rs2472 
(allelic p = 1.6x10-3, genotypic p = 1.2x10-3
In fetal samples there were significant haplotype associations spanning two areas 
of the gene (Figure 5-3a). One appears to be driven by the fetal single locus effect at 
rs420257 and the other appears to be driven by the fetal single locus effect at rs2472. In 
maternal samples haplotype associations center around the maternal single locus effect at 
rs2472. The LD patterns between maternal and fetal cases and maternal and fetal controls 
were very similar (Appendix Figure 2a, b, i, j).  
) (Table 5-2a). This SNP had an OR of 0.32 
(95% CI = 0.16-0.66, p = 0.002) when comparing the AG/GG genotypes to the AA 
genotype (Table 5-2b). This SNP was also significantly associated in fetal samples 
(allelic p = 0.01, genotypic p = 0.01) (Appendix Table 11).  
 
TFPI  
Seventeen SNPs in TFPI were examined for association with PTB in maternal and 
fetal samples and nine of these associated with PTB (Figure 5-3b and Appendix Table 
11). Eight SNPs were significantly associated with PTB in both maternal and fetal 
samples and one SNP (rs6434222) was associated only in fetal samples. Rs6434222, was 
the most significant fetal single locus association (allelic p = 5.8x10-5, genotypic p = 
106 
1.0x10-4) (Table 5-3a). The best logistic regression model was additive with an OR of 
2.49 (95% CI = 1.59-3.91, p = 7.02x10-5
In fetal samples there were significant haplotype associations spanning two areas 
of the gene (Figure 5-3b). One appears to be driven by five significant fetal single locus 
associations (rs12693471, rs8176541, rs7586970, rs3213739 and rs8176508). Three of 
these SNPs (rs12693471, rs8176541 and rs7586970) had both significant single locus and 
haplotype associations in maternal samples. The other significant haplotype effects in 
fetal samples appear to be driven by rs6434222. Maternal single locus and haplotype 
associations were not observed for this SNP. In maternal controls there was very weak 
LD between the 3-SNP block (defined by rs12693471, rs8176541and rs7586970) and 
rs6434222 (D′ = 0.41) compared to fetal control samples where there is strong LD 
between rs6434222 and the SNPs in the 3-SNP block (D′ = 0.83) (Appendix Figure 2h 
and l). The LD patterns between maternal and fetal cases were very similar with strong 
LD between the 3-SNP block and rs6434222 (D′ > 0.84) (Appendix Figure 2g and k).  
) (Table 5-3b).  
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Figure 5-3. Maternal and fetal significant single locus and haplotype associations. a) 
COL1A2, b) TFPI Asterisks to the right of a SNP indicates significant single locus allelic associations with 
PTB, red indicates significance in maternal samples and black indicates significance in fetal samples. The 
number of asterisks denotes the strength of significance. Lines denote a significant haplotype, red is for 
maternal samples and black is in fetal samples. The thickness of the line denotes the strength of 
significance. Only SNPs with MAF > 0.05 in maternal or fetal samples are presented in graph. 
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Discussion 
There are four main pathways hypothesized to lead to PTB: 1) activation of 
maternal or fetal hypothalamic pituitary-adrenal axis, 2) inflammation/infection, 3) 
decidual hemorrhage, and 4) uterine distension (Lockwood and Kuczynski, 2001). Our 
study explored candidate genes in these pathways for associations with PTB. Recent 
studies based on epidemiological data, including one involving the MoBa, suggest that 
paternal factors have very little contribution on the risk of PTB (Basso et al., 1999; 
Wilcox et al., 2008). These studies suggest that paternal genes and therefore fetal genes 
will not contribute the risk of PTB. Of the 167 genes studied, 29 associated in maternal 
but not fetal samples, 29 associated in fetal but not maternal samples, and 26 associated 
in both maternal and fetal samples (Figure 5-4). Interestingly, the only association 
significant after correction for multiple testing was in fetal samples at rs6434222 in TFPI. 
This SNP was not significantly associated with PTB in maternal samples and there was 
only weak LD in maternal controls with this SNP, whereas in fetal controls there was 
strong LD between this SNP and other SNPs with significant associations. This indicates 
that this SNP may exhibit an independent fetal single locus association that is not driven 
entirely by the maternal genome. However, careful interpretation is needed, as there may 
not be enough power to detect significantly different LD patterns between maternal and 
fetal samples. Our study suggests that there is, in fact, a fetal and, therefore, paternal 
genetic contribution to the risk of PTB.  
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Figure 5-4. Significant allelic or genotypic maternal and fetal results. Bolded genes 
indicate that the same SNP in this gene was significant in both maternal and fetal samples for either allele 
or genotype tests. A: ADRB2, AP3M2, CARD15, CBS, COL1A1, EDN2, EPHX1, F3, F7, F10, FAS, 
GSTP1, IL18, IL1β, IL1R2, IL1RN, IL2RB, IL6R, IL8RA, KL, MMP2, MTHFD1, NAT1, PAFAH1B1, 
PGRMC2, PLA2G4A, PLAT, PTGES, SLC35B2  B: ADH1B, COL1A2, COL3A1, COL5A1, CRHR2, 
CYP19A1, IL1R1, IL1RAP, IL2RA, IL4R, MTHFR, MTRR, NFKB1, NR3C1, PGR, PLG, PON1, 
PON2, PTGER3, PTGFR, SLC6A4, TFPI, TIMP3, TREM1, TSHR, UGT1A1 C: C6orf48, COL5A2, 
CRH, CRHBP, EPHX2, F2R, F5, G0S2, HSD11B1, HSD17B7, HSPA1A, HSPA6, IGSF4C, IL1α, IL4, 
IL10RB, IL13, IL15, MMP8, NFKBIB, PGRMC1, PLAUR, PTGER2, SERPINE1, SMCR8, TCN2, 
TIMP4, TLR4, TOMM22 
 
 
Based on the most significant associations in maternal and fetal samples, several 
pathways can be highlighted as being strongly associated with PTB. The strongest 
associations in maternal samples were in genes involved in collagen synthesis related to 
ECM stability; while the strongest fetal effects were from genes involved in the 
complement/coagulation pathway. Of the five collagen genes studied, all were associated 
with PTB in maternal or fetal samples. Three of these genes, including COL1A2, which 
was the single strongest maternal effect, were associated in both maternal and fetal 
samples. Two of the SNPs examined in COL1A2 for associations with PTB were located 
in exons, one is a synonymous change (rs1800222) and the other is a missense mutation 
(rs42524) where alanine is changed to a proline. Alanine and proline are both nonpolar 
amino acids, making this a conservative change; however, proline is hydrophilic and 
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alanine is hydrophobic, therefore this change may affect the protein structure and may be 
an important variant in the association with PTB. These variants were not associated with 
PTB in maternal samples; however, rs42524 was associated with PTB in fetal samples 
(allelic p = 0.01, genotypic p = 0.02). Additionally, rs42524 is in strong LD with 
rs2521205 in both maternal and fetal samples (D′ = 1.0). SNP rs2521205 was associated 
with PTB in both maternal and fetal samples. This may indicate that this missense 
mutation (rs42524) is responsible for changes that may alter the functionality of this 
gene. Collagen, particularly types I and III, is an important component of the ECM that 
makes up most of the cervix. Perturbations in these genes may contribute to cervical 
ripening and ECM degradation that is a possible mechanism for PTL and eventually PTB. 
These genes have not been previously associated with PTB; however, few studies have 
focused on these genes despite the fact that they are good candidate for associations with 
PTB.  
Another important pathway identified by this study is the 
complement/coagulation pathway. SNPs in many genes in this pathway, particularly 
PLAT, associated with PTB in a recent study (Velez et al, 2008). Of the 12 genes studied 
in this pathway, 10 of them contained SNPs that associated with PTB in either maternal 
samples, fetal samples, or both (Figure 5-5). Intronic SNPs in TFPI had the strongest 
associations in fetal samples and several SNPs in TFPI associated with PTB in both 
maternal and fetal samples. There was one coding SNP genotyped in TFPI (rs5940); 
however, this SNP was not associated with PTB in maternal or fetal samples. 
Additionally, there was no detectable LD or very little LD (D′ < 0.40) between this SNP 
and other associated SNPs. This may be due to the low minor allele frequency of this 
111 
SNP (≤ 0.02 for maternal and fetal samples); therefore, the power to detect an association 
at an odds ratio of 2.0 with this SNP is small (13%, calculated with PS power). This SNP 
(rs5940) is a conservative missense mutation where methonine is changed to valine. 
While both these amino acids are hydrophobic and nonpolar, due to the differences in the 
structures of the side chains, this amino acid may still represent a functional change in the 
protein, and therefore may be an important variant in PTB risk. 
 
 
 
Figure 5-5. Complement/coagulation pathway. Genes shaded blue indicate SNPs were 
associated in fetal samples only. Genes shaded red indicate SNPs were associated in 
maternal samples only. Genes shaded green indicate SNPs were associated in both 
maternal and fetal samples. Genes shaded tan indicate there were no associations in 
maternal or fetal samples. 
 
 
TFPI inhibits F3 and F10, both of which are important for the production of F2, a 
critical component in clot formation. Overproduction of F2 can cause contractions and 
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activate MMPs, leading to degradation of the ECM. ECM degradation causes changes in 
the cervix and rupture of the membranes that may result in PTB. 
We demonstrated that multiple genes involved in ECM degradation and 
complement coagulation are associated with PTB. Many of these genes are associated in 
both maternal and fetal samples. Importantly, we also demonstrated that there are many 
genes associated with PTB in fetal samples only, supporting a paternal contribution to the 
risk for PTB, a result previously discounted based on epidemiological data alone.  
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B. Corroboration of Maternal and Fetal Single Locus Associations with PTB 
 
Introduction 
PTB is a serious reproductive disorder that accounts for a large proportion of 
perinatal mortality and morbidity. There has been an extensive amount of research in the 
last ten years looking for genetic associations with PTB. Many studies have found 
positive associations with this disorder, particularly in the inflammation/infection 
pathway; however, many of these studies fail to replicate (Menon et al., 2006b).  
Recently, one such candidate gene study of PTB was performed, examining 1,536 
SNPs in 130 candidate genes (Velez et al., 2008a). This study examined maternal and 
fetal DNA of European-descent from 172 PTBs (<36 weeks gestation) and 198 term 
labors (≥37 weeks gestation). The strongest maternal associations were in genes involved 
in the complement-coagulation pathway related to decidual hemorrhage. The genes F5, 
F7 and PLAT were all found to associate with PTB. The strongest association was at 
marker rs879293 in PLAT (allelic p = 2.00x10-3 and genotypic p =2.0x10-6) with an odds 
ratio (OR) of 2.80 [CI 1.77 - 4.44] for a recessive model. The strongest fetal association 
was at rs17121510 in IL-10RA (allelic p = 0.01 and genotypic p = 3.34x10-4
Studies in part A of this chapter demonstrated significant maternal and fetal 
associations with PTB. In this study we examine SNPs that were associated in both study 
populations and analyze the data together to determine the effect size of these replicating 
SNPs.   
). The best 
model for the IL-10RA association was additive with an OR of 1.92 [CI 1.15-3.19]. 
However, this study did not include a replication dataset. 
114 
Materials and Methods 
 
Demographic and clinical characteristics 
Sample collection and results from the MoBa study are described in detail in part 
A of this chapter and the Cenn study is described in detail elsewhere (Velez et al. 2008). 
Both populations consisted of maternal and fetal EA samples. The combined data yielded 
a total of 764 maternal samples (353 cases and 411 controls) and 738 fetal samples (343 
cases and 395 controls).  
 
Table 5-4. Comparisons of clinical variables between MoBa and Cenn a) 
controls b) cases 
 
a) 
Variable MoBa (n=217) Cenn (n = 199) 1p 
Gravidity 1 [0-7] 2 [1-8] <0.0001 
Gestational Age (days) 280 [273-286] 274 [257-296] <0.0001 
Birthweight (grams) 3650 [2610-4970] 3446 [2100-4661] <0.0001 
APGAR at 1 minute (% <7) 12 (6%) 4 (2%) 0.081 
APGAR at 5 minutes (% <7) 5   (2%) 0 (0%) 0.037 
Maternal Age (yrs) 30 [21-34] 28 [16-43] 0.045 
Smoking (%) 21 (11%) 28 (15%) 0.284 
 
b) 
Variable MoBa (n=207) Cenn (n = 172) 1p 
Gravidity 0 [0-5] 2 [1-9] <0.0001 
Gestational Age (days) 253 [182-258] 239 [166-255] <0.0001 
Birthweight (grams) 2810 [950-4000] 2150 [370-3790] <0.0001 
APGAR at 1 minute (% <7) 16 (8%) 42 (25%) <0.001 
APGAR at 5 minutes (% <7) 3   (1%) 10 (6%) 0.018 
Maternal Age (yrs) 29 [20-34] 27 [17-40] 0.065 
Smoking (%) 22 (12%) 54 (32%) <0.001 
Medians are reported with the range in brackets 
1P-values are calculated by Mann Whitney U- test for continuous variables and chi-square test for 
dichotomous variables.
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Case-control status definitions were different between the two studies. In the 
MoBa study cases were defined by a gestational age of < 370/7 weeks and in the Cenn 
study cases were defined by a gestational age of < 360/7 weeks. The controls were defined 
by a gestational age of ≥ 390/7 weeks in the Moba study and ≥ 370/7
 
 weeks in the Cenn 
study.  Gravidity, gestational age and birthweight differed between the two study 
populations in cases and controls. When data from the two studies are combined, the 
median gestational age was 248 days (range = 166-258) in cases and 278 days in controls 
(range = 257-296).   
Statistical analysis    
 A total of 1,316 SNPs overlapped with the previous study on PTB in EA maternal 
and fetal samples. Sample collection and results from the Cenn study are described in 
detail elsewhere (Velez et al. 2008). SNPs were included for pooled analysis if the allele 
or genotype p-values were less than 0.05 in one study (MoBa or Cenn) and less than 0.20 
in the other study. This criterion, while arbitrary, was designed to capture associations 
that may have been missed due to inadequate power in an individual study. However, this 
criterion was also designed to exclude associations that were primarily driven by only 
one of the two studies. The MoBa and Cenn samples were pooled together, and the SNPs 
that met the above criteria were analyzed for allelic and genotypic association as 
described in part A of this chapter. A pooled effect size was determined with logistic 
regression.   
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Results 
 
Maternal results 
 Of the 58 SNPs that met the criterion for the pooled analysis, 15 had significant 
allelic or genotypic pooled p < 5x10-3 
The most significant single locus result in the pooled sample was in prostaglandin 
E receptor 3 (PTGER3). There were six SNPs in this gene that met the criteria for pooled 
analysis and three of these (rs2072947, rs977214 and rs6665776) had significant allelic 
or genotypic results in the pooled samples. Two of these SNPs (rs977214 and rs6665776) 
strongly associated with PTB in the pooled sample (rs977214: genotypic p = 2.6x10
(Table 5-5 and Appendix Table 13a). These 15 
SNPs were from 11 different genes involved in several PTB pathways such as collagen 
synthesis, inflammation/infection, complement/coagulation and prostaglandin synthesis. 
-4; 
rs6665776: genotypic p = 4.8x10-4
Additionally, there were 13 SNPs with significant allelic or genotypic p-values less than 
0.05 in both studies (Appendix Table 13). This included both SNPs with significant 
pooled p-values in PTGER3.  
) (Table 5-5a). The best model for rs977214 compared 
the AG/GG genotypes to the AA genotype and resulted in an OR of 0.56 (95% CI = 0.38-
0.82, p = 0.003), indicating a protective effect (Table 5-5b). The best model for 
rs6665776 compared the CC genotype to the AA/AC genotypes and had an OR of 1.75 
(95% CI = 1.19-2.58, p = 0.005) (Table 5-5b). There was strong LD between these two 
SNPs in the pooled cases and controls (D′ = 1). Haplotype associations spanned three 
general regions of the gene; two of these regions were significant in the Cenn study only 
and one of these regions was significant in the Moba study only (Figure 5-6).  
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Table 5-5. Genetic associations in maternal samples. a) significant allelic and genotypic results. b) OR of significant results in 
pooled data. 
 
a) 
   Centennial Study Norway MoBa Study Pooled Data 
   Allele Freq. p-value Allele Freq. p-value Allele Freq. p-value 
Gene SNP Allele Case Cont Allele Genotype Case Cont Allele Genotype Case Cont Allele Genotype 
AP3M2 rs4581040 G 0.32 0.24 0.042 0.131 0.30 0.24 0.041 0.112 0.31 0.24 0.004 0.017 
COL1A1 rs1061237 C 0.23 0.28 0.090 0.055 0.26 0.29 0.332 0.044 0.24 0.29 1 0.069 0.003 
COL5A1 rs10745387 A 0.54 0.61 0.110 0.150 0.37 0.44 0.031 0.101 0.44 0.52 0.003 0.009 
IL1R2 rs1108338 C 0.28 0.21 0.038 0.082 0.29 0.23 0.022 0.012 0.29 0.22 1 0.002 0.001 
IL1RAP rs7628333 T 0.21 0.24 0.358 0.080 0.22 0.32 0.002 0.005 0.22 0.28 0.004 0.012 
IL6R 
rs4845374 T 0.87 0.82 0.139 0.110 0.12 0.17 0.042 0.027 0.43 0.481 0.051 2 0.002 
rs4329505 C 0.13 0.17 0.129 0.067 0.12 0.17 0.042 0.027 0.13 0.17 0.011 0.003 
NAT1 
rs7017402 A 0.15 0.10 0.038 0.088 0.13 0.09 0.043 0.048 0.14 0.09 0.004 0.013 
rs9325827 C 0.18 0.11 0.012 0.040 0.16 0.11 0.048 0.083 0.17 0.11 0.002 0.008 
PLA2G4A rs2076075 A 0.14 0.10 0.110 0.236 0.17 0.12 0.020 0.056 0.16 0.11 0.004 0.016 
PLAT rs2020922 A 0.32 0.24 0.029 0.095 0.30 0.24 0.034 0.081 0.31 0.24 1 0.003 0.009 
PTGER3 
rs977214 G 0.09 0.13 0.166 0.005 0.06 0.09 0.064 0.039 0.07 0.11 1 0.016 2.6x10-4 
rs6665776 A 0.09 0.12 0.235 0.010 0.06 0.09 0.064 0.039 0.07 0.11 1 0.024 4.8x10-4 
TSHR 
rs17630128 C 0.33 0.25 0.031 0.023 0.36 0.30 0.072 0.192 0.35 0.28 0.004 0.010 
rs12883801 G 0.41 0.52 0.005 0.011 0.37 0.43 0.107 0.137 0.39 0.47 1 0.001 9.4x10-4 
1cases deviated from HWE at rs1061237 (p = 0.01), rs1108338 (p = 0.04), rs4845374 (p < 10-3), rs2020922 (p = 0.05), rs977214 (p = 0.02), rs6665776 (p = 0.02), 
rs12883801 (p = 0.04) 
2controls deviated from HWE at rs4845374 (p < 10-3), rs4329505 (p = 0.03), rs977214 (p = 0.05) 
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b) 
Gene Gene Name SNP rs# Role Model OR 95% CI Model p 
AP3M2 Adaptor-related protein complex 3 rs4581040 Downstream Additive 1.36 1.09-1.70 0.006 
COL1A1 Collagen, type 1, alpha 1 rs1061237 3′UTR CCvsCT/TT 3.02 1.56-5.86 0.001 
COL5A1 Collagen, type 5, alpha 1 rs10745387 Intron Additive 1.35 1.11-1.65 0.003 
IL1R2 Interleukin 1 receptor 2 rs1108338 Intron AA/ACvsCC 2.89 1.58-5.29 5.8x10-4 
IL1RAP Interleukin 1 receptor accessory protein rs7628333 Intron Additive 0.71 0.56-0.90 0.005 
IL6R Interleukin 6 receptor rs4845374 Intron AAvsAT/TT 0.65 0.49-0.88 0.004 rs4329505 Intron CC/CTvsTT 1.66 1.20-2.29 0.002 
NAT1 N-acetyltransferase rs7017402 Intron Additive 0.63 0.45-0.87 0.005 rs9325827 Intron Additive 0.63 0.47-0.85 0.002 
PLA2G4A Phospholipase A2 rs2076075 Intron Additive 0.65 0.48-0.87 0.004 
PLAT Tissue plasminogen activator rs2020922 Intron Additive 0.72 0.58-0.90 0.004 
PTGER3 Prostaglandin E receptor 3 rs977214 Intron AAvsAG/GG 0.56 0.38-0.82 0.003 rs6665776 Intron AA/ACvsCC 1.75 1.19-2.58 0.005 
TSHR Thyroid stimulating hormone receptor 
rs17630128 3′UTR CC/CTvsTT 0.64 0.48-0.86 0.003 
rs12883801 Downstream AA/AGvsGG 0.49 0.33-0.72 3.1x10-4 
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Figure 5-6. Significant maternal single locus and haplotype associations in MoBa 
and Cenn studies. PTGER3, Asterisks to the right of a SNP indicates significant single locus allelic 
associations with PTB, blue denotes significance in pooled samples, red indicates significance in the MoBa 
study only and black indicates significance in the Cenn study only. The number of asterisks denotes the 
strength of significance. Lines denote a significant haplotype, red is for the MoBa study and black is for the 
Cenn study. The thickness of the line denotes the strength of significance. 
 
 
Fetal results 
 Of the 45 SNPs that met the criteria for the pooled analysis, 4 SNPs in 4 different 
genes had pooled allelic or genotypic p < 5x10-3 (Table 5-6 and Appendix Table 13b). 
The most significant single locus association in pooled samples was in PON1 at rs854552 
(allelic p = 0.001, genotypic p = 7.6x10-4). The best model compared the TT genotype to 
the CC/CT genotypes and resulted in an OR of 1.69 (95% CI = 1.26-2.27, p = 5.1x10-4) 
(Table 5-6b). There were very few haplotype or single locus associations in the Cenn 
study for PON1; however, there were strong haplotype associations in the MoBa data, 
and rs854552 was the most significant single locus association in this gene in the MoBa 
study (Figure 5-7). Additionally, there were 6 SNPs with allelic or genotypic p-values 
less than 0.05 in both studies. This did not include rs854552 in PON1; however, a 
different SNP in this gene (rs2272365) had significant allelic association at p < 0.05 in 
both studies (MoBa p = 0.041, Cenn p = 0.046). The pooled allelic p-value for this 
marker was 0.005. 
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Table 5-6. Genetic associations in fetal samples. a) significant allelic and genotypic results, b) OR of significant results in pooled 
data. 
 
a) 
   Centennial Study Norway MoBa Study Pooled Data 
   Allele Freq. p-value Allele Freq. p-value Allele Freq. p-value 
Gene SNP Allele Case Cont Allele Genotype Case Cont Allele Genotype Case Cont Allele Genotype 
COL1A2 rs42524 G 0.77 0.79 0.440 0.055 0.19 0.26 0.010 0.022 0.43 0.501 0.003 2 0.001 
COL3A1 rs3134656 A 0.50 0.39 0.005 0.026 0.47 0.41 0.067 0.098 0.48 0.40 0.001 0.004 
MTHFR rs4846052 T 0.39 0.46 0.085 0.205 0.36 0.45 0.009 0.010 0.37 0.46 0.002 0.003 
PON1 rs854552 C 0.22 0.28 0.120 0.248 0.21 0.30 0.002 0.006 0.21 0.29 0.001 7. 6x10-4 
1cases deviated from HWE and PRAT at rs42524 (p < 10-3) 
2controls deviated from HWE and PRAT at rs42524 (p < 10-3
 
) 
b) 
Gene Gene Name SNP rs# Role Model OR 95% CI Model p 
COL1A2 Collagen, type 1, alpha 2 rs42524 Coding exon P549A CCvsCG/GG 0.58 0.43-0.79 4.5x10
-4 
COL3A1 Collagen, type 3, alpha 1 rs3134656 Intron Additive 0.71 0.57-0.87 0.001 
MTHFR 5, 10-methylenetetrahydrofolate reductase rs4846052 Intron CCvsCT/TT 0.59 0.43-0.80 7.4x10
-4 
PON1 Paraoxonase 1 rs854552 3′UTR CC/CTvsTT 1.69 1.26-2.27 5.1x10-4 
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Figure 5-7. Significant fetal single locus and haplotype associations in MoBa and 
Cenn studies. PON1, Asterisks to the right of a SNP indicates significant single locus allelic 
associations with PTB, blue denotes significance in pooled samples, red indicates significance in the MoBa 
study only and black indicates significance in the Cenn study only. The number of asterisks denotes the 
strength of significance. Lines denote a significant haplotype, red is for the MoBa study and black is for the 
Cenn study. The thickness of the line denotes the strength of significance. 
 
 
Discussion 
In this study associations with several genes from multiple biological pathways 
had modest to strong associations with PTB in two independent studies and when these 
studies were pooled, several SNPs had significant associations with PTB (Figure 5-8). 
Previous studies in part A of this chapter identified significant maternal and fetal 
associations with PTB in COL1A2 in the MoBa study. In this section we demonstrated 
that there were significant associations in COL1A2 in maternal and fetal samples in the 
Cenn study as well and when these two studies were pooled, associations in COL1A2 
remained significant (Figure 5-8). This was also the case for COL3A1. Additionally, 
COL5A1 and COL5A2 were associated with PTB in three of the four sample sets studied 
(Figure 5-8). Collagen plays an important role in all stages of cervical function during 
pregnancy (Word et al., 2007). These studies suggest that collagen genes are particularly 
important in the pathogenesis of PTB. 
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Figure 5-8. Identification of genes associated with PTB in multiple populations. A: 
ADRB2, CARD15, CBS, COL1A1, EDN2, EPHX1, FAS, GSTP1, IL1B, IL1RN, IL2RB, IL8RA, 
KL, MMP2, PAFAH1B1, PGRMC2, PTGES, SLC35B2 B: ADH1B, MTHFR, NFKB1, PTGFR 
C: C6orf48, CRH, F5, G0S2, HSD11B1, HSD17B7, HSPA1A, IL10RB, IL13, IL15, NFKBIB, 
PGRMC1, PTGER2, SERPINE1, TCN2, TIMP4, TLR4, TOMM22 D: HSPA6, IL1A, IL4, 
MMP8, TLR8 E: CBS, EDN2, GSTP1, HSPA14, IL1B, IL1RN, IL2RB, KIAA0664, KL, 
NFKBIA, PAFAH1B1, PTGS2, SLC23A1, SLC35B2 F: IL10RA, IL5, MMP1, MMP3 G: CCL2, 
CTLA4, DHFR, F5, IL10, NFKBIB, PGRMC1, PTGS1, SCNN1A, TEX12, TLR2, TLR3, TLR7, 
TNFRI, TNFRII  H: AP3M2, F7, IL18, IL1R2, IL6R, MTHFD1, NAT1, PLA2G4A I: COL5A1, 
IL1R1, IL4R J: PLAT K: COL1A2, COL3A1, CYP19A1, IL1RAP, IL2RA, PON2, PTGER3, 
TIMP3, TSHR, UGT1A1 L: CRHR2, NR3C1, PGR, PON1, SLC6A4, TREM1 M: COL5A2, 
CRHBP, EPHX2 
 
 
Additionally, the most significant associations in the pooled samples were from 
two major PTB pathways: 1) HPA axis activation (PTGER3) and 2) decidual hemorrhage 
(PON1). Activation of the HPA axis results in an increase of prostaglandins. 
Prostaglandins play a central role in myometrial contractions, and elevated uterine levels 
of prostaglandins can lead to contractions and labor. PTGER3 is a stimulatory receptor 
that plays a role in smooth muscle contraction. PTGER3 was significant in all four 
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populations studied in part A and B of this chapter (Figure 5-8). Additionally, three of the 
six SNPs examined in the pooled sample were associated with PTB. It is likely that 
polymorphisms in this gene could lead to early contractions and therefore PTB. 
Another important pathway that is consistently associated with PTB is the 
decidual hemorrhage pathway which activates ECM degradation. PON1 is a member of 
the paraoxonase gene family, and mutations in this gene are associated with high-density 
lipoprotein (HDL) and modification of low-density lipoprotein (LDL) (Mackness et al., 
1993; Mackness et al., 1996). HDL increases the production of prostaglandin E, which 
can lead to contractions (Chen et al., 2004a). Therefore, it is likely that the mechanisms 
driving the most significant association in the maternal pooled samples (PTGER3) and 
the most significant association in the fetal pooled samples (PON1) are functionally 
related. Additionally, hypothesized mutations in this gene could indirectly disrupt the 
balance of procoagulant and anticoagulant mechanisms in pregnancy and result in 
thrombosis, infarction and eventually PTB (Girling and de, 1998; Chen et al., 2004a).  
The studies in this chapter were limited in that these were candidate gene studies, 
therefore many associations may be missed, including genes representing novel biology 
with respect to PTB. In addition, the case-control criteria for the MoBa and Cenn studies 
were different and while there were still many associations discovered, studies with more 
carefully defined phenotypic criteria are needed to validate these results. However, this 
study identified multiple genes with significant or marginally significant associations 
with PTB in two separate studies, which has not often been done with respect to this 
disorder. When these samples were combined, multiple SNPs with strong allelic or 
genotypic p-values were identified, including SNPs involved in inflammation and 
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infection, ECM degradation and decidual hemorrhage. This study has validated 
previously identified genetic associations with PTB and further studies can address the 
biological role these genes play in PTB. 
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CHAPTER VI 
 
CONCLUSIONS AND FUTURE DIRECTIONS 
 
A. Summary 
Reproductive disorders, such as PTB and BV, are serious gynecological problems 
responsible for a large portion of perinatal morbidity and mortality. Identifying the 
environmental and genetic risk factors of these reproductive disorders has proven 
difficult, as these are complex diseases that do not follow a Mendelian pattern of 
inheritance. The majority of factors discovered to date either do not replicate or only 
explain a fraction of the risk for developing these diseases. Studies presented in the 
previous chapters were aimed at elucidating the genetic immunology of BV and the 
genetics of PTB. 
 
Genetic Associations with BV 
There are several important points that have been revealed by these studies. First, 
while many studies have demonstrated that vaginal and cervical cytokine concentrations 
differ by BV status, many of these are inconsistent. We have demonstrated that the 
cytokine concentrations in BV+ and BV- women differ between AA and EA, and the 
correlation structure of these cytokines is also very different between AA and EA. This 
may help to explain the inconsistencies of previous studies where there was ethnic 
heterogeneity as well as identify potential mechanisms that may explain why AA are at 
an increased risk for developing BV, even after accounting for socio-economic variables.  
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Figure 6-1. Hypothesized genetic mechanism for the regulation of cervical 
cytokine concentrations. Genetic associations with cytokine concentrations differs between 
EA (left panel) and AA (right panel). Genes and cytokines are represented as follows: blue – anti-
inflammatory, pink – pro-inflammatory and green – downstream signaling molecules. Dashed 
lines indicate that there is an indirect connection between the two molecules, meaning that other 
factors lead to the inhibition or stimulation of the proceeding factor. Solid lines indicate a direct 
connection between the two factors, meaning that the factor shown is necessary and sufficient to 
stimulate the proceeding factor. 
 
 
Secondly, the associations with cervical cytokine concentrations are involved with 
different signaling pathways between AA and EA (Figure 6-1). IL-6R, IL-10RA and 
TLR4, all associated with cervical cytokine concentrations in EA but not AA, act through 
the JAK/STAT signaling pathway to either inhibit (IL-10RA) or stimulate pro-
inflammatory cytokine production (IL-6 and TLR4). IL-1RAP and TNFR2, both 
associated with cervical cytokine concentrations in AA but not EA, signal through the 
MAPK/NF-kB signaling pathway to induce production and release of pro-inflammatory 
cytokines. This may be another plausible mechanism for the ethnic disparity observed in 
the prevalence of BV. Separate downstream signaling molecules may be contributing to 
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not only the differences in genetic associations with cervical cytokines but also 
differences in the correlation structure observed between EA and AA.  
Lastly, the genetic associations with cervical cytokine concentration involve the 
cytokine receptor genes, not the genes themselves. Most studies of the cervical milieu 
focus on cytokine genes, not other cofactors and receptors. This may be an indication of 
why many genetic association studies examining vaginal and cervical cytokines fail to 
detect associations or fail to replicate. Genetic associations with cervical cytokine 
concentrations appear to involve a complex mechanism of regulation that may contribute 
to the pathogenesis and possibly the progression of BV. 
 
Genetic Associations with PTB 
Four main pathways have been hypothesized to lead to PTB: 1) activation of 
maternal or fetal hypothalamic pituitary-adrenal axis, 2) inflammation/infection, 3) 
decidual hemorrhage, and 4) uterine distension (Lockwood and Kuczynski, 2001). These 
pathways converge on a final terminal pathway where uterotonins, proteases and 
prostaglandins are released, which lead to contractions, rupture of the membranes, and 
eventually, PTB. Our studies have identified genes associated with PTB that are involved 
in the previously mentioned pathways (Figure 6-2). 
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Figure 6-2. Hypothesized mechanisms for PTB. Major pathways are highlighted in 
pink, secondary pathways in blue and terminal pathways in grey. Genes with significant 
(p < 5x10-3) associations from the MoBa study or significant pooled (MoBa and Cenn) p-
values (p < 5x10-3
 
) are listed above the secondary pathway. Genes in red text indicate 
maternal associations, blue text indicates fetal associations and green text indicates 
maternal and fetal associations. Genes with a red asterisk indicate maternal replication, 
blue asterisk indicates fetal replication. 
 
Several studies have identified SNPs in the inflammation/infection pathway that 
are associated with PTB; however, these studies often fail to replicate (Velez et al., 2007; 
Velez et al., 2008b). In this study we identified many SNPs in inflammation/infection 
related genes such as IL-1R2, IL-1RAP and IL-6R that consistently associated with PTB 
(Figure 6-2). The majority of these associations are in maternal samples only, indicating 
the importance of the maternal genome on infection related genetic associations with 
PTB. Studies in part B of chapter IV demonstrated that in a separate EA population, a 
SNP in IL-6R was significantly associated with cervical IL-6 concentrations. In an AA 
population SNPs in IL-1RAP were associated with IL-1β concentrations. Both of these 
associations were affected by the presence of BV. The SNPs associated with BV and 
PTB were not the same. Also there was no LD between these SNPs in the population 
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studied. Nevertheless, it is possible that there is a pleiotropic effect for these genes in 
influencing two related reproductive disorders. Further studies will need to be conducted 
to determine if one or multiple SNPs in these genes are affecting these disorders. 
Another important pathway that is consistently associated with PTB is the 
decidual hemorrhage pathway that activates ECM degradation. Collagen genes play a 
central role in ECM degradation, and several SNPs from many of these genes were 
significant in maternal (COL1A1 and COL5A1) and fetal (COL1A2 and COL3A1) 
pooled samples with allelic or genotypic p < 5x10-3
Collagen plays an important role in all stages of cervical function during 
pregnancy (Word et al., 2007). During the dilation and ripening phases, collagen 
concentration decreases with increased collagen dispersal, solubility and degradation 
(Word et al., 2007). Collagen, in particular types I and types III, plays vital roles in the 
changes in tissue consistency associated with cervical ripening (Word et al., 2007). 
Perturbations in these collagen genes could cause an increased weakening of the 
membranes surrounding the fetus and result in rupture of the membranes, thereby leading 
to PTB. It is evident from significant results in two separate studies, that contributions 
from both the maternal and fetal genomes are involved in the associations of collagen 
genes with PTB. 
. This suggests that collagen genes are 
particularly important in the pathogenesis of PTB. Additionally, collagen genes are 
critical in the uterine distension pathway, suggesting that through collagen genes multiple 
pathways are activated that lead to PTB.  
This study identified multiple genes with significant or marginally significant 
associations with PTB in two separate studies. When these samples were combined, 
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multiple SNPs with strong allelic or genotypic p-values were identified, including SNPs 
involved in inflammation and infection, ECM degradation and decidual hemorrhage. This 
study has validated previously identified genetic associations with PTB and further 
studies can address the biological role these genes play in PTB. 
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B. Future Directions  
Reproductive disorders such as BV and PTB involve complex mechanisms with 
built in redundancies and checkpoints. Our genetic association studies of BV, while 
examining an important intermediate phenotype, were limited in the ability to connect 
these findings directly with reproductive disorders such as BV and PTB. These 
limitations were due to small sizes. For this same reason other important environmental 
risk factors such as smoking and gene-gene interactions were not examined. Our studies 
of PTB were limited in the ability to identify novel biological pathways that may be 
associated with PTB, as our study was a candidate gene study. Additionally, our study 
lacked complex environmental risk factors that may be influenced by the genetic variants 
identified, such as serum biomarker measurements. 
Therefore, while these studies have identified genes of interest, more intricate 
analyses must be performed to identify the true mechanisms underlying the genetic 
regulation of cervical immunity and PTB. Additional studies are required to validate 
these findings. Re-sequencing of the variants identified in the cervical cytokine studies, 
particularly IL-1RAP, IL-6R, IL-8RA, IL-10RA, and TLR4 and those identified in the 
PTB studies, particularly COL1A2, TFPI, PON1 and PTGER3 are warranted to identify 
functional candidate loci. 
Due to the complex nature of these disorders genome wide association studies 
(GWAS) may be useful in identifying associations not previously examined. However, 
due to the large number of tests performed in these studies, large sample sizes are needed 
to have adequate power to detect associations. These studies may also be hard to 
interpret, as there will likely be thousands of significant associations. However, these 
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studies may identify new pathways of interest that have not previously been examined 
with PTB and therefore, follow-up studies can be performed to pinpoint important 
associations.  
Many environmental factors such as nutrition, serum protein levels, smoking and 
race will need to be evaluated to better identify mechanisms that are influencing these 
disorders. In particular, studies examining multiple races are needed to determine if the 
genes and pathways identified are dependent on geographic ancestry or if these genes and 
mechanisms apply to the global population. Additional studies with intermediate 
phenotypes such as cervical cytokines and serum biomarkers are critical to determine 
important biological associations with reproductive disorders. Gene-gene and gene-
environment interactions will need to be determined to realistically discern the 
complexity of these diseases. This will require much larger sample sizes than the current 
studies and will demand a well defined and characterized phenotype, as well as additional 
physiological measures. 
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Appendix Table 1. Median and ranges of all cytokines by BV status and race 
 
Cytokine EA BV EA BV- AA BV+ AA BV- 
p 
value+ 
p 
1  value
p 
value2 
p 
value3 4 
EGF 232.3 
(12.0 – 1740.6) 
181.4 
(12.0 – 445.0) 
176.2 
(12.0 – 762.2) 
179.8 
(0.6 – 1595.2) 
0.144 0.881 0.462 0.824 
EOTAXIN 184.0 
(56.0 – 2165.8) 
169.9 
(40.0 – 4200.0) 
159.3 
(5.0 – 1235.0) 
182.2 
(28.6 – 3301.6) 
0.473 0.596 0.375 0.765 
FGF2 134.7 
(12.0 – 7368.4) 
122.5 
(12.0 – 1437.4) 
95.0 
(12.0 – 1555.4) 
65.8 
(12.0 – 7716.3) 
0.980 0.996 0.248 0.444 
FLT3 260.5 
(12.0 – 1603.8) 
330.9 
(12.0 – 1692.0) 
245.0 
(12.0 – 1170.0) 
353.5 
(12.0 – 15139.1) 
0.339 0.046 0.649 0.555 
GMCSF 113.0 
(5.0 – 2524.0) 
80.0 
(5.0 – 2796.0) 
89.9 
(5.0 – 2202.0) 
113.0 
(5.0 – 5438.6) 
0.355 0.283 0.392 0.293 
IFN-γ 219.9 
(5.0 – 1735.0) 
172.0 
(49.6 – 2021.0) 
227.9 
(5.0 – 1418.0) 
181.0 
(5.0 – 3538.1) 
0.769 0.499 0.833 0.494 
IL-1α 904.9 
(166.0 – 11098.1) 
1973.1 
(82.4 – 25581.0) 
558.4 
(104.0 – 5554.6) 
1165.2 
(163.8 – 
33876.5) 
0.030 <0.001 0.047 0.422 
IL-1β 106.6 
(5.0 – 7787.5) 
265.0 
(5.0 – 7374.2) 
116.1 
(0.6 – 6170.9) 
188.5 
(5.0 – 10125.8) 
0.106 0.085 0.405 0.287 
IL-2 129.0 
(5.0 – 944.0) 
90.6 
(5.0 – 910.7) 
108.5 
(5.0 – 630.0) 
169.8 
(5.0 – 1228.9) 
0.497 0.120 0.602 0.111 
IL-3 324.6 
(5.0 – 2524.7) 
254.7 
(5.0 – 1316.8) 
237.4 
(5.0 – 2321.3) 
281.2 
(5.0 – 38028.7) 
0.325 0.232 0.290 0.226 
IL-4 62.9 
(0.0 – 498.5) 
52.5 
(0.0 – 547.0) 
55.0 
(5.0 – 430.0) 
60.9 
(0.0 – 668.4) 
0.211 0.909 0.464 0.571 
IL-5 18.0 
(5.0 – 302.0) 
12.8 
(5.0 – 183.0) 
11.6 
(3.0 – 297.0) 
13.1 
(5.0 – 758.4) 
0.980 0.230 0.269 0.846 
IL-6 3967.1 
(62.2 – 25000.0) 
2129.6 
(117.9 – 
14256.0) 
2162.2 
(5.0 – 14744.0) 
2290.3 
(288.3 – 
40000.0) 
0.287 0.526 0.010 0.779 
IL-7 328.9 
(5.0 – 1494.0) 
236.3 
(5.0 – 2080.0) 
405.6 
(5.0 – 1170.0) 
392.0 
(5.0 – 2365.2) 
0.245 0.820 0.863 0.326 
IL-8 11677.7 
(260.6 – 
169470.6) 
6315.0 
(771.0 – 
30000.0) 
7632.5 
(1068.6 – 
31552.9) 
15363.8 
(486.8 – 
30000.0) 
0.474 0.249 0.182 0.710 
IL-10 73.3 
(0.0 – 497.4) 
37.5 
(0.0 – 443.0) 
43.0 
(1.3 – 391.0) 
49.3 
(0.0 – 1381.6) 
0.016 0.553 0.016 0.580 
IL12P40 289.5 
(8.0 – 926.0) 
267.9 
(38.0 – 879.3) 
215.2 
(8.0 – 950.0) 
229.8 
(8.0 – 735.5) 
0.849 0.695 0.070 0.331 
IL12P70 79.9 
(20.0 – 1141.0) 
62.6 
(5.0 – 1842.0) 
73.2 
(5.0 – 683.0) 
91.0 
(5.0 – 665.2) 
0.377 0.087 0.394 0.101 
IL-13 100.1 
(5.0 – 959.0) 
81.9 
(5.0 – 592.0) 
83.3 
(5.0 – 488.0) 
133.8 
(5.0 – 397.1) 
0.446 0.167 0.170 0.337 
IL-15 68.0 
(5.0 – 564.3) 
61.1 
(5.0 – 302.4) 
67.0 
(5.0 – 396.7) 
87.6 
(5.0 – 706.3) 
0.609 0.250 0.707 0.234 
IP10 3972.8 
(5.0 – 30181.9) 
1807.8 
(146.6 – 
25000.0) 
4162.0 
(185.6 – 
25000.0) 
2932.4 
(163.3 – 
20303.2) 
0.001 0.174 0.741 0.108 
MCP1 859.0 
(40.0 – 30631.9) 
348.0 
(48.0 – 22146.0) 
773.9 
(66.0 – 5500.0) 
519.6 
(96.1 – 4204.0) 
0.006 0.313 0.191 0.171 
MIP-1 α 833.2 
(122.1 – 12604.3) 
417.3 
(97.0 – 15810.0) 
911.0 
(126.1 – 
10194.0) 
714.8 
(8.0 – 6236.6) 
0.043 0.315 0.507 0.149 
PDGF-AA 1093.5 
(78.4 – 10122.0) 
499.1 
(99.3 – 10916.0) 
672.0 
(160.3 – 7969.0) 
666.2 
(33.0 – 7894.8) 
0.048 0.290 0.168 0.839 
PDGF-BB 2362.2 
(236.2 – 33201.0) 
1445.1 
(40.0 – 14663.7) 
1204.7 
(12.0 – 9651.0) 
1259.6 
(12.0 – 36153.1) 
0.015 0.534 0.010 0.443 
RANTES 545.0 
(3.0 – 8000.0) 
445.5 
(25.0 – 8000.0) 
563.0 
(21.0 – 8400.0) 
506.0 
(3.0 – 5520.8) 
0.234 0.444 0.632 0.863 
TNF 6.0 
(1.4 – 861.2) 
6.0 
(1.4 – 857.0) 
14.0 
(5.0 – 633.7) 
6.0 
(1.4 – 2887.6) 
0.494 0.915 0.732 0.373 
VEGF 925.3 
(12.0 – 17585.4) 
1163.9 
(90.0 – 26310.0) 
873.9 
(12.0 – 12302.0) 
873.9 
(67.7 – 28705.8) 
0.762 0.802 0.304 0.415 
1 p values compare BV+ to BV- in EA 
2 p values compare BV+ to BV- in AA 
3 p values compare EA to AA in BV- women  
4 p values compare EA to AA in BV+
 
 women 
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Appendix Table 2. Correlation coefficients and p-values in AA and EA BV- and BV+
 
 
women.  
  Black BV Black BV+ White BV- White BV+ - 
  Rho p Rho p Rho p Rho p 
EOTAXIN EGF 0.295 0.068 0.446 0.005 0.285 0.142 0.314 0.021 
FGF2 EGF 0.371 0.017 0.583 <0.001 0.288 0.138 0.230 0.095 
FGF2 EOTAXIN 0.550 <0.001 0.492 0.001 0.613 0.001 0.410 0.002 
FLT3 EGF 0.397 0.020 0.487 0.006 0.338 0.091 0.340 0.024 
FLT3 EOTAXIN 0.463 0.008 0.731 <0.001 0.018 0.931 0.422 0.004 
FLT3 FGF2 0.489 0.003 0.606 <0.001 0.323 0.107 0.385 0.010 
GM-CSF EGF 0.415 0.008 0.409 0.011 0.465 0.013 0.299 0.028 
GM-CSF EOTAXIN 0.652 <0.001 0.548 <0.001 0.522 0.004 0.514 <0.001 
GM-CSF FGF2 0.621 <0.001 0.642 <0.001 0.469 0.012 0.416 0.002 
GM-CSF FLT3 0.728 <0.001 0.666 <0.001 0.400 0.043 0.645 <0.001 
IFN-γ EGF 0.358 0.022 0.666 <0.001 0.378 0.047 0.318 0.019 
IFN-γ EOTAXIN 0.664 <0.001 0.571 <0.001 0.407 0.031 0.589 <0.001 
IFN-γ FGF2 0.445 0.004 0.508 0.001 0.505 0.006 0.410 0.002 
IFN-γ FLT3 0.586 <0.001 0.648 <0.001 0.704 <0.001 0.592 <0.001 
IFN-γ GM-CSF 0.667 <0.001 0.628 <0.001 0.608 0.001 0.688 <0.001 
IL-1α EGF 0.121 0.461 0.634 <0.001 -0.012 0.953 0.233 0.091 
IL-1α EOTAXIN -0.089 0.591 0.273 0.093 -0.349 0.069 -0.082 0.552 
IL-1α FGF2 -0.400 0.012 0.278 0.087 -0.241 0.217 -0.085 0.542 
IL-1α FLT3 0.033 0.858 0.317 0.082 0.424 0.031 0.180 0.237 
IL-1α GM-CSF -0.039 0.816 0.231 0.156 -0.065 0.742 0.120 0.381 
IL-1α IFN-γ 0.189 0.249 0.505 0.001 0.284 0.143 0.221 0.104 
IL-1β EGF 0.367 0.025 0.311 0.057 -0.028 0.889 0.116 0.405 
IL-1β EOTAXIN 0.072 0.673 0.180 0.272 -0.251 0.199 0.030 0.830 
IL-1β FGF2 -0.036 0.834 0.106 0.521 -0.064 0.747 -0.255 0.063 
IL-1β FLT3 0.050 0.791 0.355 0.050 0.646 <0.001 0.213 0.161 
IL-1β GM-CSF 0.270 0.106 0.220 0.177 0.181 0.355 0.132 0.335 
IL-1β IFN-γ 0.188 0.266 0.318 0.048 0.574 0.001 0.193 0.157 
IL-1β IL-1α 0.564 <0.001 0.620 <0.001 0.720 <0.001 0.620 <0.001 
IL-2 EGF 0.101 0.542 0.359 0.027 0.249 0.201 0.257 0.061 
IL-2 EOTAXIN 0.496 0.001 0.532 <0.001 0.450 0.016 0.276 0.042 
IL-2 FGF2 0.601 <0.001 0.612 <0.001 0.276 0.155 0.357 0.008 
IL-2 FLT3 0.642 <0.001 0.804 <0.001 0.410 0.038 0.658 <0.001 
IL-2 GM-CSF 0.791 <0.001 0.745 <0.001 0.638 <0.001 0.726 <0.001 
IL-2 IFN-γ 0.373 0.019 0.579 <0.001 0.356 0.063 0.522 <0.001 
IL-2 IL-1α -0.295 0.068 0.095 0.564 -0.066 0.738 -0.114 0.409 
IL-2 IL-1β 0.139 0.411 0.106 0.521 0.176 0.371 -0.006 0.963 
IL-3 EGF 0.313 0.052 0.276 0.094 0.291 0.141 0.317 0.022 
IL-3 EOTAXIN 0.590 <0.001 0.466 0.003 0.325 0.098 0.354 0.010 
IL-3 FGF2 0.592 <0.001 0.411 0.010 0.389 0.045 0.320 0.021 
IL-3 FLT3 0.769 <0.001 0.746 <0.001 0.627 0.001 0.683 <0.001 
IL-3 GM-CSF 0.826 <0.001 0.571 <0.001 0.714 <0.001 0.651 <0.001 
IL-3 IFN-γ 0.694 <0.001 0.454 0.004 0.737 <0.001 0.640 <0.001 
IL-3 IL-1α -0.047 0.778 0.155 0.352 0.151 0.451 0.167 0.237 
IL-3 IL-1β 0.232 0.174 0.345 0.034 0.521 0.005 0.225 0.109 
IL-3 IL-2 0.833 <0.001 0.672 <0.001 0.650 <0.001 0.555 <0.001 
IL-4 EGF 0.303 0.064 0.295 0.072 0.064 0.747 0.111 0.427 
IL-4 EOTAXIN 0.538 <0.001 0.667 <0.001 0.405 0.032 0.398 0.003 
IL-4 FGF2 0.334 0.041 0.350 0.029 0.098 0.618 0.139 0.322 
IL-4 FLT3 0.433 0.015 0.896 <0.001 -0.043 0.834 0.461 0.002 
IL-4 GM-CSF 0.320 0.050 0.606 <0.001 0.135 0.492 0.440 0.001 
IL-4 IFN-γ 0.554 <0.001 0.484 0.002 -0.061 0.756 0.323 0.017 
IL-4 IL-1α -0.221 0.182 0.163 0.321 -0.368 0.054 -0.090 0.518 
IL-4 IL-1β 0.092 0.588 0.193 0.239 -0.203 0.300 -0.049 0.727 
IL-4 IL-2 0.232 0.161 0.581 <0.001 0.488 0.008 0.395 0.003 
IL-4 IL-3 0.368 0.025 0.642 <0.001 0.153 0.446 0.311 0.026 
IL-5 EGF 0.319 0.042 0.248 0.133 0.591 0.001 0.017 0.901 
IL-5 EOTAXIN 0.716 <0.001 0.663 <0.001 0.337 0.080 0.479 <0.001 
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IL-5 FGF2 0.444 0.004 0.152 0.355 0.317 0.100 0.197 0.154 
IL-5 FLT3 0.597 <0.001 0.582 0.001 0.234 0.250 0.484 0.001 
IL-5 GM-CSF 0.598 <0.001 0.631 <0.001 0.515 0.005 0.611 <0.001 
IL-5 IFN-γ 0.566 <0.001 0.585 <0.001 0.365 0.056 0.580 <0.001 
IL-5 IL-1α -0.024 0.887 0.196 0.231 0.014 0.946 -0.154 0.262 
IL-5 IL-1β 0.004 0.980 0.320 0.047 -0.029 0.885 0.068 0.623 
IL-5 IL-2 0.476 0.002 0.445 0.004 0.128 0.516 0.394 0.003 
IL-5 IL-3 0.554 <0.001 0.401 0.013 0.198 0.322 0.387 0.005 
IL-5 IL-4 0.267 0.105 0.620 <0.001 0.001 0.997 0.245 0.074 
IL-6 EGF 0.177 0.294 0.284 0.084 0.149 0.479 0.111 0.429 
IL-6 EOTAXIN 0.314 0.062 0.588 <0.001 0.252 0.224 0.184 0.183 
IL-6 FGF2 0.244 0.146 0.327 0.045 0.289 0.161 0.093 0.506 
IL-6 FLT3 0.265 0.158 0.430 0.018 0.293 0.176 0.226 0.140 
IL-6 GM-CSF 0.353 0.032 0.306 0.062 0.466 0.019 0.232 0.092 
IL-6 IFN-γ 0.340 0.039 0.298 0.069 0.510 0.009 0.382 0.004 
IL-6 IL-1α 0.069 0.689 0.286 0.082 0.112 0.596 0.405 0.002 
IL-6 IL-1β 0.277 0.113 0.302 0.066 0.352 0.085 0.479 <0.001 
IL-6 IL-2 0.173 0.313 0.241 0.144 0.399 0.048 0.090 0.517 
IL-6 IL-3 0.409 0.013 0.224 0.176 0.778 <0.001 0.163 0.253 
IL-6 IL-4 0.221 0.201 0.271 0.100 -0.011 0.958 0.050 0.722 
IL-6 IL-5 0.066 0.698 0.422 0.008 -0.110 0.599 0.079 0.569 
IL-7 EGF 0.304 0.054 0.578 <0.001 0.310 0.108 0.363 0.007 
IL-7 EOTAXIN 0.630 <0.001 0.520 0.001 0.456 0.015 0.586 <0.001 
IL-7 FGF2 0.501 0.001 0.568 <0.001 0.605 0.001 0.394 0.003 
IL-7 FLT3 0.443 0.009 0.301 0.099 0.592 0.001 0.406 0.006 
IL-7 GM-CSF 0.670 <0.001 0.400 0.012 0.495 0.007 0.415 0.002 
IL-7 IFN-γ 0.741 <0.001 0.665 <0.001 0.716 <0.001 0.744 <0.001 
IL-7 IL-1α -0.033 0.844 0.671 <0.001 0.127 0.519 0.165 0.229 
IL-7 IL-1β -0.021 0.903 0.413 0.009 0.274 0.159 0.102 0.460 
IL-7 IL-2 0.345 0.032 0.291 0.072 0.126 0.522 0.218 0.109 
IL-7 IL-3 0.574 <0.001 0.147 0.379 0.476 0.012 0.450 0.001 
IL-7 IL-4 0.174 0.297 0.072 0.662 -0.124 0.529 0.078 0.576 
IL-7 IL-5 0.633 <0.001 0.314 0.052 0.266 0.171 0.434 0.001 
IL-7 IL-6 0.130 0.442 0.444 0.005 0.396 0.050 0.206 0.134 
IL-8 EGF 0.132 0.415 0.327 0.048 0.159 0.427 0.167 0.227 
IL-8 EOTAXIN 0.099 0.547 0.175 0.294 -0.189 0.344 -0.066 0.634 
IL-8 FGF2 0.136 0.402 0.074 0.661 -0.059 0.769 -0.129 0.351 
IL-8 FLT3 0.303 0.087 0.305 0.102 0.013 0.950 0.049 0.752 
IL-8 GM-CSF 0.264 0.100 -0.077 0.646 0.273 0.168 -0.165 0.230 
IL-8 IFN-γ 0.199 0.218 0.205 0.218 0.211 0.290 -0.171 0.212 
IL-8 IL-1α 0.337 0.036 0.281 0.088 0.244 0.219 0.495 <0.001 
IL-8 IL-1β 0.527 0.001 0.339 0.038 0.338 0.084 0.464 <0.001 
IL-8 IL-2 0.241 0.140 -0.084 0.614 -0.019 0.926 -0.175 0.201 
IL-8 IL-3 0.384 0.016 0.058 0.733 0.447 0.022 0.007 0.961 
IL-8 IL-4 0.057 0.733 0.259 0.117 -0.177 0.378 -0.077 0.579 
IL-8 IL-5 0.145 0.371 0.077 0.645 0.124 0.536 -0.272 0.045 
IL-8 IL-6 0.559 <0.001 0.332 0.045 0.565 0.003 0.316 0.020 
IL-8 IL-7 0.051 0.756 0.086 0.608 -0.003 0.989 -0.182 0.184 
IL-10 EGF 0.473 0.002 0.534 0.001 0.392 0.039 0.407 0.002 
IL-10 EOTAXIN 0.504 0.001 0.628 <0.001 0.635 <0.001 0.455 <0.001 
IL-10 FGF2 0.519 0.001 0.749 <0.001 0.573 0.001 0.425 0.001 
IL-10 FLT3 0.703 <0.001 0.686 <0.001 0.107 0.602 0.617 <0.001 
IL-10 GM-CSF 0.686 <0.001 0.795 <0.001 0.688 <0.001 0.633 <0.001 
IL-10 IFN-γ 0.660 <0.001 0.646 <0.001 0.347 0.070 0.582 <0.001 
IL-10 IL-1α 0.011 0.949 0.333 0.038 -0.233 0.232 -0.032 0.814 
IL-10 IL-1β 0.303 0.069 0.248 0.128 -0.134 0.498 -0.116 0.401 
IL-10 IL-2 0.403 0.011 0.767 <0.001 0.523 0.004 0.589 <0.001 
IL-10 IL-3 0.561 <0.001 0.581 <0.001 0.365 0.061 0.589 <0.001 
IL-10 IL-4 0.680 <0.001 0.550 <0.001 0.284 0.143 0.539 <0.001 
IL-10 IL-5 0.444 0.004 0.522 0.001 0.520 0.005 0.375 0.005 
IL-10 IL-6 0.493 0.002 0.378 0.019 0.252 0.225 0.293 0.032 
IL-10 IL-7 0.461 0.002 0.603 <0.001 0.474 0.011 0.391 0.003 
IL-10 IL-8 0.440 0.004 -0.138 0.407 0.082 0.684 -0.125 0.361 
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IL-12p40 EGF 0.357 0.038 0.289 0.082 0.319 0.105 0.331 0.016 
IL-12p40 EOTAXIN 0.227 0.196 0.228 0.168 0.011 0.957 0.230 0.094 
IL-12p40 FGF2 0.363 0.035 0.563 <0.001 0.233 0.241 0.152 0.278 
IL-12p40 FLT3 0.587 0.001 0.624 <0.001 0.504 0.010 0.266 0.080 
IL-12p40 GM-CSF 0.479 0.004 0.282 0.086 0.527 0.005 0.351 0.009 
IL-12p40 IFN-γ 0.303 0.082 0.110 0.511 0.334 0.089 0.184 0.183 
IL-12p40 IL-1α 0.042 0.813 0.191 0.252 0.098 0.628 0.097 0.487 
IL-12p40 IL-1β 0.371 0.031 0.282 0.086 0.351 0.073 0.282 0.039 
IL-12p40 IL-2 0.442 0.009 0.539 <0.001 0.502 0.008 0.412 0.002 
IL-12p40 IL-3 0.569 0.001 0.641 <0.001 0.524 0.006 0.457 0.001 
IL-12p40 IL-4 0.267 0.127 0.320 0.050 0.284 0.152 0.244 0.075 
IL-12p40 IL-5 -0.176 0.319 -0.041 0.808 0.305 0.122 0.021 0.880 
IL-12p40 IL-6 0.434 0.015 0.164 0.332 0.475 0.016 0.308 0.025 
IL-12p40 IL-7 0.080 0.654 0.156 0.349 0.149 0.459 0.041 0.767 
IL-12p40 IL-8 0.434 0.010 0.101 0.554 0.287 0.147 0.315 0.020 
IL-12p40 IL-10 0.455 0.007 0.470 0.003 0.402 0.037 0.368 0.006 
IL-12p70 EGF 0.102 0.532 0.255 0.122 0.455 0.017 0.267 0.051 
IL-12p70 EOTAXIN 0.523 0.001 0.549 <0.001 0.345 0.078 0.490 <0.001 
IL-12p70 FGF2 0.565 <0.001 0.442 0.005 0.535 0.004 0.420 0.002 
IL-12p70 FLT3 0.601 <0.001 0.679 <0.001 0.712 <0.001 0.645 <0.001 
IL-12p70 GM-CSF 0.763 <0.001 0.696 <0.001 0.681 <0.001 0.680 <0.001 
IL-12p70 IFN-γ 0.674 <0.001 0.548 <0.001 0.821 <0.001 0.790 <0.001 
IL-12p70 IL-1α -0.197 0.237 0.208 0.204 0.121 0.548 0.095 0.490 
IL-12p70 IL-1β 0.020 0.908 -0.060 0.715 0.448 0.019 -0.033 0.809 
IL-12p70 IL-2 0.690 <0.001 0.663 <0.001 0.576 0.002 0.600 <0.001 
IL-12p70 IL-3 0.739 <0.001 0.535 0.001 0.870 <0.001 0.646 <0.001 
IL-12p70 IL-4 0.293 0.074 0.623 <0.001 -0.023 0.910 0.403 0.003 
IL-12p70 IL-5 0.492 0.001 0.495 0.001 0.303 0.125 0.551 <0.001 
IL-12p70 IL-6 0.302 0.073 0.347 0.033 0.687 <0.001 0.178 0.199 
IL-12p70 IL-7 0.673 <0.001 0.292 0.071 0.639 <0.001 0.546 <0.001 
IL-12p70 IL-8 0.130 0.431 -0.193 0.246 0.252 0.205 -0.091 0.507 
IL-12p70 IL-10 0.502 0.001 0.690 <0.001 0.427 0.026 0.691 <0.001 
IL-12p70 IL-12p40 0.325 0.061 0.298 0.069 0.418 0.030 0.220 0.110 
IL-13 EGF 0.325 0.044 0.311 0.057 0.468 0.012 0.351 0.009 
IL-13 EOTAXIN 0.434 0.007 0.475 0.002 0.409 0.031 0.470 <0.001 
IL-13 FGF2 0.417 0.008 0.490 0.002 0.361 0.059 0.392 0.003 
IL-13 FLT3 0.646 <0.001 0.496 0.005 0.340 0.089 0.532 <0.001 
IL-13 GM-CSF 0.788 <0.001 0.843 <0.001 0.800 <0.001 0.794 <0.001 
IL-13 IFN-γ 0.551 <0.001 0.581 <0.001 0.434 0.021 0.659 <0.001 
IL-13 IL-1α 0.043 0.796 0.184 0.263 -0.057 0.774 -0.025 0.857 
IL-13 IL-1β 0.334 0.044 0.097 0.558 0.097 0.623 -0.077 0.576 
IL-13 IL-2 0.683 <0.001 0.704 <0.001 0.629 <0.001 0.651 <0.001 
IL-13 IL-3 0.749 <0.001 0.431 0.007 0.549 0.003 0.487 <0.001 
IL-13 IL-4 0.303 0.064 0.434 0.006 0.323 0.094 0.452 0.001 
IL-13 IL-5 0.536 <0.001 0.587 <0.001 0.467 0.012 0.629 <0.001 
IL-13 IL-6 0.230 0.184 0.272 0.098 0.412 0.040 0.094 0.500 
IL-13 IL-7 0.509 0.001 0.461 0.003 0.255 0.191 0.421 0.001 
IL-13 IL-8 0.244 0.140 -0.282 0.086 0.209 0.296 -0.186 0.174 
IL-13 IL-10 0.587 <0.001 0.797 <0.001 0.642 <0.001 0.675 <0.001 
IL-13 IL-12p40 0.298 0.087 0.137 0.412 0.721 <0.001 0.221 0.108 
IL-13 IL-12p70 0.620 <0.001 0.745 <0.001 0.544 0.003 0.688 <0.001 
IL-15 EGF 0.212 0.200 0.427 0.007 0.469 0.012 0.377 0.005 
IL-15 EOTAXIN 0.614 <0.001 0.613 <0.001 0.500 0.007 0.422 0.001 
IL-15 FGF2 0.692 <0.001 0.550 <0.001 0.621 <0.001 0.521 <0.001 
IL-15 FLT3 0.688 <0.001 0.617 <0.001 0.537 0.005 0.668 <0.001 
IL-15 GM-CSF 0.805 <0.001 0.666 <0.001 0.845 <0.001 0.760 <0.001 
IL-15 IFN-γ 0.610 <0.001 0.465 0.003 0.740 <0.001 0.688 <0.001 
IL-15 IL-1α -0.168 0.315 0.216 0.187 0.029 0.886 0.012 0.929 
IL-15 IL-1β 0.128 0.452 0.133 0.420 0.342 0.075 -0.057 0.679 
IL-15 IL-2 0.769 <0.001 0.744 <0.001 0.565 0.002 0.784 <0.001 
IL-15 IL-3 0.799 <0.001 0.596 <0.001 0.743 <0.001 0.618 <0.001 
IL-15 IL-4 0.419 0.009 0.659 <0.001 0.141 0.473 0.391 0.003 
IL-15 IL-5 0.487 0.002 0.433 0.006 0.452 0.016 0.434 0.001 
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IL-15 IL-6 0.372 0.028 0.443 0.005 0.666 <0.001 0.281 0.039 
IL-15 IL-7 0.520 0.001 0.326 0.043 0.625 <0.001 0.430 0.001 
IL-15 IL-8 0.368 0.023 0.121 0.470 0.298 0.132 -0.117 0.393 
IL-15 IL-10 0.648 <0.001 0.682 <0.001 0.643 <0.001 0.785 <0.001 
IL-15 IL-12p40 0.513 0.002 0.549 <0.001 0.587 0.001 0.408 0.002 
IL-15 IL-12p70 0.708 <0.001 0.701 <0.001 0.831 <0.001 0.749 <0.001 
IL-15 IL-13 0.682 <0.001 0.584 <0.001 0.797 <0.001 0.709 <0.001 
IP10 EGF 0.274 0.083 0.076 0.651 0.225 0.250 0.125 0.367 
IP10 EOTAXIN 0.036 0.826 0.030 0.858 0.577 0.001 0.064 0.644 
IP10 FGF2 0.108 0.501 -0.167 0.309 0.362 0.058 -0.027 0.845 
IP10 FLT3 0.228 0.196 0.106 0.570 -0.218 0.284 0.214 0.157 
IP10 GM-CSF 0.115 0.481 -0.271 0.095 0.073 0.713 0.201 0.142 
IP10 IFN-γ 0.206 0.195 -0.015 0.927 -0.011 0.954 0.126 0.360 
IP10 IL-1α -0.002 0.988 0.393 0.013 -0.464 0.013 0.198 0.148 
IP10 IL-1β -0.065 0.701 0.238 0.145 -0.545 0.003 0.155 0.259 
IP10 IL-2 -0.197 0.230 -0.249 0.126 0.144 0.466 0.141 0.305 
IP10 IL-3 0.097 0.555 -0.079 0.635 -0.060 0.767 -0.043 0.763 
IP10 IL-4 0.186 0.265 -0.026 0.875 0.232 0.235 0.219 0.112 
IP10 IL-5 0.094 0.561 -0.070 0.674 0.098 0.620 0.044 0.749 
IP10 IL-6 0.421 0.010 0.116 0.488 0.172 0.410 0.448 0.001 
IP10 IL-7 0.164 0.307 0.017 0.918 0.166 0.398 -0.078 0.569 
IP10 IL-8 0.295 0.064 0.226 0.172 -0.199 0.320 0.187 0.172 
IP10 IL-10 0.330 0.035 -0.306 0.058 0.319 0.098 0.229 0.093 
IP10 IL-12p40 0.174 0.326 0.082 0.626 -0.231 0.246 0.253 0.064 
IP10 IL-12p70 0.120 0.461 -0.096 0.562 0.054 0.790 0.077 0.576 
IP10 IL-13 -0.003 0.986 -0.352 0.028 0.041 0.836 0.165 0.229 
IP10 IL-15 0.190 0.253 -0.199 0.224 0.171 0.383 0.212 0.120 
MCP1 EGF 0.392 0.014 0.254 0.124 0.138 0.493 0.122 0.387 
MCP1 EOTAXIN 0.253 0.126 0.173 0.293 0.533 0.004 0.221 0.111 
MCP1 FGF2 0.349 0.029 0.214 0.191 0.410 0.034 0.196 0.164 
MCP1 FLT3 0.423 0.016 0.532 0.002 0.125 0.553 0.173 0.267 
MCP1 GM-CSF 0.430 0.006 0.254 0.119 0.411 0.033 0.177 0.206 
MCP1 IFN-γ 0.326 0.043 0.328 0.042 0.194 0.332 0.183 0.188 
MCP1 IL-1α -0.144 0.389 0.431 0.006 -0.341 0.081 0.063 0.652 
MCP1 IL-1β -0.008 0.961 0.478 0.002 -0.141 0.484 0.145 0.300 
MCP1 IL-2 0.196 0.238 0.324 0.044 0.557 0.003 0.189 0.175 
MCP1 IL-3 0.320 0.050 0.387 0.016 0.426 0.030 0.204 0.155 
MCP1 IL-4 0.313 0.055 0.340 0.034 0.269 0.174 0.082 0.560 
MCP1 IL-5 0.170 0.302 0.194 0.238 -0.164 0.412 0.109 0.437 
MCP1 IL-6 0.611 <0.001 0.295 0.072 0.525 0.007 0.538 <0.001 
MCP1 IL-7 0.318 0.048 0.176 0.284 0.316 0.108 0.080 0.570 
MCP1 IL-8 0.251 0.124 0.064 0.704 -0.036 0.857 0.235 0.090 
MCP1 IL-10 0.592 <0.001 0.281 0.083 0.394 0.042 0.319 0.020 
MCP1 IL-12p40 0.460 0.006 0.391 0.015 0.132 0.511 0.324 0.018 
MCP1 IL-12p70 0.258 0.113 0.282 0.082 0.442 0.021 0.197 0.156 
MCP1 IL-13 0.404 0.012 0.218 0.182 0.346 0.077 0.169 0.226 
MCP1 IL-15 0.415 0.010 0.207 0.207 0.512 0.006 0.326 0.017 
MCP1 IP10 0.494 0.001 0.411 0.009 0.673 <0.001 0.455 0.001 
MIP-1α  EGF 0.415 0.008 0.388 0.016 0.460 0.014 0.190 0.169 
MIP-1α  EOTAXIN 0.489 0.002 0.173 0.293 0.415 0.028 0.221 0.105 
MIP-1α  FGF2 0.466 0.002 0.347 0.030 0.428 0.023 0.019 0.893 
MIP-1α  FLT3 0.450 0.009 0.363 0.045 0.479 0.013 0.272 0.071 
MIP-1α  GM-CSF 0.741 <0.001 0.360 0.024 0.726 <0.001 0.304 0.024 
MIP-1α  IFN-γ 0.502 0.001 0.552 <0.001 0.645 <0.001 0.358 0.007 
MIP-1α  IL-1α -0.086 0.604 0.402 0.011 0.033 0.866 0.314 0.020 
MIP-1α  IL-1β 0.360 0.029 0.399 0.012 0.334 0.082 0.542 <0.001 
MIP-1α  IL-2 0.530 0.001 0.465 0.003 0.723 <0.001 0.377 0.005 
MIP-1α  IL-3 0.654 <0.001 0.456 0.004 0.839 <0.001 0.198 0.160 
MIP-1α  IL-4 0.405 0.012 0.106 0.522 0.086 0.662 0.074 0.597 
MIP-1α  IL-5 0.292 0.067 0.271 0.095 0.185 0.346 0.188 0.168 
MIP-1α  IL-6 0.692 <0.001 0.310 0.059 0.692 <0.001 0.741 <0.001 
MIP-1α  IL-7 0.375 0.017 0.447 0.004 0.421 0.026 0.253 0.062 
MIP-1α  IL-8 0.435 0.005 0.082 0.624 0.407 0.035 0.230 0.092 
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MIP-1α  IL-10 0.675 <0.001 0.402 0.011 0.536 0.003 0.255 0.060 
MIP-1α  IL-12p40 0.652 <0.001 0.416 0.009 0.411 0.033 0.437 0.001 
MIP-1α  IL-12p70 0.495 0.001 0.348 0.030 0.846 <0.001 0.242 0.075 
MIP-1α  IL-13 0.643 <0.001 0.350 0.029 0.596 0.001 0.217 0.111 
MIP-1α  IL-15 0.676 <0.001 0.254 0.118 0.766 <0.001 0.343 0.010 
MIP-1α  IP10 0.364 0.021 0.144 0.383 0.167 0.396 0.381 0.004 
MIP-1α  MCP1 0.715 <0.001 0.557 <0.001 0.602 0.001 0.521 <0.001 
PDGF-AA EGF 0.536 <0.001 0.707 <0.001 0.524 0.004 0.659 <0.001 
PDGF-AA EOTAXIN 0.413 0.009 0.385 0.016 0.249 0.201 0.378 0.004 
PDGF-AA FGF2 0.316 0.044 0.536 <0.001 0.421 0.026 0.458 <0.001 
PDGF-AA FLT3 0.347 0.044 0.445 0.012 0.287 0.156 0.353 0.018 
PDGF-AA GM-CSF 0.202 0.212 0.304 0.060 0.357 0.063 0.396 0.003 
PDGF-AA IFN-γ 0.405 0.009 0.596 <0.001 0.452 0.016 0.498 <0.001 
PDGF-AA IL-1α 0.064 0.701 0.431 0.006 -0.090 0.648 0.243 0.073 
PDGF-AA IL-1β -0.091 0.592 0.172 0.295 -0.083 0.676 -0.013 0.928 
PDGF-AA IL-2 -0.163 0.321 0.231 0.158 0.072 0.715 0.369 0.006 
PDGF-AA IL-3 0.077 0.642 0.012 0.943 0.378 0.052 0.378 0.006 
PDGF-AA IL-4 0.417 0.009 0.268 0.099 -0.109 0.580 0.191 0.166 
PDGF-AA IL-5 0.306 0.052 0.154 0.349 0.175 0.374 0.037 0.788 
PDGF-AA IL-6 0.253 0.131 0.353 0.030 0.398 0.049 0.427 0.001 
PDGF-AA IL-7 0.270 0.088 0.496 0.001 0.509 0.006 0.439 0.001 
PDGF-AA IL-8 0.085 0.603 0.399 0.013 0.256 0.197 0.129 0.347 
PDGF-AA IL-10 0.443 0.004 0.390 0.014 0.233 0.232 0.541 <0.001 
PDGF-AA IL-12p40 0.075 0.675 0.054 0.747 0.106 0.600 0.316 0.020 
PDGF-AA IL-12p70 0.085 0.604 0.199 0.225 0.488 0.010 0.502 <0.001 
PDGF-AA IL-13 0.045 0.783 0.203 0.216 0.229 0.241 0.401 0.002 
PDGF-AA IL-15 0.207 0.212 0.261 0.108 0.456 0.015 0.557 <0.001 
PDGF-AA IP10 0.387 0.012 0.121 0.464 0.506 0.006 0.281 0.038 
PDGF-AA MCP1 0.448 0.004 0.192 0.241 0.488 0.010 0.451 0.001 
PDGF-AA MIP-1α  0.299 0.061 0.238 0.145 0.464 0.013 0.328 0.014 
PDGF-BB EGF 0.583 <0.001 0.623 <0.001 0.518 0.005 0.354 0.009 
PDGF-BB EOTAXIN 0.549 <0.001 0.309 0.059 0.309 0.110 0.327 0.015 
PDGF-BB FGF2 0.649 <0.001 0.564 <0.001 0.598 0.001 0.393 0.003 
PDGF-BB FLT3 0.492 0.003 0.544 0.002 0.329 0.101 0.424 0.004 
PDGF-BB GM-CSF 0.495 0.001 0.498 0.001 0.257 0.188 0.378 0.004 
PDGF-BB IFN-γ 0.561 <0.001 0.650 <0.001 0.390 0.040 0.457 <0.001 
PDGF-BB IL-1α -0.118 0.474 0.415 0.010 -0.098 0.620 -0.040 0.774 
PDGF-BB IL-1β 0.025 0.885 0.375 0.021 -0.054 0.785 -0.189 0.167 
PDGF-BB IL-2 0.209 0.202 0.468 0.003 0.107 0.587 0.394 0.003 
PDGF-BB IL-3 0.409 0.010 0.366 0.026 0.206 0.302 0.388 0.004 
PDGF-BB IL-4 0.405 0.012 0.385 0.017 0.025 0.901 0.396 0.003 
PDGF-BB IL-5 0.401 0.009 0.328 0.044 0.429 0.023 0.225 0.098 
PDGF-BB IL-6 0.359 0.029 0.092 0.589 0.296 0.151 0.159 0.252 
PDGF-BB IL-7 0.521 <0.001 0.404 0.012 0.472 0.011 0.396 0.003 
PDGF-BB IL-8 0.164 0.311 0.293 0.078 0.075 0.712 -0.084 0.543 
PDGF-BB IL-10 0.549 <0.001 0.565 <0.001 0.427 0.023 0.591 <0.001 
PDGF-BB IL-12p40 0.367 0.033 0.294 0.077 0.332 0.091 0.316 0.020 
PDGF-BB IL-12p70 0.358 0.023 0.294 0.073 0.400 0.038 0.532 <0.001 
PDGF-BB IL-13 0.261 0.108 0.405 0.012 0.249 0.201 0.399 0.003 
PDGF-BB IL-15 0.433 0.007 0.308 0.060 0.510 0.006 0.544 <0.001 
PDGF-BB IP10 0.438 0.004 0.024 0.886 0.513 0.005 0.240 0.077 
PDGF-BB MCP1 0.572 <0.001 0.275 0.094 0.408 0.034 0.293 0.033 
PDGF-BB MIP-1α  0.486 0.001 0.464 0.003 0.316 0.102 0.089 0.519 
PDGF-BB PDGF-AA 0.578 <0.001 0.607 <0.001 0.665 <0.001 0.596 <0.001 
RANTES EGF 0.274 0.083 0.345 0.034 0.289 0.143 0.159 0.250 
RANTES EOTAXIN 0.558 <0.001 0.243 0.136 0.469 0.014 0.271 0.045 
RANTES FGF2 0.608 <0.001 0.556 <0.001 0.469 0.014 0.443 0.001 
RANTES FLT3 0.467 0.005 0.240 0.194 -0.211 0.311 0.089 0.560 
RANTES GM-CSF 0.442 0.004 0.170 0.300 0.249 0.210 0.102 0.457 
RANTES IFN-γ 0.495 0.001 0.171 0.297 0.229 0.250 0.305 0.024 
RANTES IL-1α -0.256 0.115 0.328 0.042 -0.113 0.575 0.189 0.168 
RANTES IL-1β -0.087 0.608 0.118 0.474 -0.206 0.303 0.162 0.236 
RANTES IL-2 0.320 0.047 0.243 0.136 0.029 0.885 0.118 0.393 
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RANTES IL-3 0.496 0.001 0.204 0.220 0.215 0.292 0.140 0.322 
RANTES IL-4 0.303 0.064 0.197 0.229 -0.025 0.900 -0.017 0.905 
RANTES IL-5 0.387 0.012 -0.098 0.552 0.110 0.584 0.016 0.910 
RANTES IL-6 0.579 <0.001 0.374 0.021 0.535 0.006 0.570 <0.001 
RANTES IL-7 0.485 0.001 0.329 0.041 0.296 0.134 0.261 0.054 
RANTES IL-8 0.268 0.095 0.450 0.005 0.406 0.036 0.361 0.007 
RANTES IL-10 0.463 0.002 0.260 0.110 0.450 0.019 0.259 0.057 
RANTES IL-12p40 0.437 0.010 0.492 0.002 0.019 0.924 0.453 0.001 
RANTES IL-12p70 0.365 0.021 0.151 0.360 0.248 0.213 0.267 0.049 
RANTES IL-13 0.246 0.130 0.050 0.764 0.197 0.325 0.074 0.593 
RANTES IL-15 0.536 0.001 0.405 0.011 0.337 0.086 0.331 0.014 
RANTES IP10 0.414 0.007 0.179 0.276 0.522 0.005 0.181 0.186 
RANTES MCP1 0.582 <0.001 0.185 0.259 0.421 0.029 0.393 0.004 
RANTES MIP-1α  0.547 <0.001 0.334 0.038 0.449 0.019 0.410 0.002 
RANTES PDGF-AA 0.397 0.010 0.398 0.012 0.551 0.003 0.484 <0.001 
RANTES PDGF-BB 0.633 <0.001 0.387 0.016 0.472 0.013 0.387 0.003 
TNF-α EGF 0.402 0.009 0.505 0.001 0.613 0.001 0.282 0.039 
TNF-α EOTAXIN 0.614 <0.001 0.502 0.001 0.582 0.001 0.561 <0.001 
TNF-α FGF2 0.765 <0.001 0.651 <0.001 0.521 0.004 0.494 <0.001 
TNF-α FLT3 0.493 0.003 0.570 0.001 0.386 0.052 0.501 <0.001 
TNF-α GM-CSF 0.724 <0.001 0.670 <0.001 0.599 0.001 0.708 <0.001 
TNF-α IFN-γ 0.686 <0.001 0.628 <0.001 0.578 0.001 0.665 <0.001 
TNF-α IL-1α -0.356 0.026 0.254 0.118 -0.079 0.688 -0.128 0.353 
TNF-α IL-1β -0.053 0.756 0.121 0.465 0.079 0.689 -0.055 0.692 
TNF-α IL-2 0.565 <0.001 0.638 <0.001 0.418 0.027 0.618 <0.001 
TNF-α IL-3 0.660 <0.001 0.318 0.052 0.418 0.030 0.440 0.001 
TNF-α IL-4 0.508 0.001 0.396 0.013 0.260 0.181 0.564 <0.001 
TNF-α IL-5 0.539 <0.001 0.421 0.008 0.410 0.030 0.579 <0.001 
TNF-α IL-6 0.198 0.241 0.334 0.040 0.182 0.384 0.119 0.392 
TNF-α IL-7 0.741 <0.001 0.498 0.001 0.645 <0.001 0.501 <0.001 
TNF-α IL-8 0.076 0.643 -0.178 0.284 -0.095 0.638 -0.356 0.008 
TNF-α IL-10 0.654 <0.001 0.777 <0.001 0.590 0.001 0.582 <0.001 
TNF-α IL-12p40 0.183 0.300 0.242 0.144 0.189 0.346 0.115 0.409 
TNF-α IL-12p70 0.719 <0.001 0.614 <0.001 0.507 0.007 0.548 <0.001 
TNF-α IL-13 0.539 <0.001 0.697 <0.001 0.372 0.051 0.732 <0.001 
TNF-α IL-15 0.631 <0.001 0.482 0.002 0.610 0.001 0.650 <0.001 
TNF-α IP10 0.157 0.326 -0.192 0.242 0.303 0.118 0.052 0.707 
TNF-α MCP1 0.389 0.014 0.358 0.025 0.298 0.132 0.115 0.413 
TNF-α MIP-1α  0.532 <0.001 0.369 0.021 0.469 0.012 0.222 0.103 
TNF-α PDGF-AA 0.319 0.042 0.420 0.008 0.429 0.023 0.364 0.006 
TNF-α PDGF-BB 0.596 <0.001 0.563 <0.001 0.481 0.010 0.378 0.004 
TNF-α RANTES 0.439 0.004 0.150 0.363 0.222 0.266 0.097 0.483 
VEGF EGF 0.358 0.021 0.379 0.019 0.179 0.363 0.178 0.199 
VEGF EOTAXIN 0.104 0.530 0.092 0.581 0.390 0.040 0.095 0.496 
VEGF FGF2 0.146 0.363 0.058 0.728 0.542 0.003 -0.039 0.780 
VEGF FLT3 0.246 0.161 0.236 0.209 0.436 0.026 0.238 0.120 
VEGF GM-CSF 0.170 0.295 0.270 0.101 0.389 0.041 0.221 0.108 
VEGF IFN-γ 0.173 0.280 0.340 0.037 0.643 <0.001 0.356 0.008 
VEGF IL-1α 0.257 0.114 0.521 0.001 0.320 0.097 0.367 0.006 
VEGF IL-1β 0.337 0.041 0.437 0.006 0.360 0.060 0.522 <0.001 
VEGF IL-2 0.042 0.799 0.008 0.961 0.199 0.311 0.050 0.720 
VEGF IL-3 0.216 0.186 0.143 0.393 0.512 0.006 0.290 0.037 
VEGF IL-4 -0.009 0.956 0.137 0.412 -0.129 0.514 0.048 0.732 
VEGF IL-5 0.328 0.037 0.219 0.186 0.120 0.543 0.193 0.163 
VEGF IL-6 0.097 0.568 -0.009 0.956 0.683 <0.001 0.261 0.060 
VEGF IL-7 0.197 0.218 0.252 0.128 0.734 <0.001 0.260 0.058 
VEGF IL-8 0.397 0.011 0.285 0.087 0.163 0.417 0.044 0.753 
VEGF IL-10 0.255 0.108 0.049 0.770 0.360 0.060 -0.051 0.712 
VEGF IL-12p40 -0.040 0.821 0.066 0.698 0.318 0.106 0.085 0.544 
VEGF IL-12p70 0.097 0.553 0.152 0.363 0.621 0.001 0.250 0.068 
VEGF IL-13 0.035 0.833 0.111 0.508 0.305 0.115 0.079 0.569 
VEGF IL-15 0.158 0.343 0.173 0.298 0.594 0.001 <0.00
 
1.000 
VEGF IP10 0.370 0.017 0.216 0.193 0.089 0.652 -0.008 0.953 
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VEGF MCP1 -0.039 0.812 -0.008 0.963 0.275 0.165 -0.065 0.646 
VEGF MIP-1α  0.115 0.481 0.132 0.430 0.469 0.012 0.258 0.060 
VEGF PDGF-AA 0.115 0.475 0.201 0.225 0.354 0.064 0.162 0.241 
VEGF PDGF-BB 0.211 0.185 0.329 0.047 0.426 0.024 0.166 0.229 
VEGF RANTES 0.074 0.645 0.035 0.834 0.464 0.015 0.110 0.429 
VEGF TNF-α 0.168 0.292 -0.049 0.772 0.440 0.019 0.046 0.742 
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Appendix Table 3. Significant p-values for heterogeneity between correlation 
coefficients. 
 
Pairwise Correlation Comparison Group p 
IL-1β FLT3 BV+ vs BV EA - 0.033 
IL-4 FLT3 BV+ vs BV EA - 0.037 
IL-5 EGF BV+ vs BV EA - 0.007 
IL-6 IL-3 BV+ vs BV EA - 0.001 
IL-10 FLT3 BV+ vs BV EA - 0.018 
IL-12p70 IL-1β BV+ vs BV EA - 0.037 
IL-12p70 IL-3 BV+ vs BV EA - 0.025 
IL-12p70 IL-6 BV+ vs BV EA - 0.009 
IL-13 IL-12p40 BV+ vs BV EA - 0.006 
IL-15 IL-6 BV+ vs BV EA - 0.044 
IP10 EOTAXIN BV+ vs BV EA - 0.015 
IP10 IL-1α BV+ vs BV EA - 0.004 
IP10 IL-1β BV+ vs BV EA - 0.002 
IP10 IL-12p40 BV+ vs BV EA - 0.046 
MIP-1α GM-CSF BV+ vs BV EA - 0.013 
MIP-1α IL-2 BV+ vs BV EA - 0.034 
MIP-1α IL-3 BV+ vs BV EA - <0.001 
MIP-1α IL-12p70 BV+ vs BV EA - <0.001 
MIP-1α IL-15 BV+ vs BV EA - 0.007 
TNF-α IL-13 BV+ vs BV EA - 0.026 
VEGF FGF2 BV+ vs BV EA - 0.008 
VEGF IL-6 BV+ vs BV EA - 0.026 
VEGF IL-7 BV+ vs BV EA - 0.006 
VEGF IL-15 BV+ vs BV EA - 0.005 
IL-1α EGF BV+ vs BV AA - 0.008 
IL-1α FGF2 BV+ vs BV AA - 0.003 
IL-3 GM-CSF BV+ vs BV AA - 0.026 
IL-4 FLT3 BV+ vs BV AA - <0.001 
IL-7 IL-1α BV+ vs BV AA - <0.001 
IL-7 IL-3 BV+ vs BV AA - 0.033 
IL-10 IL-2 BV+ vs BV AA - 0.013 
IL-10 IL-8 BV+ vs BV AA - 0.009 
IL-12p70 IL-7 BV+ vs BV AA - 0.028 
IL-13 IL-3 BV+ vs BV AA - 0.035 
IL-13 IL-8 BV+ vs BV AA - 0.024 
IP10 IL-10 BV+ vs BV AA - 0.005 
MCP1 IL-1α BV+ vs BV AA - 0.011 
MCP1 IL-1β BV+ vs BV AA - 0.027 
MIP-1α GM-CSF BV+ vs BV AA - 0.014 
MIP-1α IL-1α BV+ vs BV AA - 0.03 
MIP-1α IL-6 BV+ vs BV AA - 0.028 
MIP-1α IL-15 BV+ vs BV AA - 0.018 
PDGF-BB IL-1α BV+ vs BV AA - 0.018 
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RANTES IL-1α BV+ vs BV AA - 0.011 
RANTES IL-5 BV+ vs BV AA - 0.029 
RANTES MCP1 BV+ vs BV AA - 0.042 
TNF-α IL-1α BV+ vs BV AA - 0.007 
IL-1β FLT3 AA vs EA BV 0.011 + 
IL-4 IFN-γ AA vs EA BV 0.009 + 
IL-5 EOTAXIN AA vs EA BV 0.035 + 
IL-6 IL-3 AA vs EA BV 0.03 + 
IL-10 FLT3 AA vs EA BV 0.005 + 
IL-10 IL-4 AA vs EA BV 0.04 + 
IL-13 IL-12p40 AA vs EA BV 0.027 + 
IP10 EOTAXIN AA vs EA BV 0.017 + 
IP10 IL-1β AA vs EA BV 0.038 + 
MIP-1α IL-12p70 AA vs EA BV 0.008 + 
PDGF-AA IL-4 AA vs EA BV 0.034 + 
RANTES FLT3 AA vs EA BV 0.01 + 
VEGF IFN-γ AA vs EA BV 0.022 + 
VEGF IL-6 AA vs EA BV 0.007 + 
VEGF IL-7 AA vs EA BV 0.004 + 
VEGF IL-12p70 AA vs EA BV 0.016 + 
VEGF IL-15 AA vs EA BV 0.045 + 
FGF2 EGF AA vs EA BV 0.049 - 
FLT3 EOTAXIN AA vs EA BV 0.049 - 
IFN-γ EGF AA vs EA BV 0.031 - 
IL-1α EGF AA vs EA BV 0.02 - 
IL-4 FLT3 AA vs EA BV <0.001 - 
IL-4 IL-3 AA vs EA BV 0.048 - 
IL-5 IL-4 AA vs EA BV 0.029 - 
IL-6 EOTAXIN AA vs EA BV 0.026 - 
IL-7 IL-1α AA vs EA BV 0.003 - 
IL-10 FGF2 AA vs EA BV 0.018 - 
IL-12p40 FGF2 AA vs EA BV 0.028 - 
IL-12p70 IFN-γ AA vs EA BV 0.036 - 
IP10 GM-CSF AA vs EA BV 0.026 - 
IP10 IL-10 AA vs EA BV 0.011 - 
IP10 IL-13 AA vs EA BV 0.014 - 
MIP-1α IL-6 AA vs EA BV 0.004 - 
PDGF-BB IL-1α AA vs EA BV 0.028 - 
PDGF-BB IL-1β AA vs EA BV 0.007 - 
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Appendix Table 4. SNP positional information and ethnic comparisons for anti-
inflammatory cytokine genes and receptors 
 
    
Allele 
Frequency AA vs EA 
Genic Region RS# Gene Position Allele EA AA Allele Genotype 
rs3024498 IL-10 chr1:205008152 G 0.29 0.24 0.475 0.232 Exon 
rs3024496 IL-10 chr1:205008487 C 0.50 0.47 0.585 0.904 Exon 
rs1800872 IL-10 chr1:205013030 A 0.16 0.38 <0.001 0.001 Promoter 
rs1800896 IL-10 chr1:205013520 A 0.50 0.53 0.586 0.469 Promoter 
rs1800890 IL-10 chr1:205015988 A 0.41 0.37 0.5 0.394 Promoter 
rs4936414 IL-10RA chr11:117358823 C 0.38 0.15 <0.001 <0.001 Promoter 
rs2512143 IL-10RA chr11:117365792 A 0.37 0.23 0.034 0.078 Intron 
rs4252254 IL-10RA chr11:117366265 T 0.16 0.30 0.007 0.01 Intron 
rs4252270 IL-10RA chr11:117369056 T 0.16 0.16 1 0.837 Intron 
rs2229113 IL-10RA chr11:117374880 A 0.34 0.15 0.001 0.002 Coding (exon) 
rs9610 IL-10RA chr11:117377296 A 0.37 0.71 <0.001 <0.001 Exon 
rs2508445 IL-10RA chr11:117377754 T 0.34 0.23 0.073 0.124 3' UTR 
rs947889 IL-10RA chr11:117379741 A 0.45 0.71 <0.001 0.001 3' UTR 
rs4938467 IL-10RA chr11:117380381 T 0.41* 0.54 0.017 0.055 3' UTR 
rs11216666 IL-10RA chr11:117381245 C 0.14 0.62 <0.001 <0.001 3' UTR 
rs17121510 IL-10RA chr11:117381365 G 0.09 0.32 <0.001 <0.001 3' UTR 
rs2284552 IL-10RB chr21:33565952 T 0.20 0.15 0.381 0.242 Intron 
rs962859 IL-10RB chr21:33569993 C 0.49 0.32 0.005 0.036 Intron 
rs2834168 IL-10RB chr21:33572661 G 0.41 0.19 0.001 0.002 Intron 
rs2834170 IL-10RB chr21:33574545 C 1.00 0.72 <0.001 <0.001 Intron 
rs2243498 IL-10RB chr21:33575536 A 0.46 0.60 0.046 0.117 Intron 
rs2834172 IL-10RB chr21:33577493 A 1.00 0.69 <0.001 <0.001 Intron (boundary) 
rs765429 IL-10RB chr21:33581871 A 0.49 0.67 0.005 0.018 Intron 
rs2276223 IL-10RB chr21:33582670 G 0.49 0.29 0.002 0.008 Intron 
rs735299 IL-10RB chr21:33586460 G 0.44 0.67 <0.001 0.003 Intron 
rs999261 IL-10RB chr21:33588030 C 0.17 0.06 0.004 0.007 Intron 
rs999259 IL-10RB chr21:33588362 A 0.45 0.62 0.011 0.05 Intron 
rs1058867 IL-10RB chr21:33591251 G 0.42 0.63 0.001 0.007 Exon 
rs8178565 IL-10RB chr21:33591549 G 1.00 0.77* <0.001 <0.001 3' UTR 
rs6517158 IL-10RB chr21:33593611 C 0.17 0.72 0.037 0.071 3' UTR 
rs2834175 IL-10RB chr21:33594831 A 0.27 0.11 0.002 0.002 3' UTR 
rs3091307 IL-13 chr5:132017035 G 0.24 0.56 <0.001 <0.001 Promoter 
rs1295686 IL-13 chr5:132023742 A 0.24 0.59 <0.001 <0.001 Intron (boundary) 
rs848 IL-13 chr5:132024399 T 0.24 0.46 0.001 0.001 Exon 
rs1295683 IL-13 chr5:132026775 T 0.14* 0.06 0.054 0.166 3' UTR 
rs2243204 IL-13 chr5:132027393 T 0.09 0.50 <0.001 <0.001 3' UTR 
rs2243209 IL-13 chr5:132029213 C 1.00 0.86 <0.001 <0.001 3' UTR 
rs2243248 IL-4 chr5:132036543 G 0.13* 0.18 0.214 0.048 Promoter 
rs2070874 IL-4 chr5:132037609 T 0.09 0.40 <0.001 <0.001 Exon 
rs2227284 IL-4 chr5:132040624 A 0.24 0.78 <0.001 <0.001 Intron 
rs2243261 IL-4 chr5:132040705 G 1.00 0.85* <0.001 <0.001 Intron 
rs2243263 IL-4 chr5:132041198 C 0.14 0.11 0.54 0.697 Intron 
rs2243268 IL-4 chr5:132041862 C 0.09 0.28 <0.001 <0.001 Intron 
rs2243274 IL-4 chr5:132042731 A 0.09 0.62 <0.001 <0.001 Intron 
rs2243290 IL-4 chr5:132046068 A 0.09 0.37 <0.001 <0.001 Intron (boundary) 
rs4787956 IL4R chr16:27285750 G 0.34 0.37 0.556 0.243 3' UTR 
rs2057768 IL-4R chr16:27229596 A 0.23 0.31 0.132 0.15 Promoter 
rs6498012 IL-4R chr16:27239475 C 0.30 0.32 0.888 0.833 Intron 
rs4787948 IL-4R chr16:27248560 G 0.25* 0.32 0.249 0.178 Intron 
rs3024530 IL-4R chr16:27258188 G 0.45 0.51 0.444 0.474 Intron 
rs3024537 IL-4R chr16:27260320 A 0.20 0.18 0.729 0.784 Intron 
rs3024547 IL-4R chr16:27261862 T 0.20 0.31 0.088 0.083 Intron 
rs3024548 IL-4R chr16:27262032 G 0.47 0.65 0.003 0.017 Intron 
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rs3024560 IL-4R chr16:27264168 G 0.34 0.38 0.494 0.647 Intron 
rs2239349 IL-4R chr16:27266389 T 0.10 0.32 <0.001 <0.001 Intron 
rs2239347 IL-4R chr16:27266522 G 0.45 0.41 0.587 0.791 Intron 
rs3024585 IL-4R chr16:27267345 A 0.41 0.41 0.895 1 Intron 
rs3024623 IL-4R chr16:27272969 G 0.11 0.04 0.027 0.11 Intron 
rs4787423 IL-4R chr16:27274835 C 0.19 0.36 0.003 0.018 Intron 
rs3024648 IL-4R chr16:27275500 C 0.08 0.26 <0.001 0.001 Intron 
rs3024658 IL-4R chr16:27277955 A 0.08 0.33 <0.001 <0.001 Intron 
rs3024668 IL-4R chr16:27279450 A 0.09 0.44 <0.001 <0.001 Intron 
rs3024670 IL-4R chr16:27279896 G 1.00 0.87 <0.001 <0.001 Intron 
rs3024675 IL-4R chr16:27280968 C 0.03 0.25 <0.001 <0.001 Intron 
rs3024676 IL-4R chr16:27281059 A 0.24 0.42 <0.001 <0.001 Intron (boundary) 
rs2234898 IL-4R chr16:27281416 T 0.16 0.51 <0.001 <0.001 Coding (exon) 
rs1805013 IL-4R chr16:27281481 T 0.05 0.02 0.142 0.303 Coding (exon) 
rs1805015 IL-4R chr16:27281681 C 0.23 0.33 0.101 0.234 Coding (exon) 
rs1801275 IL-4R chr16:27281901 G 0.26 0.70 <0.001 <0.001 Coding (exon) 
rs1805016 IL-4R chr16:27282428 G 0.08* 0.35 <0.001 <0.001 Coding (exon) 
rs8832 IL-4R chr16:27283288 A 0.46 0.81 <0.001 <0.001 Exon 
rs1029489 IL-4R chr16:27283718 T 0.41 0.79* <0.001 <0.001 3' UTR 
* indicates deviation from HWE <0.05  
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Appendix Table 5. Significant SNP or interaction ANOVA models for anti-
inflammatory cytokines a) AA, b) EA 
 
a) 
Cytokine Gene RS# Model Model SNP A BV B Intxn C  D 
IL-4 IL-4R rs3024537 AA/AG vs GG 0.120 0.469 0.145 0.042 
IL-4 IL-4R rs3024670 GG vs GT/TT 0.193 0.044 0.444 0.665 
IL-4 IL-4R rs2057768 AA/AG vs GG 0.041 0.239 0.192 0.021 
IL-10 IL-10 rs1800872 AA/AC vs CC 0.048 0.603 0.067 0.075 
IL-10 IL-10RB rs2834170 CC vs CT/TT 0.035 0.993 0.018 0.056 
IL-10 IL-10RB rs2243498 AA vs AG/GG 0.007 0.597 0.005 0.013 
IL-10 IL-10RB rs6517158 CC/CT vs TT 0.029 0.040 0.019 0.586 
IL-10 IL-10RB rs2834172 AA vs AG/GG 0.016 0.973 0.023 0.022 
 
b) 
Cytokine Gene RS# Model Model SNP A BV B Intxn C D 
IL-10 IL-10RA rs2508445 GG vs GT/TT 0.014 0.002* 0.509 0.228 
IL-10 IL-10RA rs2512143 AA/AG vs GG 0.005 6x10-4 0.428 * 0.364 
IL-10 IL-10RA rs2229113 AA/AG vs GG 0.014 0.002* 0.509 0.228 
IL-10 IL-10RA rs4936414 CC/CT vs TT 8x10 1x10-4 -4 0.688 * 0.138 
IL-10 IL-10RB rs2243498 AA/AG vs GG 0.165 0.441 0.143 0.041 
IL-10 IL-10RB rs765429 AA/AG vs GG 0.144 0.485 0.098 0.033 
IL-10 IL-10RB rs2276223 GG/GT vs TT 0.144 0.485 0.098 0.033 
IL-10 IL-10RB rs999261 CC/CT vs TT 0.115 0.031 0.295 0.183 
IL-10 IL-10RB rs6517158 CC/CT vs TT 0.129 0.045 0.267 0.131 
A Full model p-value. Full model is transformed cytokine concentration = µ + α(SNP) + β(BV status) + 
γ(BV status*SNP) + ε 
B BV status p-value adjusted for SNP and interaction 
C SNP p-value adjusted for BV status and interaction 
D
 
 Interaction p-value adjusted for BV status and SNP 
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Appendix Table 6. SNP positional information and ethnic comparisons for pro-
inflammatory cytokine genes and receptors 
 
    Allele Frequency AA vs EA Genic 
Region Marker Gene Position Allele EA AA Allele Genotype 
rs17561 IL-1α chr2:113253454 T 0.18 0.23 0.418 0.224 Coding exon 
rs2856838 IL-1α chr2:113256203 T 0.35 0.38 * 0.618 0.134 Intron 
rs1878321 IL-1α chr2:113260665 C 0.40 0.23 0.007 0.014 Promoter 
rs2853550 IL-1β chr2:113303352 T 0.28 0.04 <0.001 <0.001 3' UTR 
rs1143643 IL-1β chr2:113304533 A 0.19 0.37 0.004 0.012 Intron 
rs1143634 IL-1β chr2:113306621 T 0.11 0.19 0.066 * 0.239 Coding exon 
rs1143630 IL-1β chr2:113307886 A 0.25 0.02 <0.001 <0.001 Intron 
rs1143627 IL-1β chr2:113310618 T 0.37 0.66 <0.001 <0.001 Promoter 
rs1143623 IL-1β chr2:113312060 C 0.11 0.33 <0.001 <0.001 Promoter 
rs4848306 IL-1β chr2:113314338 A 0.29 0.51 <0.001 0.008 Promoter 
rs3917225 IL-1R1 chr2:102227820 G 0.10 0.41 <0.001 <0.001 Promoter 
rs949963 IL-1R1 chr2:102228304 A 0.19 0.19 0.868 0.434 Promoter 
rs3771202 IL-1R1 chr2:102231187 G 0.05 0.23 <0.001 <0.001 Intron 
rs2287047 IL-1R1 chr2:102232572 C 0.29 0.69 <0.001 <0.001 Intron 
rs3917254 IL-1R1 chr2:102235036 A 0.37 0.11 <0.001 <0.001 Intron 
rs3917273 IL-1R1 chr2:102238237 A 0.20 0.52 <0.001 <0.001 Intron 
rs3917292 IL-1R1 chr2:102241570 G 1.00 0.94 0.001 0.019 Intron 
rs2160227 IL-1R1 chr2:102241873 C 0.47 0.71 <0.001 * <0.001 Intron 
rs3917296 IL-1R1 chr2:102243351 G 0.02 0.08 0.073 0.067 Intron 
rs951193 IL-1R1 chr2:102244317 G 1.00 0.97 0.040 0.127 Intron 
rs3917304 IL-1R1 chr2:102246643 T 0.27 0.29 0.775 * 0.849 Intron 
rs3917306 IL-1R1 chr2:102247357 G 0.31 0.03 <0.001 * <0.001 Intron 
rs3171845 IL-1R1 chr2:102249899 A 0.13 0.11 0.840 0.646 Intron 
rs2110726 IL-1R1 chr2:102252800 T 0.07 0.27 <0.001 <0.001 Exon 
rs3732131 IL-1R1 chr2:102253121 C 0.19 0.08 0.005 0.008 Exon 
rs3917332 IL-1R1 chr2:102255042 A 0.13 0.23 0.040 0.138 3' UTR 
rs11884283 IL-1R2 chr2:102062287 T 0.37 0.30 0.269 0.284 Promoter 
rs6543105 IL-1R2 chr2:102062817 A 0.15 0.39 <0.001 0.001 Promoter 
rs12467316 IL-1R2 chr2:102063167 A 0.20 0.27 * 0.264 0.033 Promoter 
rs4141134 IL-1R2 chr2:102065044 C 0.19 0.46 <0.001 <0.001 Promoter 
rs4851520 IL-1R2 chr2:102068793 C 0.10 0.14 0.226 0.571 Intron 
rs4851521 IL-1R2 chr2:102068874 T 0.42 0.42 0.895 0.740 Intron 
rs4851522 IL-1R2 chr2:102069346 T 0.38 0.13 <0.001 <0.001 Intron 
rs4321386 IL-1R2 chr2:102071531 G 0.13 0.11 0.538 0.772 Intron 
rs1108338 IL-1R2 chr2:102072099 A 0.47 0.75 <0.001 <0.001 Intron 
rs7561191 IL-1R2 chr2:102075496 A 0.41 0.41 0.900 0.486 Intron 
rs4851526 IL-1R2 chr2:102076888 G 0.46 0.41 0.490 0.448 Intron 
rs4851527 IL-1R2 chr2:102080894 A 0.27 0.47 0.003 0.007 Intron 
rs2302589 IL-1R2 chr2:102083304 A 0.25 0.12 * 0.010 0.045 Intron 
rs3218861 IL-1R2 chr2:102085640 T 0.21 0.00 <0.001 <0.001 Intron 
rs2160140 IL-1R2 chr2:102088048 T 0.08 0.27 <0.001 0.001 Intron 
rs3218883 IL-1R2 chr2:102088791 A 0.23 0.12 0.032 0.086 Intron 
rs3218927 IL-1R2 chr2:102092844 C 0.23 0.12 0.036 0.092 Intron 
rs2072474 IL-1R2 chr2:102097727 C 0.41 0.16 <0.001 <0.001 Intron 
rs3218979 IL-1R2 chr2:102100645 A 0.17 0.14 0.582 0.684 Intron 
rs733498 IL-1R2 chr2:102102043 A 0.38 0.15 <0.001 0.001 Intron 
rs3218987 IL-1R2 chr2:102103408 A 0.23 0.00 <0.001 <0.001 3' UTR 
rs7589525 IL-1R2 chr2:102104909 C 0.08 0.27 <0.001 * 0.002 3' UTR 
rs4851531 IL-1R2 chr2:102107127 C 0.45 0.58 0.069 0.202 3' UTR 
rs9817203 IL-1RAP chr3:191711050 T 0.27 0.04 <0.001 * <0.001 Promoter 
rs6800625 IL-1RAP chr3:191717029 C 0.25 0.02 <0.001 <0.001 Intron 
rs7628333 IL-1RAP chr3:191720499 T 0.32 0.30 0.764 0.710 Intron 
rs3821744 IL-1RAP chr3:191720745 G 0.33 0.69 <0.001 <0.001 Intron 
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rs7615368 IL-1RAP chr3:191723292 T 0.20 0.02 <0.001 <0.001 Intron 
rs7615533 IL-1RAP chr3:191723446 G 0.35 0.04 <0.001 <0.001 Intron 
rs3773994 IL-1RAP chr3:191726419 A 0.26 0.05 <0.001 <0.001 Intron 
rs9290936 IL-1RAP chr3:191735337 T 0.23 0.13 0.037 * 0.028 Intron 
rs9849030 IL-1RAP chr3:191739881 G 0.21 0.13 0.120 0.182 Intron 
rs2059020 IL-1RAP chr3:191740326 T 0.11 0.17 0.171 0.218 Intron 
rs2361832 IL-1RAP chr3:191742739 G 0.33 0.21 0.034 0.135 Intron 
rs7626071 IL-1RAP chr3:191744368 G 0.25 0.06 <0.001 <0.001 Intron 
rs3773990 IL-1RAP chr3:191744754 T 0.12 0.08 0.387 0.465 Intron 
rs2193880 IL-1RAP chr3:191745501 A 0.10 0.49 <0.001 <0.001 Intron 
rs3773989 IL-1RAP chr3:191748131 T 0.12 0.38 <0.001 <0.001 Intron 
rs1988743 IL-1RAP chr3:191750602 C 0.35 0.70 <0.001 <0.001 Intron 
rs4686554 IL-1RAP chr3:191756520 T 0.43 0.70 <0.001 <0.001 Intron 
rs16865597 IL-1RAP chr3:191758247 C 0.24 0.10 0.004 0.020 Intron 
rs2885370 IL-1RAP chr3:191759697 G 0.12 0.28 * 0.002 0.002 Intron 
rs3773983 IL-1RAP chr3:191762568 T 0.12 0.07 0.164 0.321 Intron 
rs3773982 IL-1RAP chr3:191762754 T 0.40 0.16 <0.001 <0.001 Intron 
rs3773981 IL-1RAP chr3:191762867 C 0.43 0.16 <0.001 <0.001 Intron 
rs9883249 IL-1RAP chr3:191764078 A 0.18 0.54 <0.001 <0.001 Intron 
rs9845825 IL-1RAP chr3:191764293 T 0.30 0.64 <0.001 <0.001 Intron 
rs2241343 IL-1RAP chr3:191765416 G 0.31 0.14 0.001 0.013 Intron 
rs9877268 IL-1RAP chr3:191768524 A 0.12 0.33 <0.001 <0.001 Intron 
rs3773977 IL-1RAP chr3:191769911 G 0.20 0.21 0.879 0.953 Intron 
rs3773976 IL-1RAP chr3:191769987 C 0.13 0.17 0.253 0.029 Intron 
rs4687151 IL-1RAP chr3:191773332 G 0.18 0.33 0.012 0.045 Intron 
rs11929157 IL-1RAP chr3:191776207 G 0.21 0.24 0.625 0.357 Intron 
rs10937439 IL-1RAP chr3:191776257 G 0.50 0.42 0.243 0.448 Intron 
rs10937442 IL-1RAP chr3:191776910 C 0.49 0.44 0.425 0.760 Intron 
rs2161058 IL-1RAP chr3:191776992 T 0.20 0.01 <0.001 <0.001 Intron 
rs1035347 IL-1RAP chr3:191779637 G 0.45 0.30 0.021 0.089 Intron 
rs1559018 IL-1RAP chr3:191779785 G 0.36 0.29 0.311 0.542 Intron 
rs12053868 IL-1RAP chr3:191782706 G 0.02 0.16 <0.001 <0.001 Intron 
rs6444435 IL-1RAP chr3:191786507 G 0.38 0.30 0.231 0.440 Intron 
rs4687154 IL-1RAP chr3:191786874 G 0.05 0.14 0.016 0.038 Intron 
rs10513854 IL-1RAP chr3:191788576 T 0.18 0.18 0.869 0.447 Intron 
rs7628250 IL-1RAP chr3:191791229 G 0.06 0.18 0.005 0.032 Intron 
rs3773958 IL-1RAP chr3:191792305 G 0.10 0.19 0.063 0.149 Intron 
rs3773953 IL-1RAP chr3:191797422 T 0.09 0.13 0.284 0.809 Intron 
rs1469007 IL-1RAP chr3:191807272 G 0.40 0.30 0.097 0.256 Intron 
rs9875362 IL-1RAP chr3:191808349 T 0.17 0.08 0.043 0.033 Intron 
rs6781037 IL-1RAP chr3:191810223 A 0.47 0.70 0.001 0.004 Intron 
rs6765375 IL-1RAP chr3:191810454 A 0.34 0.62 <0.001 <0.001 Intron 
rs9821002 IL-1RAP chr3:191812153 A 0.33 0.70 <0.001 <0.001 Intron 
rs759783 IL-1RAP chr3:191813479 T 0.41 0.27 0.026 0.024 Intron 
rs4140711 IL-1RAP chr3:191815356 C 0.38 0.26 0.033 0.048 Intron 
rs9290939 IL-1RAP chr3:191816578 A 0.13 0.08 0.271 0.333 Intron 
rs1015704 IL-1RAP chr3:191821114 A 0.49 0.67 0.005 0.024 Intron 
rs1015705 IL-1RAP chr3:191821361 A 0.38 0.27 0.046 0.164 Intron 
rs4687163 IL-1RAP chr3:191824141 G 0.39 0.27 0.033 0.082 Intron 
rs929729 IL-1RAP chr3:191825964 A 0.42 0.31 0.098 0.030 Intron 
rs1024941 IL-1RAP chr3:191829360 T 0.03 0.11 0.023 0.038 Intron 
rs1024946 IL-1RAP chr3:191830225 A 0.47 0.66 0.002 * 0.006 Intron 
rs1024949 IL-1RAP chr3:191830434 C 0.02 0.09 * 0.040 0.005 Intron 
rs7626795 IL-1RAP chr3:191833163 G 0.37 0.16 <0.001 0.001 Intron 
rs4624606 IL-1RAP chr3:191836948 A 0.35 0.26 0.152 0.149 Intron 
rs9847868 IL-1RAP chr3:191840234 C 0.43 0.27 0.008 0.013 Intron 
rs9821122 IL-1RAP chr3:191842158 G 0.46 0.73 <0.001 <0.001 Intron 
rs4320092 IL-1RAP chr3:191843717 T 0.39 0.73 <0.001 <0.001 Intron 
rs9831803 IL-1RAP chr3:191844199 T 0.48 0.18 <0.001 <0.001 Intron 
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rs7650510 IL-1RAP chr3:191845818 G 0.27 0.25 0.643 0.405 Intron 
rs11915384 IL-1RAP chr3:191853466 G 0.47 0.09 <0.001 <0.001 3' UTR 
rs17042917 IL-1RN chr2:113586894 A 0.17 0.13 0.249 0.326 Promoter 
rs315920 IL-1RN chr2:113589249 T 0.13 0.23 0.085 * 0.043 Promoter 
rs4251961 IL-1RN chr2:113590698 C 0.13 0.34 <0.001 0.004 Promoter 
rs2637988 IL-1RN chr2:113593010 A 0.42 0.59 0.008 0.006 Intron 
rs928940 IL-1RN chr2:113593726 G 0.34 0.13 <0.001 * <0.001 Intron 
rs3213448 IL-1RN chr2:113595528 A 0.20 0.13 0.158 * 0.044 Intron 
rs1794066 IL-1RN chr2:113602581 G 0.40 0.41 0.898 0.237 Intron 
rs380092 IL-1RN chr2:113605131 A 0.33 0.68 <0.001 <0.001 Intron 
rs579543 IL-1RN chr2:113605862 T 0.15 0.31 0.003 0.009 Intron 
rs315951 IL-1RN chr2:113606817 C 0.38 0.30 0.227 0.139 Exon 
rs315949 IL-1RN chr2:113609005 T 0.38 0.37 0.889 0.344 3' UTR 
rs315946 IL-1RN chr2:113610095 T 0.03 0.15 0.001 0.015 3' UTR 
rs315943 IL-1RN chr2:113610569 C 0.40 0.37 0.558 0.152 3' UTR 
rs315942 IL-1RN chr2:113611376 A 0.31 0.32 0.886 0.865 3' UTR 
rs1880243 IL-6 chr7:22532895 A 0.18 0.20 0.617 0.570 Promoter 
rs12700386 IL-6 chr7:22536249 G 0.20 0.20 0.873 0.744 Promoter 
rs1800797 IL-6 chr7:22539461 A 0.09 0.30 <0.001 <0.001 Promoter 
rs1800796 IL-6 chr7:22539486 C 0.06 0.05 1.000 1.000 Promoter 
rs1800795 IL-6 chr7:22539885 C 0.09 0.31 <0.001 <0.001 Promoter 
rs2069840 IL-6 chr7:22541812 G 0.19 0.45 <0.001 0.001 Intron 
rs1554606 IL-6 chr7:22541947 T 0.30 0.30 1.000 0.838 Intron 
rs11766273 IL-6 chr7:22548903 A 0.03 0.09 0.027 0.145 3' UTR 
rs952146 IL-6R chr1:151182001 G 0.36 0.38 * 0.598 0.008 Promoter 
rs1552481 IL-6R chr1:151189426 G 0.18 0.01 <0.001 <0.001 Promoter 
rs6427641 IL-6R chr1:151193559 A 0.38 0.56 * 0.006 0.006 Intron 
rs11265610 IL-6R chr1:151193857 C 0.21 0.00 <0.001 <0.001 Intron 
rs1386821 IL-6R chr1:151195122 C 0.13 0.16 0.567 * 0.163 Intron 
rs4075015 IL-6R chr1:151202269 A 0.13 0.41 <0.001 <0.001 Intron 
rs4601580 IL-6R chr1:151207490 A 0.49 0.51 0.895 0.909 Intron 
rs4845618 IL-6R chr1:151213088 T 0.43 0.54 0.121 0.227 Intron 
rs6687726 IL-6R chr1:151213393 G 0.38 0.54 0.019 0.034 Intron 
rs7549338 IL-6R chr1:151217453 C 0.39 0.45 0.428 0.601 Intron 
rs4553185 IL-6R chr1:151224028 T 0.40 0.55 0.018 0.036 Intron 
rs4845622 IL-6R chr1:151224492 C 0.13 0.33 0.001 0.002 Intron 
rs4845623 IL-6R chr1:151228850 A 0.44 0.67 <0.001 0.001 Intron 
rs4537545 IL-6R chr1:151231952 C 0.40 0.67 <0.001 <0.001 Intron 
rs4845625 IL-6R chr1:151235140 T 0.37 0.45 0.229 0.446 Intron 
rs4845374 IL-6R chr1:151240020 A 0.21 0.23 0.873 0.950 Intron 
rs11265618 IL-6R chr1:151243165 T 0.29 0.23 0.230 0.533 Intron 
rs10752641 IL-6R chr1:151245115 G 0.38 0.22 0.009 0.019 Intron 
rs4329505 IL-6R chr1:151245493 C 0.36 0.22 0.027 0.049 Intron 
rs2229238 IL-6R chr1:151250969 T 0.24 0.19 * 0.360 0.077 Exon 
rs4072391 IL-6R chr1:151251953 T 0.38 0.19 0.002 0.007 Exon 
rs7526293 IL-6R chr1:151257282 T 0.47 0.19 <0.001 <0.001 3' UTR 
rs2227538 IL-8 chr4:74971410 T 0.21 0.01 <0.001 <0.001 Exon 
rs4694178 IL-8 chr4:74977723 A 0.25 0.48 <0.001 0.001 3' UTR 
rs4694637 IL-8 chr4:74977869 A 0.27 0.48 0.001 0.003 3' UTR 
rs1008563 IL-8RA chr2:218852394 T 0.39 0.42 0.672 0.726 3' UTR 
rs1008562 IL-8RA chr2:218852478 G 0.31 0.46 0.030 0.087 3' UTR 
rs2854386 IL-8RA chr2:218853008 C 0.36 0.05 <0.001 <0.001 3' UTR 
rs16858856 IL-8RA chr2:218858287 C 0.13 0.00 <0.001 <0.001 Promoter 
rs2844482 TNF-α chr6:31647746 A 0.10 0.15 0.295 0.506 Promoter 
rs1800683 TNF-α chr6:31648050 A 0.43 0.34 0.186 0.191 Promoter 
rs1799964 TNF-α chr6:31650287 C 0.14 0.17 0.606 0.896 3' UTR 
rs1800629 TNF-α chr6:31651010 A 0.13 0.15 0.859 0.908 Promoter 
rs769178 TNF-α chr6:31655493 A 0.03 0.12 0.005 0.011 3' UTR 
rs2229094 TNF-α chr6:31648535 C 0.28 0.23 0.358 0.718 Promoter 
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rs740841 TNFR1 chr12:6303550 C 0.46 0.48 0.897 0.878 3' UTR 
rs2302350 TNFR1 chr12:6306014 T 0.17 0.53 <0.001 * <0.001 3' UTR 
rs1800693 TNFR1 chr12:6310270 G 0.30 0.44 0.019 0.083 
Intron 
(boundary) 
rs1860545 TNFR1 chr12:6317038 T 0.11 0.44 <0.001 <0.001 Intron 
rs4149578 TNFR1 chr12:6317698 A 0.32 0.06 <0.001 <0.001 Intron 
rs4149577 TNFR1 chr12:6317783 C 0.20 0.49 <0.001 <0.001 Intron 
rs4149622 TNFR1 chr12:6320900 G 0.47 0.00 <0.001 <0.001 Intron 
rs4149570 TNFR1 chr12:6321851 T 0.18 0.41 <0.001 0.001 Promoter 
rs11064145 TNFR1 chr12:6325359 T 0.41 0.53 0.088 0.151 Promoter 
rs3764874 TNFR1 chr12:6328535 G 0.14 0.23 * 0.096 0.156 Promoter 
rs590368 TNFR2 chr1:12157717 T 0.13 0.38 <0.001 <0.001 Promoter 
rs522807 TNFR2 chr1:12158505 T 0.37 0.07 * <0.001 <0.001 Promoter 
rs652625 TNFR2 chr1:12159617 T 0.31 0.09 <0.001 <0.001 Promoter 
rs496888 TNFR2 chr1:12167072 G 0.34 0.30 0.570 0.747 Intron 
rs976881 TNFR2 chr1:12168020 A 0.26 0.27 0.887 0.358 Intron 
rs3766730 TNFR2 chr1:12174942 T 0.04 0.15 0.007 0.002 Intron 
rs616645 TNFR2 chr1:12175090 C 0.25 0.21 0.459 0.732 Intron 
rs816050 TNFR2 chr1:12176257 T 0.31 0.17 0.019 0.042 Intron 
rs474247 TNFR2 chr1:12180441 A 0.12 0.26 0.005 0.014 Intron 
rs1201157 TNFR2 chr1:12183297 T 0.38 0.39 0.896 0.845 
Intron 
(boundary) 
rs653667 TNFR2 chr1:12186074 C 0.31 0.34 0.680 0.167 
Intron 
(boundary) 
rs1061622 TNFR2 chr1:12187221 G 0.24 0.25 0.765 * 0.577 Coding exon 
rs5746051 TNFR2 chr1:12196238 G 0.08 0.19 0.019 0.019 
Intron 
(boundary) 
rs5746053 TNFR2 chr1:12196564 A 0.13 0.19 0.220 0.428 
Intron 
(boundary) 
rs235219 TNFR2 chr1:12198621 A 0.02 0.15 <0.001 0.003 Intron 
rs1061624 TNFR2 chr1:12201531 G 0.31 0.51 0.003 0.014 Exon 
rs1061628 TNFR2 chr1:12202265 C 0.49 0.55 0.438 0.606 Exon 
rs1061631 TNFR2 chr1:12202765 A 0.10 0.28 <0.001 0.002 Exon 
rs235214 TNFR2 chr1:12205769 T 0.15 0.12 0.437 0.275 3' UTR 
* indicates deviation from HWE <0.05  
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Appendix Table 7. Significant SNP or interaction ANOVA models for pro-
inflammatory cytokines a) AA, b) EA 
 
a) 
Cytokine Gene RS# Model Model SNP A BV B Intxn C D 
IL-1α IL-1α rs1878321 CC/CT vs TT 0.005 0.975 0.001 0.017 
IL-1α IL-1RAP rs1469007 GG vs GT/TT 0.004 0.998 0.435 0.012 
IL-1α IL-1RAP rs1469007 Additive 0.015 0.732 0.063 0.041 
IL-1β IL-1R2 rs4851521 CC/CT vs TT 0.032 0.025 0.061 0.155 
IL-1β IL-1R2 rs7561191 AA vs AT/TT 0.032 0.025 0.061 0.155 
IL-1β IL-1RAP rs1015704 AA/AG vs GG 0.101 0.599 0.748 0.043 
IL-1β IL-1RAP rs1015705 AA/AC vs CC 0.048 0.565 0.061 0.017 
IL-1β IL-1RAP rs1469007 GG vs GT/TT 0.014 0.915 0.639 0.004 
IL-1β IL-1RAP rs1469007 Additive 0.044 0.717 0.535 0.016 
IL-1β IL-1RAP rs4624606 AA/AT vs TT 0.108 0.620 0.095 0.047 
IL-1β IL-1RAP rs6765375 AA/AC vs CC 0.009 0.249 0.197 0.003 
IL-1β IL-1RAP rs6781037 AA vs AG/GG 0.012 0.033 0.011 0.014 
IL-1β IL-1RAP rs6781037 Additive 0.025 0.041 0.081 0.035 
IL-1β IL-1RAP rs9821002 AA/AC vs CC 0.017 0.133 0.192 0.008 
IL-6 IL-6R rs10752641 CC vs CG/GG 0.023 0.038 0.029 0.079 
IL-6 IL-6R rs4553185 CC vs CT/TT 0.023 0.985 0.166 0.017 
IL-8 IL-8RA rs1008562 CC vs CG/GG - - - 0.012 
IL-8 IL-8RA rs1008563 CC vs CT/TT - - - 0.047 
TNF-α TNFR2  E rs1201157 CC vs CT/TT - - - 0.006 
 
b) 
Cytokine Gene RS# Model Model SNP A BV B Intxn C D 
IL-1α IL-1RAP rs9831803 GG vs GT/TT 0.018 0.340 0.415 0.045 
IL-1β IL-1RAP rs1015705 AA/AC vs CC 0.013 0.030 0.030 0.048 
IL-1β IL-1RAP rs4140711 CC/CT vs TT 0.010 0.023 0.049 0.037 
IL-1β IL-1RAP rs4687163 AA vs AG/GG 0.008 0.019 0.028 0.031 
IL-1β IL-1RAP rs759783 CC vs CT/TT 0.013 0.030 0.030 0.048 
IL-1β IL-1RAP rs7628250 AA vs AG/GG 0.008 0.302 0.265 0.007 
IL-1β IL-1RAP rs9290939 AA/AG vs GG 0.008 0.010 0.013 0.459 
IL-6 IL-6 rs2069840 CC/CG vs GG 0.142 0.319 0.106 0.027 
IL-6 IL-6R rs4075015 AA/AT vs TT 0.029 0.048 0.083 0.004 
A Full model p-value. Full model is transformed cytokine concentration = µ + α(SNP) + β(BV status) + 
γ(BV status*SNP) + ε 
B BV status p-value adjusted for SNP and interaction 
C SNP p-value adjusted for BV status and interaction 
D Interaction p-value adjusted for BV status and SNP 
E
 
 Indicates that Kruskal-Wallis non-parametric tests were used and therefore only the interaction p-value 
was calculated 
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Appendix Table 8. SNP positional information and ethnic comparisons for toll-like 
receptors 
 
    
Allele 
Frequency AA vs EA Genic 
Region Marker Gene Position Allele EA AA Allelic Genotypic 
rs1898830 TLR2 chr4:154966058 G 0.37 0.12 <0.001 <0.001 Promoter 
rs4696483 TLR2 chr4:154976860 T 0.11 0.43 <0.001 <0.001 Intron 
rs7656411 TLR2 chr4:154985260 G 0.24 0.57 <0.001 <0.001 3' UTR 
rs1337 TLR2 chr4:154989192 C 0.23 0.07 0.001 0.002 3' UTR 
rs10759930 TLR4 chr9:117541175 T 0.40* 0.08 <0.001 <0.001 Promoter 
rs16906053 TLR4 chr9:117541736 C 0.01 0.25 <0.001 <0.001 Promoter 
rs2770150 TLR4 chr9:117542693 C 0.30 0.17 0.014 0.070 Promoter 
rs10759932 TLR4 chr9:117544698 C 0.13 0.25 0.009 0.037 Promoter 
rs1927911 TLR4 chr9:117549608 T 0.25 0.62 <0.001 <0.001 Intron 
rs1927907 TLR4 chr9:117552318 C 0.13 0.25 0.013 0.060 Intron 
rs2149356 TLR4 chr9:117553753 A 0.29 0.74 <0.001 <0.001 Intron 
rs7869402 TLR4 chr9:117557586 T 0.02 0.24 <0.001 <0.001 Exon 
rs11536889 TLR4 chr9:117557685 C 0.13 0.04 0.012 <0.001 3' UTR 
rs1927906 TLR4 chr9:117559669 G 0.05 0.41 <0.001 <0.001 3' UTR 
rs11536898 TLR4 chr9:117559764 A 0.12 0.18 0.147 0.020 3' UTR 
rs1554973 TLR4 chr9:117560366 C 0.20 0.66 <0.001 <0.001 3' UTR 
rs7856729 TLR4 chr9:117561410 T 0.16* 0.27 0.034 0.004 3' UTR 
* indicates deviation from HWE <0.05  
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Appendix Table 9: Significant SNP or interaction ANOVA models for toll-like 
receptors a) AA, b) EA 
 
a) 
Cytokine Gene RS# Model Model SNP A BV B Intxn C D 
IL-10 TLR4 rs1927906 AA vs AG/GG 0.024 0.033 0.036 0.735 
IL-10 TLR4 rs10759932 CC/CT vs TT 0.027 0.038 0.026 0.603 
IL-12(p40) TLR4 rs7869402 CC vs CT/TT 0.046 0.025 0.148 0.347 
IL-12(p70) TLR2 rs7656411 GG vs GT/TT 0.004 0.257 0.004 0.008 
IL-12(p70) TLR2 rs7656411 GG/GT vs TT 0.019 0.466 0.056 0.027 
IL-13 TLR2 rs4696483 CC vs CT/TT 0.046 0.126 0.917 0.020 
IL-13 TLR4 rs10759932 CC/CT vs TT 0.055 0.018 0.206 0.727 
IL-13 TLR4 rs1927907 AA/AG vs GG 0.077 0.024 0.152 0.967 
IL-13 TLR4 rs1927911 CC/CT vs TT 0.077 0.033 0.106 0.497 
IP-10 TLR4 rs11536898 AA/AC vs CC 0.026 0.006 0.990 0.499 
IP-10 TLR4 rs7856729 GG vs GT/TT 0.057 0.009 0.744 0.952 
IP-10 TLR4 rs7869402 CC vs CT/TT 0.176 0.738 0.525 0.044 
TNF-α TLR2  E rs7656411 GG vs GT/TT - - - 0.004 
TNF-α TLR2  E rs7656411 Additive - - - 0.005 
TNF-α TLR4  E rs2149356 AA vs AC/CC - - - 0.045 
 
b) 
Cytokine Gene RS# Model Model SNP A BV B Intxn C D 
IL-10 TLR4 rs2149356 AA/AC vs CC 0.113 0.033 0.269 0.133 
IL-12(p40) TLR4 rs2770150 CC/CT vs TT 0.043 0.009 0.988 0.816 
IL-12(p40) TLR4 rs2149356 AA/AC vs CC 0.193 0.040 0.762 0.690 
IL-12(p40) TLR4 rs1927911 CC vs CT/TT 0.205 0.045 0.770 0.752 
IL-12(p70) TLR2 rs1337 CC/CG vs GG 0.027 0.023 0.749 0.006 
IL-12(p70) TLR2 rs1337 CC/CG vs GG 0.027 0.023 0.749 0.006 
IL-12(p70) TLR4 rs2149356 AA/AC vs CC 0.071 0.009 0.848 0.316 
IL-12(p70) TLR4 rs1927911 CC vs CT/TT 0.117 0.016 0.781 0.297 
IL-12(p70) TLR4 rs2770150 CC/CT vs TT 0.126 0.020 0.687 0.581 
IL-13 TLR2 rs1337 CC/CG vs GG 0.168 0.090 0.716 0.045 
IL-13 TLR4 rs10759930 CC vs CT/TT 0.234 0.907 0.511 0.045 
IL-1β TLR4 rs1554973 CC/CT vs TT 0.000 0.000 0.090 0.940 
IL-1β TLR4 rs2149356 AA/AC vs CC 0.001 0.004 0.027 0.352 
IL-1β TLR4 rs1927911 CC vs CT/TT 0.006 0.013 0.028 0.664 
IL-1β TLR4 rs2770150 CC/CT vs TT 0.010 0.042 0.053 0.400 
IL-6 TLR4 rs2149356 AA/AC vs CC 0.005 0.009 0.559 0.280 
IL-6 TLR4 rs1554973 CC/CT vs TT 0.030 0.011 0.413 0.993 
IL-6 TLR4 rs1927911 CC vs CT/TT 0.023 0.018 0.648 0.470 
TNF-α TLR4  E rs2149356 AA/AC vs CC - - - 0.0375 
TNF-α TLR4  E rs1927911 CC vs CT/TT - - - 0.048 
A Full model p-value. Full model is transformed cytokine concentration = µ + α(SNP) + β(BV status) + 
γ(BV status*SNP) + ε 
B BV status p-value adjusted for SNP and interaction 
C SNP p-value adjusted for BV status and interaction 
D Interaction p-value adjusted for BV status and SNP 
E Indicates that Kruskal-Wallis non-parametric tests were used and therefore only the interaction p-value 
was calculated 
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Appendix Table 10. TaqSNPs genotyped for study. 
 
RS# Gene RS# Gene RS# Gene 
rs4295 ACE rs543810 IL18 rs4975220 PGRMC2 
rs4305 ACE rs5744280 IL18 rs4975180 PGRMC2 
rs4311 ACE rs360722 IL18 rs3733260 PGRMC2 
rs4362 ACE rs4937113 IL18 rs3820185 PLA2G4A 
rs4461142 ACE rs2043055 IL18 rs4651330 PLA2G4A 
rs4267385 ACE rs17561 IL1A rs2076075 PLA2G4A 
rs4459610 ACE rs2856838 IL1A rs6696406 PLA2G4A 
rs12507573 ADH1B rs1878321 IL1A rs12404877 PLA2G4A 
rs1042026 ADH1B rs2853550 IL1B rs12720497 PLA2G4A 
rs17033 ADH1B rs1143643 IL1B rs6685652 PLA2G4A 
rs13133908 ADH1B rs1143634 IL1B rs2223307 PLA2G4A 
rs1789882 ADH1B rs1143630 IL1B rs17591814 PLA2G4A 
rs1693457 ADH1B rs1143627 IL1B rs2223309 PLA2G4A 
rs4147536 ADH1B rs1143623 IL1B rs1980444 PLA2G4A 
rs1353621 ADH1B rs4848306 IL1B rs2049963 PLA2G4A 
rs1159918 ADH1B rs3917225 IL1R1 rs10911946 PLA2G4A 
rs1229982 ADH1B rs949963 IL1R1 rs12749354 PLA2G4A 
rs1229980 ADH1C rs3771202 IL1R1 rs7540602 PLA2G4A 
rs1614972 ADH1C rs2287047 IL1R1 rs6695515 PLA2G4A 
rs904096 ADH1C rs3917254 IL1R1 rs726706 PLA2G4A 
rs3762896 ADH1C rs3917273 IL1R1 rs6656909 PLA2G4A 
rs17586163 ADH1C rs3917292 IL1R1 rs1569479 PLA2G4A 
rs1662037 ADH1C rs2160227 IL1R1 rs6683515 PLA2G4A 
rs1432622 ADRB2 rs3917296 IL1R1 rs12726519 PLA2G4A 
rs12654778 ADRB2 rs951193 IL1R1 rs6683416 PLA2G4A 
rs1042713 ADRB2 rs3917304 IL1R1 rs11587539 PLA2G4A 
rs4705271 ADRB2 rs3917306 IL1R1 rs7555140 PLA2G4A 
rs745686 AKAP5 rs3171845 IL1R1 rs932476 PLA2G4A 
rs4581040 AP3M2 rs2110726 IL1R1 rs10157410 PLA2G4A 
rs4471024 AP3M2 rs3732131 IL1R1 rs7545121 PLA2G4A 
rs2373929 ATG9B rs3917332 IL1R1 rs4402086 PLA2G4A 
rs2227551 C10orf55 rs11884283 IL1R2 rs7526089 PLA2G4A 
rs2471980 C6orf48 rs6543105 IL1R2 rs761517 PLA2G4A 
rs4785224 CARD15 rs12467316 IL1R2 rs2020922 PLAT 
rs2067085 CARD15 rs4141134 IL1R2 rs879293 PLAT 
rs17312836 CARD15 rs4851520 IL1R2 rs2299609 PLAT 
rs2066843 CARD15 rs4851521 IL1R2 rs7837156 PLAT 
rs751271 CARD15 rs4851522 IL1R2 rs2020919 PLAT 
rs5743289 CARD15 rs4321386 IL1R2 rs2227562 PLAU 
rs5743291 CARD15 rs1108338 IL1R2 rs2227564 PLAU 
rs7203344 CARD15 rs7561191 IL1R2 rs34930250 PLAU 
rs8056611 CARD15 rs4851526 IL1R2 rs3805118 PLAU 
rs706208 CBS rs4851527 IL1R2 rs2461863 PLAU 
rs1051319 CBS rs2302589 IL1R2 rs4251938 PLAUR 
rs3788050 CBS rs3218861 IL1R2 rs2302524 PLAUR 
rs2124459 CBS rs2160140 IL1R2 rs4251864 PLAUR 
rs8132811 CBS rs3218883 IL1R2 rs2239372 PLAUR 
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rs1005584 CBS rs3218927 IL1R2 rs2283628 PLAUR 
rs6586282 CBS rs2072474 IL1R2 rs397374 PLAUR 
rs6586283 CBS rs3218979 IL1R2 rs4251854 PLAUR 
rs11203172 CBS rs733498 IL1R2 rs4251831 PLAUR 
rs12329764 CBS rs7589525 IL1R2 rs344787 PLAUR 
rs234705 CBS rs4851531 IL1R2 rs2286960 PLAUR 
rs234709 CBS rs9817203 IL1RAP rs344781 PLAUR 
rs2851391 CBS rs6800625 IL1RAP rs344779 PLAUR 
rs234715 CBS rs7628333 IL1RAP rs740841 PLEKHG6 
rs11701048 CBS rs3821744 IL1RAP rs2302350 PLEKHG6 
rs1788484 CBS rs7615368 IL1RAP rs783144 PLG 
rs1024611 CCL2 rs7615533 IL1RAP rs2144723 PLG 
rs1024610 CCL2 rs3773994 IL1RAP rs2314852 PLG 
rs3760396 CCL2 rs9290936 IL1RAP rs1950562 PLG 
rs4586 CCL2 rs9849030 IL1RAP rs9458011 PLG 
rs991804 CCL2 rs2059020 IL1RAP rs1652508 PLG 
rs1634491 CCL3 rs2361832 IL1RAP rs4252092 PLG 
rs1851503 CCL3 rs7626071 IL1RAP rs9295131 PLG 
rs9972960 CCL3 rs3773990 IL1RAP rs783147 PLG 
rs1634502 CCL3 rs2193880 IL1RAP rs4252125 PLG 
rs885691 CCL8 rs3773989 IL1RAP rs813641 PLG 
rs1233650 CCL8 rs1988743 IL1RAP rs4252151 PLG 
rs3138034 CCL8 rs4686554 IL1RAP rs4252159 PLG 
rs3138035 CCL8 rs16865597 IL1RAP rs4252166 PLG 
rs11575060 CCL8 rs2885370 IL1RAP rs783176 PLG 
rs3138039 CCL8 rs3773983 IL1RAP rs11060 PLG 
rs4794999 CCL8 rs3773982 IL1RAP rs9458023 PLG 
rs4914 CD14 rs3773981 IL1RAP rs783166 PLG 
rs2569190 CD14 rs9883249 IL1RAP rs6713532 POMC 
rs2569193 CD14 rs9845825 IL1RAP rs854547 PON1 
rs1061237 COL1A1 rs2241343 IL1RAP rs8491 PON1 
rs2277632 COL1A1 rs9877268 IL1RAP rs854548 PON1 
rs2586488 COL1A1 rs3773977 IL1RAP rs3735590 PON1 
rs2075559 COL1A1 rs3773976 IL1RAP rs854551 PON1 
rs2857396 COL1A1 rs4687151 IL1RAP rs854552 PON1 
rs2696247 COL1A1 rs11929157 IL1RAP rs854555 PON1 
rs2269336 COL1A1 rs10937439 IL1RAP rs3917550 PON1 
rs1107946 COL1A1 rs10937442 IL1RAP rs2269829 PON1 
rs11765563 COL1A2 rs1035347 IL1RAP rs3917542 PON1 
rs388625 COL1A2 rs1559018 IL1RAP rs662 PON1 
rs3814967 COL1A2 rs12053868 IL1RAP rs3917538 PON1 
rs1800222 COL1A2 rs6444435 IL1RAP rs854560 PON1 
rs411717 COL1A2 rs4687154 IL1RAP rs854561 PON1 
rs420257 COL1A2 rs10513854 IL1RAP rs2272365 PON1 
rs760043 COL1A2 rs7628250 IL1RAP rs3917490 PON1 
rs406226 COL1A2 rs3773958 IL1RAP rs2049649 PON1 
rs3763466 COL1A2 rs3773953 IL1RAP rs2299260 PON1 
rs17166249 COL1A2 rs1469007 IL1RAP rs2299261 PON1 
rs389328 COL1A2 rs9875362 IL1RAP rs854568 PON1 
rs42521 COL1A2 rs6781037 IL1RAP rs2299262 PON1 
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rs42523 COL1A2 rs6765375 IL1RAP rs854569 PON1 
rs42524 COL1A2 rs9821002 IL1RAP rs2237583 PON1 
rs2621213 COL1A2 rs759783 IL1RAP rs757158 PON1 
rs2521205 COL1A2 rs4140711 IL1RAP rs17166818 PON1 
rs7781954 COL1A2 rs9290939 IL1RAP rs11977702 PON2 
rs3736638 COL1A2 rs1015704 IL1RAP rs9641164 PON2 
rs42527 COL1A2 rs1015705 IL1RAP rs987539 PON2 
rs369982 COL1A2 rs4687163 IL1RAP rs2286232 PON2 
rs42528 COL1A2 rs929729 IL1RAP rs2299266 PON2 
rs4266 COL1A2 rs1024941 IL1RAP rs2237585 PON2 
rs2472 COL1A2 rs1024946 IL1RAP rs2286233 PON2 
rs42531 COL1A2 rs1024949 IL1RAP rs11981433 PON2 
rs441051 COL1A2 rs7626795 IL1RAP rs7802018 PON2 
rs400218 COL1A2 rs4624606 IL1RAP rs2299267 PON2 
rs7804898 COL1A2 rs9847868 IL1RAP rs730365 PON2 
rs413826 COL1A2 rs9821122 IL1RAP rs43037 PON2 
rs10046552 COL1A2 rs4320092 IL1RAP rs6978425 PON2 
rs6465412 COL1A2 rs9831803 IL1RAP rs16896153 PTCRA 
rs12668754 COL1A2 rs7650510 IL1RAP rs9471960 PTCRA 
rs11764718 COL1A2 rs11915384 IL1RAP rs9471966 PTCRA 
rs1062394 COL1A2 rs17042917 IL1RN rs6901007 PTCRA 
rs11982782 COL1A2 rs315920 IL1RN rs1390376 PTGER2 
rs13234022 COL1A2 rs4251961 IL1RN rs1254600 PTGER2 
rs2138533 COL3A1 rs2637988 IL1RN rs1254593 PTGER2 
rs1878201 COL3A1 rs928940 IL1RN rs708498 PTGER2 
rs1516454 COL3A1 rs3213448 IL1RN rs12147805 PTGER2 
rs1914037 COL3A1 rs1794066 IL1RN rs708505 PTGER2 
rs17358825 COL3A1 rs380092 IL1RN rs708506 PTGER2 
rs16830973 COL3A1 rs579543 IL1RN rs959 PTGER3 
rs7576108 COL3A1 rs315951 IL1RN rs1327460 PTGER3 
rs3736487 COL3A1 rs315949 IL1RN rs6656853 PTGER3 
rs3134656 COL3A1 rs315946 IL1RN rs7530345 PTGER3 
rs12693525 COL3A1 rs315943 IL1RN rs6685546 PTGER3 
rs13306267 COL3A1 rs315942 IL1RN rs17131465 PTGER3 
rs7579903 COL3A1 rs10027390 IL2 rs12119442 PTGER3 
rs2271682 COL3A1 rs2069772 IL2 rs5702 PTGER3 
rs10204508 COL3A1 rs2069771 IL2 rs1409985 PTGER3 
rs2203602 COL3A1 rs2069779 IL2 rs1327449 PTGER3 
rs3134646 COL3A1 rs2069778 IL2 rs4649932 PTGER3 
rs4667256 COL3A1 rs2069762 IL2 rs1409981 PTGER3 
rs4667258 COL3A1 rs4833248 IL2 rs4147115 PTGER3 
rs12002679 COL5A1 rs10795737 IL2RA rs4998697 PTGER3 
rs4341231 COL5A1 rs12359875 IL2RA rs7541092 PTGER3 
rs3124291 COL5A1 rs12722605 IL2RA rs1409165 PTGER3 
rs3128597 COL5A1 rs12244380 IL2RA rs17131487 PTGER3 
rs3124311 COL5A1 rs9663421 IL2RA rs4650094 PTGER3 
rs4842151 COL5A1 rs12722596 IL2RA rs875727 PTGER3 
rs11103509 COL5A1 rs2386841 IL2RA rs17541722 PTGER3 
rs4842157 COL5A1 rs12722588 IL2RA rs1327466 PTGER3 
rs4842158 COL5A1 rs2076846 IL2RA rs1887404 PTGER3 
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rs4842161 COL5A1 rs7093069 IL2RA rs17542063 PTGER3 
rs3124932 COL5A1 rs942200 IL2RA rs6424410 PTGER3 
rs12005720 COL5A1 rs2031229 IL2RA rs602383 PTGER3 
rs3128621 COL5A1 rs2228150 IL2RA rs578096 PTGER3 
rs4842167 COL5A1 rs12722563 IL2RA rs6670616 PTGER3 
rs3811161 COL5A1 rs7910961 IL2RA rs2421735 PTGER3 
rs11999194 COL5A1 rs6602392 IL2RA rs977214 PTGER3 
rs3811153 COL5A1 rs7072398 IL2RA rs6665776 PTGER3 
rs3811152 COL5A1 rs11256457 IL2RA rs594454 PTGER3 
rs3811151 COL5A1 rs6602398 IL2RA rs2300161 PTGER3 
rs10776908 COL5A1 rs11598648 IL2RA rs5697 PTGER3 
rs10745387 COL5A1 rs4749926 IL2RA rs2072947 PTGER3 
rs3827848 COL5A1 rs1107345 IL2RA rs481940 PTGER3 
rs4842172 COL5A1 rs11256497 IL2RA rs3819783 PTGER3 
rs4841937 COL5A1 rs791589 IL2RA rs3819790 PTGER3 
rs4842174 COL5A1 rs791590 IL2RA rs726764 PTGER3 
rs10114036 COL5A1 rs2476491 IL2RA rs1409164 PTGER3 
rs11103543 COL5A1 rs706779 IL2RA rs2256385 PTGER3 
rs13946 COL5A1 rs706778 IL2RA rs2300164 PTGER3 
rs6760780 COL5A2 rs3134883 IL2RA rs2050066 PTGER3 
rs3923384 COL5A2 rs12722486 IL2RA rs6424414 PTGER3 
rs6434317 COL5A2 rs7072793 IL2RA rs2300167 PTGER3 
rs6434322 COL5A2 rs7073236 IL2RA rs6678886 PTGER3 
rs10165260 COL5A2 rs2743827 IL2RB rs10789314 PTGER3 
rs7420331 COL5A2 rs228937 IL2RB rs5693 PTGER3 
rs13024858 COL5A2 rs3218339 IL2RB rs5680 PTGER3 
rs6752781 COL5A2 rs3218329 IL2RB rs5673 PTGER3 
rs1515864 COL5A2 rs84458 IL2RB rs11209736 PTGER3 
rs9288163 COL5A2 rs84460 IL2RB rs8179390 PTGER3 
rs10191420 COL5A2 rs228945 IL2RB rs2817864 PTGER3 
rs1399991 COL5A2 rs228947 IL2RB rs3000466 PTGER3 
rs10497699 COL5A2 rs2072861 IL2RB rs11999368 PTGES 
rs12611950 COL5A2 rs3218315 IL2RB rs4636306 PTGES 
rs11691604 COL5A2 rs3218312 IL2RB rs2302821 PTGES 
rs10105164 CRH rs228953 IL2RB rs4837405 PTGES 
rs6996265 CRH rs3218297 IL2RB rs10739757 PTGES 
rs3176921 CRH rs228954 IL2RB rs2241270 PTGES 
rs6472257 CRH rs3218295 IL2RB rs10988496 PTGES 
rs7839698 CRH rs3218292 IL2RB rs3766354 PTGFR 
rs10098823 CRH rs228957 IL2RB rs1555541 PTGFR 
rs32897 CRHBP rs2281094 IL2RB rs1322934 PTGFR 
rs6453267 CRHBP rs228968 IL2RB rs1322931 PTGFR 
rs10055255 CRHBP rs1362904 IL2RB rs6424776 PTGFR 
rs1875999 CRHBP rs1003694 IL2RB rs6701594 PTGFR 
rs10514082 CRHBP rs2235330 IL2RB rs12725125 PTGFR 
rs17689966 CRHR1 rs3218264 IL2RB rs3766345 PTGFR 
rs4722999 CRHR2 rs228975 IL2RB rs668005 PTGFR 
rs12701020 CRHR2 rs3218258 IL2RB rs622346 PTGFR 
rs973002 CRHR2 rs2243248 IL4 rs3766333 PTGFR 
rs929377 CRHR2 rs2070874 IL4 rs12074883 PTGFR 
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rs2240404 CRHR2 rs2227284 IL4 rs1330344 PTGS1 
rs2190242 CRHR2 rs2243263 IL4 rs1213266 PTGS1 
rs2284217 CRHR2 rs2243268 IL4 rs10306135 PTGS1 
rs6462219 CRHR2 rs2243274 IL4 rs7866582 PTGS1 
rs2284219 CRHR2 rs2243290 IL4 rs3842788 PTGS1 
rs2267716 CRHR2 rs2057768 IL4R rs10306150 PTGS1 
rs2267717 CRHR2 rs6498012 IL4R rs4273915 PTGS1 
rs3093066 CRP rs4787948 IL4R rs4240474 PTGS1 
rs1800947 CRP rs3024530 IL4R rs3842798 PTGS1 
rs1417938 CRP rs3024537 IL4R rs10306153 PTGS1 
rs231770 CTLA4 rs3024547 IL4R rs4836885 PTGS1 
rs16840252 CTLA4 rs3024548 IL4R rs9299282 PTGS1 
rs11571317 CTLA4 rs3024560 IL4R rs12238505 PTGS1 
rs5742909 CTLA4 rs2239349 IL4R rs3842801 PTGS1 
rs231777 CTLA4 rs2239347 IL4R rs10306188 PTGS1 
rs231779 CTLA4 rs3024585 IL4R rs10306202 PTGS1 
rs3087243 CTLA4 rs3024623 IL4R rs2066826 PTGS2 
rs231726 CTLA4 rs4787423 IL4R rs2745557 PTGS2 
rs231727 CTLA4 rs3024648 IL4R rs689466 PTGS2 
rs4775932 CYP19A1 rs3024658 IL4R rs689462 PTGS2 
rs4275794 CYP19A1 rs3024668 IL4R rs12042763 PTGS2 
rs2899470 CYP19A1 rs3024675 IL4R rs10911905 PTGS2 
rs16964201 CYP19A1 rs3024676 IL4R rs2179555 PTGS2 
rs2899472 CYP19A1 rs2234898 IL4R rs352143 PTK9L 
rs12439137 CYP19A1 rs1805015 IL4R rs2476601 PTPN22 
rs4775934 CYP19A1 rs1801275 IL4R rs10897270 SCGB1A1 
rs2899473 CYP19A1 rs1805016 IL4R rs3741240 SCGB1A1 
rs4775935 CYP19A1 rs8832 IL4R rs17145874 SCGB1A1 
rs3784308 CYP19A1 rs1029489 IL4R rs3764874 SCNN1A 
rs700518 CYP19A1 rs4787956 IL4R rs3917854 SELP 
rs17703883 CYP19A1 rs743562 IL5 rs6950982 SERPINE1 
rs726547 CYP19A1 rs739719 IL5 rs2227631 SERPINE1 
rs10519295 CYP19A1 rs739718 IL5 rs2227667 SERPINE1 
rs727479 CYP19A1 rs2069812 IL5 rs2227672 SERPINE1 
rs10459592 CYP19A1 rs1880243 IL6 rs2070682 SERPINE1 
rs12591359 CYP19A1 rs12700386 IL6 rs1050813 SERPINE1 
rs767199 CYP19A1 rs1800797 IL6 rs11560324 SERPINE1 
rs12911554 CYP19A1 rs1800795 IL6 rs646474 SERPINH1 
rs17703982 CYP19A1 rs2069840 IL6 rs649257 SERPINH1 
rs7172156 CYP19A1 rs1554606 IL6 rs7526293 SHE 
rs11856927 CYP19A1 rs11766273 IL6 rs11868708 SHMT1 
rs4545755 CYP19A1 rs952146 IL6R rs2273027 SHMT1 
rs1054984 CYP19A1 rs6427641 IL6R rs2273026 SHMT1 
rs4614671 CYP19A1 rs11265610 IL6R rs6596471 SLC23A1 
rs12050767 CYP19A1 rs1386821 IL6R rs6596473 SLC23A1 
rs749292 CYP19A1 rs4075015 IL6R rs11950646 SLC23A1 
rs17647719 CYP19A1 rs4601580 IL6R rs1875324 SLC35B2 
rs2305707 CYP19A1 rs4845618 IL6R rs520639 SLC35B2 
rs1902586 CYP19A1 rs6687726 IL6R rs2282151 SLC35B2 
rs16953058 CYP19A1 rs7549338 IL6R rs7224199 SLC6A4 
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rs936306 CYP19A1 rs4553185 IL6R rs1042173 SLC6A4 
rs936307 CYP19A1 rs4845622 IL6R rs3794808 SLC6A4 
rs2470176 CYP19A1 rs4845623 IL6R rs140701 SLC6A4 
rs3764221 CYP19A1 rs4537545 IL6R rs140700 SLC6A4 
rs17523880 CYP19A1 rs4845625 IL6R rs2020942 SLC6A4 
rs2470152 CYP19A1 rs4845374 IL6R rs6354 SLC6A4 
rs17523922 CYP19A1 rs11265618 IL6R rs25528 SLC6A4 
rs16964258 CYP19A1 rs10752641 IL6R rs2020936 SLC6A4 
rs3751592 CYP19A1 rs4329505 IL6R rs12150214 SLC6A4 
rs3751591 CYP19A1 rs2229238 IL6R rs4251417 SLC6A4 
rs2470150 CYP19A1 rs4072391 IL6R rs9903602 SLC6A4 
rs1902584 CYP19A1 rs4694178 IL8 rs16965628 SLC6A4 
rs1004983 CYP19A1 rs4694637 IL8 rs2020933 SLC6A4 
rs1004982 CYP19A1 rs1008563 IL8RA rs1979277 SMCR8 
rs1902585 CYP19A1 rs1008562 IL8RA rs2267163 TCN2 
rs10163138 CYP19A1 rs2854386 IL8RA rs1946519 TEX12 
rs7174997 CYP19A1 rs878887 IMP5 rs5744222 TEX12 
rs8025191 CYP19A1 rs12451328 KCNH6 rs1293344 TEX12 
rs1961177 CYP19A1 rs4790355 KIAA0664 rs12693471 TFPI 
rs4646421 CYP1A1 rs4790356 KIAA0664 rs5940 TFPI 
rs2470893 CYP1A1 rs398655 KL rs8176541 TFPI 
rs5758589 CYP2D6 rs495392 KL rs7586970 TFPI 
rs2977814 DEFA1 rs2283368 KL rs3213739 TFPI 
rs5028372 DEFA1 rs526906 KL rs8176508 TFPI 
rs11137085 DEFA3 rs9526983 KL rs8176605 TFPI 
rs4841815 DEFA3 rs9536239 KL rs34047509 TFPI 
rs4284061 DEFA3 rs577912 KL rs2041778 TFPI 
rs17466573 DEFA3 rs1207362 KL rs2192824 TFPI 
rs7825750 DEFA3 rs685417 KL rs3755248 TFPI 
rs4512398 DEFA3 rs1334928 KL rs12613071 TFPI 
rs12517451 DHFR rs1888057 KL rs2192825 TFPI 
rs1650723 DHFR rs657049 KL rs16829086 TFPI 
rs1677693 DHFR rs9527025 KL rs7573488 TFPI 
rs10072026 DHFR rs2149860 KL rs7594359 TFPI 
rs1650697 DHFR rs522796 KL rs10179730 TFPI 
rs380691 DHFR rs648202 KL rs6434222 TFPI 
rs12069358 EDN2 rs643780 KL rs10187622 TFPI 
rs1407550 EDN2 rs659117 KL rs8179181 TGFB1 
rs6690839 EDN2 rs582524 KL rs5754289 TIMP3 
rs734359 EDN2 rs2844482 LTA rs9606994 TIMP3 
rs11572340 EDN2 rs1800683 LTA rs9619311 TIMP3 
rs3754287 EDN2 rs2229094 LTA rs130274 TIMP3 
rs1077218 EDN2 rs1799964 LTA rs11704261 TIMP3 
rs883304 EDN2 rs769178 LTB rs738992 TIMP3 
rs12718439 EDN2 rs16933062 MBL2 rs242089 TIMP3 
rs4660541 EDN2 rs12771266 MBL2 rs130287 TIMP3 
rs2854450 EPHX1 rs2506 MBL2 rs242088 TIMP3 
rs3753658 EPHX1 rs10082466 MBL2 rs130290 TIMP3 
rs1877724 EPHX1 rs930507 MBL2 rs130293 TIMP3 
rs2671272 EPHX1 rs1838065 MBL2 rs5749524 TIMP3 
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rs1051740 EPHX1 rs1838066 MBL2 rs242082 TIMP3 
rs2260863 EPHX1 rs10824793 MBL2 rs80272 TIMP3 
rs2740168 EPHX1 rs11003123 MBL2 rs242078 TIMP3 
rs2740170 EPHX1 rs10824796 MBL2 rs242076 TIMP3 
rs2234922 EPHX1 rs11003129 MBL2 rs130300 TIMP3 
rs1051741 EPHX1 rs10417924 MGC20255 rs130301 TIMP3 
rs3753663 EPHX1 rs1982072 MGC4093 rs242072 TIMP3 
rs360063 EPHX1 rs16879258 MGC5297 rs4504 TIMP3 
rs4149239 EPHX2 rs17184211 MGC5297 rs135029 TIMP3 
rs2741334 EPHX2 rs1801394 MGC5297 rs5754312 TIMP3 
rs17057288 EPHX2 rs1939008 MMP1 rs2267183 TIMP3 
rs7816586 EPHX2 rs17293823 MMP1 rs1427378 TIMP3 
rs891401 EPHX2 rs7945189 MMP1 rs1427376 TIMP3 
rs721619 EPHX2 rs2071230 MMP1 rs9862 TIMP3 
rs10503812 EPHX2 rs470747 MMP1 rs137485 TIMP3 
rs17057312 EPHX2 rs7125062 MMP1 rs5749527 TIMP3 
rs4149252 EPHX2 rs5031036 MMP1 rs137487 TIMP3 
rs4149253 EPHX2 rs996999 MMP1 rs5749529 TIMP3 
rs13269963 EPHX2 rs470358 MMP1 rs137489 TIMP3 
rs1042064 EPHX2 rs514921 MMP1 rs2040435 TIMP3 
rs4149259 EPHX2 rs1155764 MMP1 rs3773364 TIMP4 
rs4149260 EPHX2 rs484915 MMP1 rs4684841 TIMP4 
rs7341557 EPHX2 rs243866 MMP2 rs99365 TIMP4 
rs2640726 EPHX2 rs1477017 MMP2 rs3755724 TIMP4 
rs3212998 F10 rs865094 MMP2 rs1898830 TLR2 
rs474810 F10 rs11646643 MMP2 rs4696483 TLR2 
rs3211744 F10 rs1053605 MMP2 rs7656411 TLR2 
rs547138 F10 rs866770 MMP2 rs1337 TLR2 
rs3211764 F10 rs2241145 MMP2 rs4862632 TLR3 
rs2026160 F10 rs243845 MMP2 rs5743303 TLR3 
rs3211770 F10 rs243842 MMP2 rs5743305 TLR3 
rs776897 F10 rs183112 MMP2 rs11721827 TLR3 
rs3213004 F10 rs1992116 MMP2 rs5743312 TLR3 
rs9549675 F10 rs11639960 MMP2 rs7668666 TLR3 
rs559054 F10 rs243836 MMP2 rs3775292 TLR3 
rs5960 F10 rs243834 MMP2 rs3775291 TLR3 
rs2070852 F2 rs11541998 MMP2 rs10025405 TLR3 
rs3136485 F2 rs243832 MMP2 rs4862633 TLR3 
rs2227744 F2R rs243831 MMP2 rs10759930 TLR4 
rs27593 F2R rs9922534 MMP2 rs16906053 TLR4 
rs37249 F2R rs2241148 MMP2 rs2770150 TLR4 
rs2227827 F2R rs8054459 MMP2 rs10759932 TLR4 
rs153311 F2R rs2192853 MMP2 rs1927911 TLR4 
rs250738 F2R rs569444 MMP3 rs1927907 TLR4 
rs11954573 F2R rs650108 MMP3 rs2149356 TLR4 
rs250731 F2R rs520540 MMP3 rs7869402 TLR4 
rs6453251 F2RL1 rs522616 MMP3 rs11536889 TLR4 
rs639342 F2RL1 rs645419 MMP3 rs1927906 TLR4 
rs2242991 F2RL1 rs1276284 MMP8 rs11536898 TLR4 
rs2243073 F2RL1 rs2508383 MMP8 rs1554973 TLR4 
160 
rs2243004 F2RL1 rs1939020 MMP8 rs7856729 TLR4 
rs2243010 F2RL1 rs17099443 MMP8 rs5741880 TLR7 
rs34308580 F2RL1 rs1940475 MMP8 rs1731478 TLR7 
rs631465 F2RL1 rs11225394 MMP8 rs179021 TLR7 
rs2243083 F2RL1 rs6590985 MMP8 rs1731479 TLR7 
rs2243066 F2RL1 rs10895354 MMP8 rs5743740 TLR7 
rs6453253 F2RL1 rs4810482 MMP9 rs179016 TLR7 
rs773902 F2RL3 rs8113877 MMP9 rs179012 TLR7 
rs2227356 F2RL3 rs6104420 MMP9 rs179011 TLR7 
rs773901 F2RL3 rs1956545 MTHFD1 rs179009 TLR7 
rs1054533 F2RL3 rs3783731 MTHFD1 rs179008 TLR7 
rs2608732 F2RL3 rs1950902 MTHFD1 rs864058 TLR7 
rs762485 F3 rs17751556 MTHFD1 rs179007 TLR7 
rs762484 F3 rs2295640 MTHFD1 rs179006 TLR7 
rs696619 F3 rs17824591 MTHFD1 rs5935438 TLR7 
rs28672143 F3 rs1885031 MTHFD1 rs178996 TLR8 
rs2187952 F5 rs8016556 MTHFD1 rs3761621 TLR8 
rs2420369 F5 rs2236225 MTHFD1 rs3761623 TLR8 
rs2213865 F5 rs3818239 MTHFD1 rs5741883 TLR8 
rs3766103 F5 rs11849530 MTHFD1 rs3764880 TLR8 
rs12131397 F5 rs1256146 MTHFD1 rs17256081 TLR8 
rs9332624 F5 rs4846048 MTHFR rs1548731 TLR8 
rs9332618 F5 rs4846049 MTHFR rs4830807 TLR8 
rs6427197 F5 rs1476413 MTHFR rs5741886 TLR8 
rs4656687 F5 rs1801131 MTHFR rs5744068 TLR8 
rs1557572 F5 rs12121543 MTHFR rs2159377 TLR8 
rs6020 F5 rs1994798 MTHFR rs2407992 TLR8 
rs6035 F5 rs1801133 MTHFR rs3747414 TLR8 
rs12120605 F5 rs17421462 MTHFR rs5741890 TLR8 
rs6427198 F5 rs17421511 MTHFR rs16987224 TLR8 
rs1894697 F5 rs4846052 MTHFR rs1800629 TNF 
rs9332575 F5 rs11121832 MTHFR rs1800693 TNFRSF1A 
rs6022 F5 rs9651118 MTHFR rs1860545 TNFRSF1A 
rs7534848 F5 rs17367504 MTHFR rs4149578 TNFRSF1A 
rs9287095 F5 rs3753582 MTHFR rs4149577 TNFRSF1A 
rs2298908 F5 rs3737964 MTHFR rs4149622 TNFRSF1A 
rs6019 F5 rs12759827 MTR rs4149570 TNFRSF1A 
rs12755775 F5 rs4659723 MTR rs11064145 TNFRSF1A 
rs10489185 F5 rs4077829 MTR rs590368 TNFRSF1B 
rs555212 F7 rs1805087 MTR rs522807 TNFRSF1B 
rs1475931 F7 rs4659743 MTR rs652625 TNFRSF1B 
rs488703 F7 rs7730643 MTRR rs496888 TNFRSF1B 
rs6045 F7 rs326121 MTRR rs976881 TNFRSF1B 
rs6046 F7 rs326123 MTRR rs3766730 TNFRSF1B 
rs3093261 F7 rs326124 MTRR rs616645 TNFRSF1B 
rs3211719 F7 rs1532268 MTRR rs816050 TNFRSF1B 
rs983751 FAS rs7703033 MTRR rs474247 TNFRSF1B 
rs4934434 FAS rs162031 MTRR rs1201157 TNFRSF1B 
rs3758483 FAS rs162033 MTRR rs653667 TNFRSF1B 
rs6586165 FAS rs162036 MTRR rs1061622 TNFRSF1B 
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rs1571011 FAS rs3815743 MTRR rs5746051 TNFRSF1B 
rs9658727 FAS rs10380 MTRR rs5746053 TNFRSF1B 
rs9658742 FAS rs8659 MTRR rs235219 TNFRSF1B 
rs7901656 FAS rs10888150 NAT1 rs1061624 TNFRSF1B 
rs2031611 FAS rs7017402 NAT1 rs1061628 TNFRSF1B 
rs9658761 FAS rs4298522 NAT1 rs1061631 TNFRSF1B 
rs982764 FAS rs9325827 NAT1 rs235214 TNFRSF1B 
rs2234978 FAS rs17126350 NAT1 rs2234185 TNRC5 
rs1051070 FAS rs4921880 NAT1 rs6519132 TOMM22 
rs7915235 FAS rs7003890 NAT1 rs5757231 TOMM22 
rs2859242 FASLG rs8190837 NAT1 rs6001193 TOMM22 
rs2639614 FASLG rs8190870 NAT1 rs10781520 TRAF2 
rs6700734 FASLG rs4646246 NAT2 rs2784075 TRAF2 
rs17370527 FASLG rs7832071 NAT2 rs908831 TRAF2 
rs5030772 FASLG rs1801280 NAT2 rs16894387 TREM1 
rs12041613 FASLG rs1799929 NAT2 rs2234243 TREM1 
rs17389016 G0S2 rs1208 NAT2 rs1817537 TREM1 
rs947895 GSTP1 rs721398 NAT2 rs3804277 TREM1 
rs140199 GSTT2 rs721399 NAT2 rs4711668 TREM1 
rs2586482 HILS1 rs980455 NFKB1 rs6910730 TREM1 
rs2586485 HILS1 rs3774933 NFKB1 rs6940092 TREM1 
rs2235543 HSD11B1 rs1599961 NFKB1 rs6939973 TREM1 
rs4844880 HSD11B1 rs1585213 NFKB1 rs3827632 TREM1 
rs846910 HSD11B1 rs230528 NFKB1 rs3789204 TREM1 
rs3753519 HSD11B1 rs4648011 NFKB1 rs1385105 TREM1 
rs846911 HSD11B1 rs13117745 NFKB1 rs8009058 TSHR 
rs11799643 HSD11B1 rs1801 NFKB1 rs2268451 TSHR 
rs12040780 HSD11B1 rs4648058 NFKB1 rs12892567 TSHR 
rs846906 HSD11B1 rs3755867 NFKB1 rs179247 TSHR 
rs6672256 HSD11B1 rs4648090 NFKB1 rs179259 TSHR 
rs9430012 HSD11B1 rs3774968 NFKB1 rs179260 TSHR 
rs932335 HSD11B1 rs3817685 NFKB1 rs179261 TSHR 
rs1780019 HSD17B7 rs4648135 NFKB1 rs2110696 TSHR 
rs11589262 HSD17B7 rs4648141 NFKB1 rs1035145 TSHR 
rs4656381 HSD17B7 rs1609798 NFKB1 rs3783950 TSHR 
rs1039874 HSD17B7 rs7674640 NFKB1 rs3783948 TSHR 
rs2805053 HSD17B7 rs997476 NFKB1 rs7143071 TSHR 
rs2803865 HSD17B7 rs10489113 NFKB1 rs17111361 TSHR 
rs10906772 HSPA14 rs11574845 NFKB2 rs6574616 TSHR 
rs11593057 HSPA14 rs7897947 NFKB2 rs724169 TSHR 
rs17155992 HSPA14 rs1056890 NFKB2 rs2300520 TSHR 
rs7894284 HSPA14 rs3138056 NFKBIA rs4903964 TSHR 
rs9787671 HSPA14 rs696 NFKBIA rs917986 TSHR 
rs7905174 HSPA14 rs3138045 NFKBIA rs17545310 TSHR 
rs10906774 HSPA14 rs11575002 NFKBIB rs3783943 TSHR 
rs1043618 HSPA1A rs2053071 NFKBIB rs8012937 TSHR 
rs2763979 HSPA1A rs2241704 NFKBIB rs10483973 TSHR 
rs2075800 HSPA1L rs2241705 NFKBIB rs2300521 TSHR 
rs2227956 HSPA1L rs3136641 NFKBIB rs12881268 TSHR 
rs4574536 HSPA4 rs9636109 NFKBIB rs2268466 TSHR 
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rs4705990 HSPA4 rs11083487 NFKBIB rs4903967 TSHR 
rs4616886 HSPA4 rs3136646 NFKBIB rs7161100 TSHR 
rs7730747 HSPA4 rs730775 NFKBIE rs2300525 TSHR 
rs10075878 HSPA4 rs483536 NFKBIE rs2110697 TSHR 
rs9427401 HSPA6 rs10277237 NOS3 rs1005292 TSHR 
rs12129787 HSPA6 rs12703107 NOS3 rs722540 TSHR 
rs4657053 HSPA6 rs1800783 NOS3 rs17111394 TSHR 
rs4657054 HSPA6 rs1799983 NOS3 rs2268474 TSHR 
rs404508 HSPA6 rs3918227 NOS3 rs2300528 TSHR 
rs2099684 HSPA6 rs743507 NOS3 rs2284735 TSHR 
rs10878763 IFNG rs17287758 NR3C1 rs2075173 TSHR 
rs2069727 IFNG rs10482682 NR3C1 rs17111431 TSHR 
rs2069718 IFNG rs4986593 NR3C1 rs10129380 TSHR 
rs2069716 IFNG rs33388 NR3C1 rs17111481 TSHR 
rs2069705 IFNG rs17100236 NR3C1 rs7150670 TSHR 
rs1520220 IGF1 rs2918417 NR3C1 rs2268475 TSHR 
rs2471551 IGFBP3 rs2963155 NR3C1 rs11159491 TSHR 
rs4803648 IGSF4C rs9324918 NR3C1 rs2024426 TSHR 
rs4802189 IGSF4C rs9324921 NR3C1 rs11845715 TSHR 
rs3024498 IL10 rs4634384 NR3C1 rs12885526 TSHR 
rs3024496 IL10 rs9324924 NR3C1 rs8017455 TSHR 
rs1800872 IL10 rs7701443 NR3C1 rs917984 TSHR 
rs1800896 IL10 rs4244032 NR3C1 rs7158881 TSHR 
rs1800890 IL10 rs4607376 NR3C1 rs6574629 TSHR 
rs4936414 IL10RA rs13182800 NR3C1 rs2268476 TSHR 
rs2512143 IL10RA rs4912911 NR3C1 rs3783938 TSHR 
rs4252254 IL10RA rs12656106 NR3C1 rs17111530 TSHR 
rs4252270 IL10RA rs12655166 NR3C1 rs930099 TSHR 
rs2229113 IL10RA rs6502385 PAFAH1B1 rs7157900 TSHR 
rs9610 IL10RA rs7209407 PAFAH1B1 rs1957547 TSHR 
rs2508445 IL10RA rs7213463 PAFAH1B1 rs2300540 TSHR 
rs947889 IL10RA rs3785958 PAFAH1B1 rs1991517 TSHR 
rs4938467 IL10RA rs1029744 PAFAH1B1 rs2268477 TSHR 
rs11216666 IL10RA rs11078302 PAFAH1B1 rs7144481 TSHR 
rs17121510 IL10RA rs12938775 PAFAH1B1 rs17630128 TSHR 
rs2284552 IL10RB rs2317297 PAFAH1B1 rs2288493 TSHR 
rs962859 IL10RB rs7223411 PAFAH1B1 rs12883801 TSHR 
rs2834168 IL10RB rs4790353 PAFAH1B1 rs6742078 UGT1A1 
rs2834170 IL10RB rs4938347 PAFAH1B2 rs4148324 UGT1A1 
rs2243498 IL10RB rs3736120 PAFAH1B2 rs12479045 UGT1A1 
rs2834172 IL10RB rs6001188 PGEA1 rs4663971 UGT1A1 
rs765429 IL10RB rs11224561 PGR rs929596 UGT1A1 
rs2276223 IL10RB rs471767 PGR rs2302538 UGT1A1 
rs735299 IL10RB rs563656 PGR rs4148328 UGT1A1 
rs999261 IL10RB rs504372 PGR rs11888492 UGT1A1 
rs999259 IL10RB rs578029 PGR rs10929303 UGT1A1 
rs1058867 IL10RB rs635984 PGR rs8330 UGT1A1 
rs6517158 IL10RB rs11224575 PGR rs4148329 UGT1A1 
rs2834175 IL10RB rs492457 PGR rs6717546 UGT1A1 
rs3091307 IL13 rs518382 PGR rs1500482 UGT1A1 
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rs1295686 IL13 rs553272 PGR rs6719561 UGT1A1 
rs848 IL13 rs660149 PGR rs4663972 UGT1A1 
rs1295683 IL13 rs653752 PGR rs7586006 UGT1A1 
rs2243204 IL13 rs538915 PGR rs1500477 UGT1A1 
rs12508866 IL15 rs503362 PGR rs3755319 UGT1A3 
rs1519551 IL15 rs542384 PGR rs699947 VEGF 
rs17461269 IL15 rs555572 PGR rs833068 VEGF 
rs1519552 IL15 rs11224589 PGR rs833069 VEGF 
rs7698675 IL15 rs619487 PGR rs3025010 VEGF 
rs13117878 IL15 rs537681 PGR rs3025033 VEGF 
rs12498901 IL15 rs518162 PGR rs3025035 VEGF 
rs6850492 IL15 rs507141 PGR rs998584 VEGF 
rs1907949 IL15 rs2499043 PGRMC1 rs6900017 VEGF 
rs17007610 IL15 rs2428757 PGRMC1   
rs6537061 IL15 rs11726595 PGRMC2   
rs10833 IL15 rs2036687 PGRMC2   
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Appendix Table 11. Significant maternal and fetal single locus results. 
 
MATERNAL SAMPLES FETAL SAMPLES 
Gene RS # Allele p 
Genotype 
p Gene RS # 
Allele 
p 
Genotype 
p 
ADH1B rs17033 0.09 0.02 ADH1B rs17033 0.04 0.05 
ADRB2 rs1432622 0.05 0.13 C6orf48 rs2471980 0.02 3.8E-03 
ADRB2 rs12654778 0.03 0.09 COL1A2 rs388625 0.01 0.01 
AP3M2 rs4581040 0.04 0.11 COL1A2 rs411717 0.01 0.01 
CARD15 rs8056611 0.11 0.04 COL1A2 rs420257 1.4E-03 9.6E-04 
CBS rs6586282 0.22 4.7E-03 COL1A2 rs389328 0.01 0.01 
CBS rs11203172 0.32 0.05 COL1A2 rs42524 0.01 0.02 
COL1A1 rs1061237 0.33 0.04 COL1A2 rs2521205 0.04 0.13 
COL1A2 rs2521205 0.02 0.05 COL1A2 rs42528 0.01 0.02 
COL1A2 rs2472 1.6E-03 1.2E-03 COL1A2 rs2472 0.01 0.01 
COL1A2 rs7804898 0.21 0.02 COL1A2 rs441051 2.8E-03 0.01 
COL3A1 rs2271682 0.04 0.05 COL3A1 rs2138533 0.32 0.01 
COL5A1 rs12005720 0.28 0.04 COL5A1 rs3124932 0.03 0.06 
COL5A1 rs4842167 0.01 0.04 COL5A2 rs7420331 0.07 0.01 
COL5A1 rs3811161 0.01 0.04 CRH rs6996265 0.03 0.01 
COL5A1 rs10745387 0.03 0.10 CRH rs3176921 0.03 0.01 
COL5A1 rs13946 0.04 0.12 CRH rs6472257 0.02 4.2E-03 
CRHR2 rs4722999 5.0E-03 0.02 CRHBP rs10514082 0.34 0.01 
CRHR2 rs12701020 0.09 0.02 CRHR2 rs2190242 0.82 0.05 
CRHR2 rs929377 0.01 0.03 CYP19A1 rs8025191 0.04 0.05 
CRHR2 rs2190242 0.03 0.09 EPHX2 rs4149239 0.58 0.03 
CRHR2 rs2284219 0.01 0.04 EPHX2 rs891401 0.57 0.03 
CYP19A1 rs727479 0.69 0.05 EPHX2 rs10503812 0.57 0.03 
CYP19A1 rs17647719 0.04 0.08 EPHX2 rs4149252 0.58 0.03 
CYP19A1 rs3751592 0.43 0.03 EPHX2 rs4149259 0.42 0.02 
EDN2 rs4660541 0.86 0.05 F2R rs27593 0.33 0.04 
EPHX1 rs2740168 0.85 0.02 F5 rs1557572 0.54 0.05 
F10 rs3211744 0.07 0.05 G0S2 rs17389016 0.01 0.02 
F3 rs762484 0.01 0.04 HSD11B1 rs3753519 0.01 1.5E-03 
F3 rs696619 0.05 0.09 HSD17B7 rs4656381 0.03 2.9E-03 
F7 rs1475931 0.46 2.3E-03 HSPA1A rs2763979 0.03 0.01 
FAS rs9658742 0.62 0.03 HSPA6 rs9427401 0.01 0.02 
GSTP1 rs947895 0.07 0.04 IGSF4C rs4803648 0.95 0.01 
IL18 rs543810 0.31 0.04 IGSF4C rs4802189 0.72 0.01 
IL1B rs1143630 0.03 0.04 IL10RB rs999261 0.01 0.03 
IL1R1 rs3917273 0.04 0.02 IL10RB rs6517158 0.04 0.09 
IL1R1 rs2110726 0.43 0.03 IL13 rs1295683 0.02 0.04 
IL1R2 rs11884283 0.17 0.02 IL15 rs17461269 0.03 0.01 
IL1R2 rs12467316 0.06 0.01 IL15 rs1519552 0.02 0.06 
IL1R2 rs1108338 0.02 0.01 IL15 rs7698675 0.03 0.07 
IL1RAP rs7628333 1.8E-03 4.7E-03 IL15 rs13117878 0.02 0.05 
IL1RAP rs3821744 4.7E-03 0.01 IL15 rs6850492 0.04 0.09 
IL1RAP rs9883249 0.03 0.07 IL15 rs17007610 0.03 0.07 
IL1RN rs315920 4.9E-03 0.01 IL15 rs6537061 0.01 0.03 
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IL1RN rs4251961 0.03 0.08 IL1A rs17561 0.02 0.06 
IL1RN rs315946 0.01 0.03 IL1A rs2856838 0.03 0.02 
IL2RA rs11598648 0.25 0.02 IL1A rs1878321 0.02 0.06 
IL2RA rs1107345 0.04 0.06 IL1R1 rs3917225 0.03 0.08 
IL2RA rs11256497 0.03 0.10 IL1R1 rs2287047 0.01 0.04 
IL2RA rs706778 0.05 0.11 IL1R1 rs3917273 0.01 0.03 
IL2RA rs3134883 0.04 0.10 IL1R1 rs2160227 0.02 0.08 
IL2RB rs228954 0.01 0.03 IL1R1 rs3917304 0.02 0.07 
IL2RB rs228957 0.01 0.03 IL1RAP rs7628333 0.18 0.02 
IL2RB rs2281094 0.03 0.08 IL1RAP rs2193880 0.03 0.08 
IL4R rs3024548 0.13 0.04 IL1RAP rs9877268 0.24 0.05 
IL4R rs3024623 0.05 0.02 IL1RAP rs759783 0.03 0.09 
IL6R rs4845374 0.04 0.03 IL1RAP rs4140711 0.03 0.09 
IL6R rs4329505 0.04 0.03 IL1RAP rs1015704 0.02 0.04 
IL8RA rs1008562 0.05 0.04 IL1RAP rs1015705 0.03 0.09 
KL rs495392 0.85 0.02 IL1RAP rs4687163 0.03 0.09 
KL rs522796 0.16 0.04 IL1RAP rs929729 0.04 0.10 
MMP2 rs1053605 0.04 0.07 IL2RA rs12722596 0.03 0.08 
MTHFD1 rs17824591 0.03 0.11 IL2RA rs11256497 0.01 0.03 
MTHFD1 rs2236225 0.97 0.04 IL2RA rs2476491 0.03 0.02 
MTHFR rs11121832 0.03 0.05 IL2RA rs706778 0.03 0.09 
MTHFR rs3737964 0.02 0.03 IL2RA rs3134883 0.04 0.09 
MTRR rs162031 0.02 0.05 IL4 rs2070874 0.02 0.03 
MTRR rs3815743 0.03 0.01 IL4 rs2227284 0.01 0.03 
NAT1 rs7017402 0.04 0.05 IL4 rs2243268 0.02 0.04 
NAT1 rs9325827 0.05 0.08 IL4 rs2243274 0.02 0.03 
NAT1 rs4921880 0.52 0.02 IL4 rs2243290 0.02 0.04 
NFKB1 rs10489113 0.39 0.04 IL4R rs3024530 0.03 0.05 
NR3C1 rs33388 0.77 0.01 IL4R rs3024537 0.06 0.02 
NR3C1 rs2918417 0.97 0.04 IL4R rs3024547 0.06 0.02 
NR3C1 rs4634384 0.72 0.01 IL4R rs3024548 0.02 0.05 
PAFAH1
 
rs7213463 0.02 0.06 IL4R rs3024560 0.02 0.06 
PGR rs555572 0.01 0.03 IL4R rs2239347 1.4E-03 3.8E-03 
PGR rs11224589 0.01 0.02 IL4R rs3024676 0.03 0.08 
PGR rs619487 0.04 0.02 IL4R rs1805015 0.04 0.10 
PGRMC2 rs11726595 0.11 4.7E-03 MMP8 rs1939020 0.03 0.06 
PLA2G4A rs2076075 0.02 0.06 MTHFR rs4846048 0.05 0.10 
PLAT rs2020922 0.03 0.08 MTHFR rs1476413 0.05 0.02 
PLG rs4252092 0.01 0.03 MTHFR rs1994798 3.9E-03 0.01 
PLG rs783147 0.03 0.06 MTHFR rs17421462 0.01 0.01 
PLG rs4252166 0.04 0.01 MTHFR rs17421511 0.25 0.01 
PON1 rs2299260 0.34 0.03 MTHFR rs4846052 0.01 0.01 
PON1 rs854569 0.04 4.4E-03 MTHFR rs11121832 0.01 0.02 
PON2 rs43037 0.17 0.03 MTHFR rs9651118 2.5E-03 0.01 
PTGER3 rs959 0.58 0.03 MTHFR rs3737964 0.01 0.02 
PTGER3 rs6685546 0.03 0.08 MTRR rs1532268 0.88 0.05 
PTGER3 rs17131465 0.03 0.06 NFKB1 rs13117745 0.01 0.02 
PTGER3 rs12119442 0.03 0.06 NFKB1 rs4648090 0.02 0.03 
PTGER3 rs5702 0.57 0.02 NFKB1 rs4648141 0.05 0.10 
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PTGER3 rs7541092 0.03 0.03 NFKBIB rs3136646 0.07 0.03 
PTGER3 rs1409165 0.02 0.03 NR3C1 rs9324918 0.38 0.04 
PTGER3 rs17131487 0.03 0.09 PGR rs518162 0.01 0.02 
PTGER3 rs875727 0.18 0.05 PGRMC1 rs2428757 0.07 0.03 
PTGER3 rs977214 0.06 0.04 PLAUR rs4251854 0.21 0.03 
PTGER3 rs6665776 0.06 0.04 PLG rs9458011 0.03 0.07 
PTGER3 rs2072947 0.20 0.03 PON1 rs854547 0.05 0.10 
PTGES rs2302821 0.05 0.01 PON1 rs854548 2.5E-03 0.01 
PTGES rs2241270 0.05 0.11 PON1 rs854551 0.01 0.02 
PTGFR rs3766345 0.03 0.08 PON1 rs854552 1.8E-03 0.01 
PTGFR rs668005 0.04 0.13 PON1 rs2272365 0.04 0.12 
SLC35B2 rs2282151 0.02 0.06 PON1 rs757158 0.01 0.01 
SLC6A4 rs4251417 0.01 0.01 PON2 rs2286233 0.04 0.11 
TFPI rs12693471 0.01 0.01 PTGER2 rs1254600 0.11 0.04 
TFPI rs8176541 0.01 0.01 PTGER3 rs17131465 0.05 0.04 
TFPI rs7586970 0.01 0.01 PTGER3 rs2256385 0.03 0.10 
TFPI rs3213739 0.03 2.4E-03 PTGER3 rs6424414 0.03 0.08 
TFPI rs8176508 0.16 0.05 PTGER3 rs2300167 0.06 0.01 
TFPI rs2041778 0.04 0.06 PTGFR rs1322934 0.11 0.02 
TFPI rs3755248 0.01 0.02 PTGFR rs668005 0.02 0.01 
TFPI rs7573488 0.01 0.01 SERPINE
 
rs2227667 0.03 0.05 
TIMP3 rs2040435 0.83 0.05 SLC6A4 rs7224199 0.01 0.03 
TREM1 rs16894387 0.04 0.12 SLC6A4 rs1042173 0.01 0.03 
TREM1 rs4711668 2.9E-03 0.01 SLC6A4 rs3794808 0.02 0.06 
TREM1 rs6940092 0.02 0.05 SLC6A4 rs140701 0.02 0.07 
TSHR rs1035145 0.05 0.17 SLC6A4 rs2020942 0.02 0.06 
TSHR rs2300520 0.04 0.08 SLC6A4 rs4251417 8.0E-04 2.7E-03 
TSHR rs2110697 0.40 0.04 SMCR8 rs1979277 0.02 0.01 
TSHR rs11845715 0.78 0.02 TCN2 rs2267163 0.03 0.07 
TSHR rs3783938 0.05 0.17 TFPI rs12693471 4.0E-03 0.01 
UGT1A1 rs4148329 0.43 0.03 TFPI rs8176541 4.3E-03 0.01 
UGT1A1 rs6719561 0.07 0.01 TFPI rs7586970 3.7E-03 0.01 
    TFPI rs3213739 4.4E-03 0.01 
    TFPI rs8176508 3.7E-03 0.01 
    TFPI rs2041778 0.03 0.08 
    TFPI rs3755248 0.03 0.09 
    TFPI rs7573488 0.02 0.06 
    TFPI rs6434222 5.8E-05 1.0E-04 
    TIMP3 rs5754289 0.87 0.03 
    TIMP4 rs3773364 0.29 0.04 
    TLR4 rs7869402 0.04 0.05 
    TOMM22 rs6519132 0.05 0.05 
    TREM1 rs6939973 0.02 0.04 
    TSHR rs4903964 0.44 0.03 
    TSHR rs3783943 0.05 0.14 
    TSHR rs930099 0.03 0.07 
    UGT1A1 rs929596 0.22 0.03 
    UGT1A1 rs2302538 0.86 0.04 
    UGT1A1 rs11888492 0.45 0.03 
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Appendix Table 12. Significant haplotype results. a) Maternal, b) Fetal 
 
a) 
Gene Haplotype p 
COL1A2  rs369982 rs42528 rs4266 rs2472  0.04 
COL1A2  rs42528 rs4266 rs2472  4.9E-03 
COL1A2  rs42528 rs4266 rs2472 rs42531  0.02 
COL1A2  rs4266 rs2472  0.01 
COL1A2  rs4266 rs2472 rs42531 rs441051  0.01 
COL1A2  rs4266 rs2472 rs42531  0.01 
COL1A2  rs2472 rs42531 rs441051  3.1E-03 
COL1A2  rs2472 rs42531  4.9E-03 
COL1A2  rs2472 rs42531 rs441051 rs400218  0.01 
COL1A2  rs12668754 rs11764718 rs1062394  0.01 
COL1A2  rs12668754 rs11764718 rs1062394 rs11982782  0.03 
CRHR2  rs4722999 rs12701020  0.02 
CRHR2  rs4722999 rs12701020 rs973002  0.04 
CRHR2  rs973002 rs929377  0.03 
CRHR2  rs973002 rs929377 rs2240404  0.05 
CRHR2  rs929377 rs2240404  0.04 
CRHR2  rs6462219 rs2284219  0.03 
CRHR2  rs6462219 rs2284219 rs2267716  0.04 
CRHR2  rs2284219 rs2267716  0.04 
IL1RAP  rs7628333 rs3821744  1.8E-03 
IL1RAP  rs7628333 rs3821744 rs9290936  0.01 
IL1RAP  rs7628333 rs3821744 rs9290936 rs9849030  0.03 
IL1RAP  rs3821744 rs9290936  0.02 
IL1RN  rs17042917 rs315920 rs4251961  3.2E-03 
IL1RN  rs17042917 rs315920  0.01 
IL1RN  rs17042917 rs315920 rs4251961 rs2637988  0.01 
IL1RN  rs315920 rs4251961  0.01 
IL1RN  rs315920 rs4251961 rs2637988  0.01 
IL1RN  rs315920 rs4251961 rs2637988 rs928940  0.02 
IL1RN  rs4251961 rs2637988  0.01 
IL1RN  rs4251961 rs2637988 rs928940 rs3213448  0.01 
IL1RN  rs4251961 rs2637988 rs928940  0.01 
IL1RN  rs928940 rs3213448 rs1794066 rs380092  0.01 
IL1RN  rs3213448 rs1794066 rs380092  0.01 
IL1RN  rs3213448 rs1794066 rs380092 rs579543  0.01 
IL1RN  rs1794066 rs380092 rs579543  0.01 
IL1RN  rs1794066 rs380092 rs579543 rs315951  0.01 
IL1RN  rs1794066 rs380092  0.02 
IL1RN  rs579543 rs315951 rs315949 rs315946  0.01 
IL1RN  rs315951 rs315949 rs315946  0.01 
IL1RN  rs315951 rs315949 rs315946 rs315943  0.01 
IL1RN  rs315949 rs315946  0.02 
IL1RN  rs315949 rs315946 rs315943  0.02 
IL1RN  rs315949 rs315946 rs315943 rs315942  0.04 
IL1RN  rs315946 rs315943 rs315942 rs12693471  3.2E-03 
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IL1RN  rs315946 rs315943  0.02 
IL1RN  rs315946 rs315943 rs315942  0.04 
IL1RN  rs315943 rs315942 rs12693471  0.02 
IL1RN  rs315943 rs315942 rs12693471 rs8176541  0.02 
IL1RN  rs315942 rs12693471  0.05 
IL1RN  rs315942 rs12693471 rs8176541  0.05 
IL1RN  rs315942 rs12693471 rs8176541 rs7586970  0.05 
TFPI  rs12693471 rs8176541  0.01 
TFPI  rs12693471 rs8176541 rs7586970  0.01 
TFPI  rs12693471 rs8176541 rs7586970 rs3213739  0.03 
TFPI  rs8176541 rs7586970  0.01 
TFPI  rs8176541 rs7586970 rs3213739  0.03 
TFPI  rs7586970 rs3213739  0.03 
TFPI  rs2041778 rs2192824 rs3755248  0.04 
TFPI  rs2192824 rs3755248  0.02 
TFPI  rs2192824 rs3755248 rs12613071  0.04 
TFPI  rs12613071 rs16829086 rs7573488  0.02 
TFPI  rs16829086 rs7573488  0.03 
TFPI  rs7573488 rs7594359  0.03 
TFPI  rs7573488 rs7594359 rs10179730  0.04 
TREM1  rs16894387 rs2234243 rs1817537  0.04 
TREM1  rs16894387 rs2234243 rs1817537 rs3804277  0.04 
TREM1  rs2234243 rs1817537 rs3804277 rs4711668  0.02 
TREM1  rs2234243 rs1817537  0.03 
TREM1  rs2234243 rs1817537 rs3804277  0.03 
TREM1  rs1817537 rs3804277 rs4711668  0.01 
TREM1  rs1817537 rs3804277 rs4711668 rs6910730  0.02 
TREM1  rs3804277 rs4711668  0.01 
TREM1  rs3804277 rs4711668 rs6910730  0.02 
TREM1  rs3804277 rs4711668 rs6910730 rs6940092  0.02 
TREM1  rs4711668 rs6910730 rs6940092 rs6939973  0.01 
TREM1  rs4711668 rs6910730  0.01 
TREM1  rs4711668 rs6910730 rs6940092  0.01 
TREM1  rs6910730 rs6940092 rs6939973 rs3827632  0.01 
TREM1  rs6910730 rs6940092 rs6939973  0.01 
TREM1  rs6910730 rs6940092  0.01 
TREM1  rs6940092 rs6939973 rs3827632  0.01 
TREM1  rs6940092 rs6939973 rs3827632 rs1385105  0.01 
TREM1  rs6940092 rs6939973  0.02 
 
b) 
Gene Haplotype p 
C6orf48  rs2471980 rs16894387  0.02 
C6orf48  rs2471980 rs16894387 rs2234243  0.02 
C6orf48  rs2471980 rs16894387 rs2234243 rs1817537  0.04 
COL1A2  rs11765563 rs388625 rs1800222  0.01 
COL1A2  rs11765563 rs388625 rs1800222 rs411717  0.01 
COL1A2  rs11765563 rs388625  0.02 
COL1A2  rs388625 rs1800222  4.4E-03 
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COL1A2  rs388625 rs1800222 rs411717  4.4E-03 
COL1A2  rs388625 rs1800222 rs411717 rs420257  0.01 
COL1A2  rs1800222 rs411717  4.4E-03 
COL1A2  rs1800222 rs411717 rs420257  0.01 
COL1A2  rs1800222 rs411717 rs420257 rs760043  0.01 
COL1A2  rs411717 rs420257  0.01 
COL1A2  rs411717 rs420257 rs760043  0.01 
COL1A2  rs411717 rs420257 rs760043 rs406226  0.03 
COL1A2  rs420257 rs760043  0.01 
COL1A2  rs420257 rs760043 rs406226  0.01 
COL1A2  rs420257 rs760043 rs406226 rs3763466  0.04 
COL1A2  rs760043 rs406226 rs3763466 rs17166249  0.05 
COL1A2  rs406226 rs3763466  0.04 
COL1A2  rs17166249 rs389328  0.04 
COL1A2  rs389328 rs42521  0.04 
COL1A2  rs42523 rs42524  0.03 
COL1A2  rs42524 rs2621213  0.03 
COL1A2  rs369982 rs42528 rs4266 rs2472  1.0E-03 
COL1A2  rs369982 rs42528  0.02 
COL1A2  rs369982 rs42528 rs4266  0.03 
COL1A2  rs42528 rs4266 rs2472  4.2E-04 
COL1A2  rs42528 rs4266 rs2472 rs42531  5.2E-04 
COL1A2  rs42528 rs4266  0.01 
COL1A2  rs4266 rs2472 rs42531 rs441051  3.9E-04 
COL1A2  rs4266 rs2472 rs42531  1.7E-03 
COL1A2  rs4266 rs2472  0.01 
COL1A2  rs2472 rs42531 rs441051  1.9E-04 
COL1A2  rs2472 rs42531 rs441051 rs400218  5.5E-04 
COL1A2  rs2472 rs42531  2.4E-03 
COL1A2  rs42531 rs441051  0.01 
COL1A2  rs42531 rs441051 rs400218  0.03 
COL1A2  rs441051 rs400218  0.01 
COL1A2  rs441051 rs400218 rs7804898 rs10046552  0.03 
COL1A2  rs441051 rs400218 rs7804898  0.03 
COL1A2  rs400218 rs7804898 rs10046552  0.03 
COL1A2  rs13234022 rs854547 rs8491 rs854548  0.02 
CRH  rs6996265 rs3176921 rs6472257  0.02 
CRH  rs6996265 rs3176921  0.03 
CRH  rs3176921 rs6472257  0.02 
HSD11B1  rs2235543 rs4844880 rs846910 rs3753519  0.01 
HSD11B1  rs4844880 rs846910 rs3753519  0.04 
HSD11B1  rs4844880 rs846910 rs3753519 rs6672256  0.04 
HSD11B1  rs846910 rs3753519 rs6672256  0.01 
HSD11B1  rs846910 rs3753519 rs6672256 rs9430012  0.01 
HSD11B1  rs846910 rs3753519  0.03 
HSD11B1  rs3753519 rs6672256  0.01 
HSD11B1  rs3753519 rs6672256 rs9430012  0.01 
HSD11B1  rs3753519 rs6672256 rs9430012 rs932335  0.01 
IL4R  rs4787948 rs3024530 rs3024537  0.04 
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IL4R  rs4787948 rs3024530 rs3024537 rs3024547  0.04 
IL4R  rs4787948 rs3024530  0.05 
IL4R  rs3024537 rs3024547 rs3024548  0.04 
IL4R  rs3024547 rs3024548 rs3024560 rs2239347  0.04 
IL4R  rs3024547 rs3024548  0.04 
IL4R  rs3024548 rs3024560 rs2239347  0.01 
IL4R  rs3024548 rs3024560 rs2239347 rs3024623  0.01 
IL4R  rs3024548 rs3024560  0.05 
IL4R  rs3024560 rs2239347  1.8E-03 
IL4R  rs3024560 rs2239347 rs3024623 rs4787423  3.7E-03 
IL4R  rs3024560 rs2239347 rs3024623  0.01 
IL4R  rs2239347 rs3024623 rs4787423 rs3024676  2.1E-03 
IL4R  rs2239347 rs3024623 rs4787423  2.7E-03 
IL4R  rs2239347 rs3024623  0.01 
MTHFR  rs4846048 rs4846049 rs1476413  1.4E-03 
MTHFR  rs4846048 rs4846049 rs1476413 rs1801131  2.0E-03 
MTHFR  rs4846048 rs4846049  2.8E-03 
MTHFR  rs1476413 rs1801131 rs12121543 rs1994798  1.7E-03 
MTHFR  rs1801131 rs12121543 rs1994798  3.1E-03 
MTHFR  rs1801131 rs12121543 rs1994798 rs1801133  0.02 
MTHFR  rs12121543 rs1994798 rs1801133 
  
0.01 
MTHFR  rs12121543 rs1994798  0.01 
MTHFR  rs12121543 rs1994798 rs1801133  0.03 
MTHFR  rs1994798 rs1801133 rs17421462  0.01 
MTHFR  rs1994798 rs1801133  0.02 
MTHFR  rs1994798 rs1801133 rs17421462 
  
0.02 
MTHFR  rs1801133 rs17421462 rs17421511 
  
0.02 
MTHFR  rs1801133 rs17421462 rs17421511  0.02 
MTHFR  rs1801133 rs17421462  0.03 
MTHFR  rs17421462 rs17421511  0.01 
MTHFR  rs17421462 rs17421511 rs4846052  0.01 
MTHFR  rs17421462 rs17421511 rs4846052 
  
0.01 
MTHFR  rs17421511 rs4846052 rs11121832 
  
3.9E-03 
MTHFR  rs17421511 rs4846052 rs11121832  0.01 
MTHFR  rs17421511 rs4846052  0.03 
MTHFR  rs4846052 rs11121832 rs9651118  0.01 
MTHFR  rs4846052 rs11121832 rs9651118 
  
0.01 
MTHFR  rs4846052 rs11121832  0.02 
MTHFR  rs11121832 rs9651118  2.3E-03 
MTHFR  rs11121832 rs9651118 rs17367504 
  
2.8E-03 
MTHFR  rs11121832 rs9651118 rs17367504  0.01 
MTHFR  rs9651118 rs17367504 rs3753582 rs3737964  2.5E-03 
MTHFR  rs9651118 rs17367504 rs3753582  4.6E-03 
MTHFR  rs9651118 rs17367504  0.01 
MTHFR  rs17367504 rs3753582 rs3737964  4.7E-03 
MTHFR  rs17367504 rs3753582 rs3737964 rs590368  0.01 
MTHFR  rs3753582 rs3737964  2.8E-03 
MTHFR  rs3753582 rs3737964 rs590368  0.01 
MTHFR  rs3753582 rs3737964 rs590368 rs652625  0.04 
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MTHFR  rs3737964 rs590368  0.05 
PON1  rs854547 rs8491 rs854548  0.02 
PON1  rs854547 rs8491 rs854548 rs854551  0.03 
PON1  rs8491 rs854548  0.01 
PON1  rs8491 rs854548 rs854551 rs854552  0.01 
PON1  rs8491 rs854548 rs854551  0.01 
PON1  rs854548 rs854551 rs854552  3.2E-03 
PON1  rs854548 rs854551  3.6E-03 
PON1  rs854548 rs854551 rs854552 rs854555  0.01 
PON1  rs854551 rs854552  0.01 
PON1  rs854551 rs854552 rs854555  0.01 
PON1  rs854551 rs854552 rs854555 rs3917550  0.02 
PON1  rs854552 rs854555  3.1E-03 
PON1  rs854552 rs854555 rs3917550  0.01 
PON1  rs854552 rs854555 rs3917550 rs2269829  0.01 
PON1  rs854555 rs3917550 rs2269829 rs3917542  0.01 
PON1  rs854555 rs3917550 rs2269829  0.02 
PON1  rs3917550 rs2269829 rs3917542 rs662  0.05 
PON1  rs2299262 rs854569 rs2237583 rs757158  0.03 
PON1  rs854569 rs2237583 rs757158 rs11977702  0.03 
PON1  rs854569 rs2237583 rs757158  0.04 
PON1  rs2237583 rs757158  0.02 
PON1  rs757158 rs11977702  0.01 
SLC6A4  rs7224199 rs1042173  0.01 
SLC6A4  rs7224199 rs1042173 rs3794808  0.01 
SLC6A4  rs7224199 rs1042173 rs3794808 rs140701  0.01 
SLC6A4  rs1042173 rs3794808  0.01 
SLC6A4  rs1042173 rs3794808 rs140701  0.01 
SLC6A4  rs1042173 rs3794808 rs140701 rs140700  0.02 
SLC6A4  rs3794808 rs140701  0.02 
SLC6A4  rs3794808 rs140701 rs140700  0.04 
SLC6A4  rs140701 rs140700  0.04 
SLC6A4  rs2020942 rs6354 rs2020936  0.05 
SLC6A4  rs6354 rs2020936 rs12150214 rs4251417  3.2E-03 
SLC6A4  rs2020936 rs12150214 rs4251417  2.7E-03 
SLC6A4  rs2020936 rs12150214 rs4251417 
  
0.01 
SLC6A4  rs12150214 rs4251417  2.0E-03 
SLC6A4  rs12150214 rs4251417 rs16965628  0.01 
SLC6A4  rs12150214 rs4251417 rs16965628 
  
0.02 
SLC6A4  rs4251417 rs16965628 rs2020933  2.8E-03 
SLC6A4  rs4251417 rs16965628  3.3E-03 
SLC6A4  rs4251417 rs16965628 rs2020933 rs1024610  0.01 
SLC6A4  rs2020933 rs1024610  0.05 
TFPI  rs12693471 rs8176541  4.5E-03 
TFPI  rs12693471 rs8176541 rs7586970  4.5E-03 
TFPI  rs12693471 rs8176541 rs7586970 rs3213739  0.01 
TFPI  rs8176541 rs7586970  4.2E-03 
TFPI  rs8176541 rs7586970 rs3213739  0.01 
TFPI  rs8176541 rs7586970 rs3213739 rs8176508  0.01 
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TFPI  rs7586970 rs3213739  0.01 
TFPI  rs7586970 rs3213739 rs8176508  0.01 
TFPI  rs7586970 rs3213739 rs8176508 rs2041778  0.01 
TFPI  rs3213739 rs8176508 rs2041778 rs2192824  0.01 
TFPI  rs3213739 rs8176508  0.01 
TFPI  rs3213739 rs8176508 rs2041778  0.02 
TFPI  rs8176508 rs2041778 rs2192824 rs3755248  3.5E-03 
TFPI  rs8176508 rs2041778 rs2192824  3.5E-03 
TFPI  rs8176508 rs2041778  0.01 
TFPI  rs2041778 rs2192824 rs3755248 rs12613071  0.04 
TFPI  rs2192824 rs3755248 rs12613071 
  
0.03 
TFPI  rs2192824 rs3755248 rs12613071  0.05 
TFPI  rs3755248 rs12613071 rs16829086 
  
0.02 
TFPI  rs12613071 rs16829086 rs7573488 
  
4.9E-04 
TFPI  rs12613071 rs16829086 rs7573488  0.01 
TFPI  rs16829086 rs7573488 rs7594359 
  
2.9E-04 
TFPI  rs16829086 rs7573488 rs7594359  4.1E-04 
TFPI  rs16829086 rs7573488  0.01 
TFPI  rs7573488 rs7594359 rs10179730 rs6434222  2.9E-04 
TFPI  rs7573488 rs7594359 rs10179730  5.1E-04 
TFPI  rs7573488 rs7594359  0.01 
TFPI  rs7594359 rs10179730 rs6434222 
  
2.9E-04 
TFPI  rs7594359 rs10179730 rs6434222  4.7E-04 
TFPI  rs10179730 rs6434222 rs10187622  2.3E-04 
TFPI  rs10179730 rs6434222  2.7E-04 
TFPI  rs6434222 rs10187622  2.7E-04 
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Appendix Table 13. Replication of maternal and fetal results. a) maternal samples, b) fetal samples 
 
a) 
   Centennial Study Norway MoBa Study Pooled Data 
   Allele Freq. Association Allele Freq. Association Allele Freq. Association 
Gene SNP Allele Case Cont Allele Genotype Case Cont Allele Genotype Case Cont Allele Genotype 
ADRB2 rs1432622 T 0.47 0.42 0.195 0.264 0.45 0.38 0.048 0.128 0.46 0.40 0.023 0.048 
ADRB2 rs12654778 A 0.33 0.40 0.083 0.129 0.37 0.45 0.028 0.088 0.36 0.42 0.008 0.019 
AP3M2 rs4581040 G 0.32 0.24 0.042 0.131 0.30 0.24 0.041 0.112 0.31 0.24 0.004 0.017 
CBS rs6586282 T 0.19 0.19 0.837 0.165 0.18 0.15 0.219 0.005 0.19 0.17 0.330 0.585 
CBS rs11203172 T 0.22 0.16 0.092 0.176 0.17 0.20 0.318 0.049 0.19 0.18 0.714 0.591 
CCL2 rs1024610 A 0.21 0.20 0.657 0.007 0.18 0.15 0.184 0.180 0.19 0.17 0.258 0.185 
COL1A1 rs1061237 C 0.23 0.28 0.090 0.055 0.26 0.29 0.332 0.044 0.24 0.29 0.069 0.003 
COL1A2 rs420257 C 0.36 0.29 0.042 0.128 0.23 0.29 0.064 0.111 0.29 0.29 0.924 0.637 
COL1A2 rs389328 T 0.20 0.13 0.031 0.083 0.12 0.16 0.131 0.334 0.15 0.15 0.760 0.851 
COL1A2 rs2521205 G 0.57 0.47 0.015 0.066 0.43 0.51 0.021 0.045 0.49 0.49 0.832 0.758 
COL1A2 rs7804898 G 0.08 0.12 0.050 0.105 0.17 0.14 0.214 0.015 0.13 0.13 0.984 0.059 
COL3A1 rs2271682 A 0.75 0.71 0.195 0.181 0.25 0.31 0.040 0.053 0.46 0.50 0.099 0.302 
COL5A1 rs12005720 C 0.11 0.17 0.032 0.091 0.19 0.16 0.284 0.041 0.16 0.17 0.681 0.122 
COL5A1 rs4842167 C 0.48 0.38 0.009 0.021 0.36 0.44 0.011 0.037 0.41 0.41 0.845 0.526 
COL5A1 rs3811161 C 0.43 0.51 0.028 0.087 0.53 0.44 0.012 0.044 0.49 0.48 0.646 0.897 
COL5A1 rs10745387 A 0.54 0.61 0.110 0.150 0.37 0.44 0.031 0.101 0.44 0.52 0.003 0.009 
CRHBP rs10055255 A 0.67 0.55 0.001 0.006 0.41 0.36 0.125 0.286 0.52 0.45 0.006 0.026 
CRHBP rs1875999 G 0.29 0.40 0.005 0.023 0.38 0.33 0.113 0.250 0.34 0.36 0.485 0.784 
CRHR2 rs12701020 T 0.16 0.15 0.551 0.191 0.18 0.14 0.086 0.015 0.17 0.14 0.090 0.006 
CYP19A1 rs17703982 T 0.09 0.06 0.141 0.037 0.07 0.04 0.060 0.086 0.07 0.05 0.023 0.017 
F5 rs2187952 A 0.24 0.31 0.045 0.098 0.24 0.29 0.126 0.242 0.24 0.30 0.012 0.026 
IL1B rs1143630 A 0.09 0.07 0.436 0.168 0.04 0.08 0.025 0.044 0.06 0.08 0.263 0.131 
IL1R1 rs3917273 T 0.39 0.47 0.034 0.092 0.42 0.35 0.036 0.015 0.41 0.41 1.000 0.396 
IL1R1 rs2110726 T 0.44 0.34 0.007 0.014 0.40 0.43 0.425 0.026 0.42 0.38 0.216 0.211 
IL1R2 rs4851520 C 0.15 0.10 0.046 0.103 0.15 0.11 0.059 0.162 0.15 0.11 0.006 0.016 
IL1R2 rs4851522 T 0.16 0.11 0.042 0.072 0.15 0.11 0.090 0.233 0.16 0.11 0.009 0.022 
IL1R2 rs1108338 C 0.28 0.21 0.038 0.082 0.29 0.23 0.022 0.012 0.29 0.22 0.002 0.001 
IL1RAP rs7628333 T 0.21 0.24 0.358 0.080 0.22 0.32 0.002 0.005 0.22 0.28 0.004 0.012 
174 
IL2RA rs2031229 A 0.19 0.26 0.036 0.142 0.28 0.23 0.088 0.074 0.25 0.25 0.999 0.408 
IL2RA rs1107345 A 0.21 0.25 0.198 0.471 0.28 0.22 0.042 0.063 0.25 0.23 0.464 0.443 
IL2RA rs11256497 A 0.32 0.37 0.167 0.314 0.31 0.38 0.035 0.104 0.31 0.37 0.012 0.045 
IL4R rs3024530 G 0.52 0.44 0.025 0.062 0.47 0.42 0.157 0.061 0.49 0.43 0.014 0.010 
IL4R rs3024548 C 0.49 0.57 0.039 0.075 0.46 0.41 0.132 0.038 0.47 0.49 0.637 0.048 
IL6R rs4845374 T 0.87 0.82 0.139 0.110 0.12 0.17 0.042 0.027 0.43 0.48 0.051 0.002 
IL6R rs4329505 C 0.13 0.17 0.129 0.067 0.12 0.17 0.042 0.027 0.13 0.17 0.011 0.003 
MMP2 rs1053605 T 0.04 0.06 0.184 0.304 0.09 0.05 0.037 0.068 0.07 0.06 0.383 0.482 
NAT1 rs7017402 A 0.15 0.10 0.038 0.088 0.13 0.09 0.043 0.048 0.14 0.09 0.004 0.013 
NAT1 rs9325827 C 0.18 0.11 0.012 0.040 0.16 0.11 0.048 0.083 0.17 0.11 0.002 0.008 
NAT1 rs4921880 T 0.28 0.23 0.147 0.055 0.27 0.25 0.523 0.021 0.27 0.24 0.149 0.290 
PGR rs555572 C 0.30 0.34 0.243 0.130 0.35 0.27 0.007 0.026 0.33 0.30 0.235 0.135 
PGR rs11224589 C 0.30 0.35 0.210 0.138 0.37 0.28 0.007 0.021 0.34 0.31 0.253 0.125 
PGR rs619487 G 0.37 0.31 0.102 0.132 0.33 0.39 0.040 0.018 0.34 0.35 0.682 0.065 
PLA2G4A rs2076075 A 0.14 0.10 0.110 0.236 0.17 0.12 0.020 0.056 0.16 0.11 0.004 0.016 
PLAT rs2020922 A 0.32 0.24 0.029 0.095 0.30 0.24 0.034 0.081 0.31 0.24 0.003 0.009 
PTGER3 rs959 G 0.25 0.25 0.858 0.055 0.25 0.24 0.581 0.035 0.25 0.24 0.780 0.955 
PTGER3 rs5702 T 0.24 0.25 0.681 0.154 0.27 0.25 0.575 0.020 0.25 0.25 0.852 0.862 
PTGER3 rs1409165 C 0.14 0.11 0.169 0.432 0.09 0.14 0.024 0.031 0.11 0.12 0.443 0.763 
PTGER3 rs977214 G 0.09 0.13 0.166 0.005 0.06 0.09 0.064 0.039 0.07 0.11 0.016 0.000 
PTGER3 rs6665776 A 0.09 0.12 0.235 0.010 0.06 0.09 0.064 0.039 0.07 0.11 0.024 0.000 
PTGER3 rs2072947 C 0.53 0.44 0.017 0.034 0.41 0.46 0.205 0.027 0.46 0.45 0.582 0.039 
TIMP3 rs130290 T 0.06 0.11 0.013 0.022 0.08 0.05 0.151 0.234 0.07 0.08 0.373 0.644 
TIMP3 rs130293 C 0.05 0.11 0.011 0.025 0.08 0.05 0.150 0.228 0.07 0.08 0.378 0.636 
TLR2 rs1898830 G 0.29 0.38 0.015 0.052 0.33 0.38 0.152 0.345 0.31 0.38 0.008 0.025 
TNFRSF1A rs4149578 A 0.12 0.07 0.033 0.044 0.14 0.10 0.156 0.314 0.13 0.09 0.012 0.028 
TSHR rs11845715 T 0.22 0.15 0.025 0.099 0.17 0.17 0.779 0.023 0.19 0.16 0.093 0.025 
TSHR rs17630128 C 0.33 0.25 0.031 0.023 0.36 0.30 0.072 0.192 0.35 0.28 0.004 0.010 
TSHR rs12883801 G 0.41 0.52 0.005 0.011 0.37 0.43 0.107 0.137 0.39 0.47 0.001 0.001 
 
 
 
 
 
 
175 
b) 
   Centennial Study Norway MoBa Study Pooled Data 
   Allele Freq. Association Allele Freq. Association Allele Freq. Association 
Gene SNP Allele Case Cont Allele Genotype Case Cont Allele Genotype Case Cont Allele Genotype 
C6orf48 rs2471980 G 0.36 0.31 0.239 0.170 0.28 0.36 0.019 0.004 0.31 0.34 0.316 0.458 
COL1A2 rs42524 G 0.77 0.79 0.440 0.055 0.19 0.26 0.010 0.022 0.43 0.50 0.003 0.001 
COL1A2 rs42528 T 0.24 0.23 0.699 0.135 0.20 0.28 0.008 0.018 0.21 0.25 0.079 0.025 
COL3A1 rs2271682 A 0.76 0.71 0.120 0.045 0.26 0.32 0.062 0.108 0.47 0.49 0.251 0.008 
COL3A1 rs3134656 A 0.50 0.39 0.005 0.026 0.47 0.41 0.067 0.098 0.48 0.40 0.001 0.004 
COL5A2 rs9288163 A 0.11 0.06 0.025 0.034 0.08 0.09 0.467 0.192 0.09 0.08 0.361 0.057 
EDN2 rs4660541 T 0.24 0.28 0.254 0.012 0.27 0.28 0.648 0.159 0.26 0.28 0.287 0.538 
EPHX2 rs10503812 A 0.21 0.15 0.040 0.118 0.15 0.13 0.574 0.029 0.17 0.14 0.082 0.025 
EPHX2 rs4149239 G 0.21 0.15 0.047 0.110 0.15 0.13 0.575 0.028 0.17 0.14 0.092 0.017 
EPHX2 rs4149252 T 0.20 0.15 0.052 0.153 0.15 0.13 0.575 0.028 0.17 0.14 0.097 0.029 
EPHX2 rs4149259 T 0.21 0.14 0.024 0.053 0.15 0.13 0.420 0.015 0.17 0.14 0.040 0.005 
EPHX2 rs891401 G 0.21 0.15 0.030 0.081 0.15 0.13 0.574 0.029 0.17 0.14 0.070 0.025 
HSPA6 rs9427401 C 0.86 0.89 0.160 0.381 0.15 0.09 0.007 0.022 0.44 0.45 0.508 0.027 
IL1A rs17561 T 0.24 0.33 0.012 0.043 0.35 0.28 0.025 0.058 0.30 0.30 0.887 0.891 
IL1A rs1878321 C 0.24 0.33 0.014 0.056 0.35 0.28 0.025 0.058 0.31 0.30 0.875 0.814 
IL1A rs2856838 T 0.42 0.35 0.073 0.158 0.32 0.40 0.027 0.023 0.36 0.38 0.607 0.547 
IL1B rs1143630 A 0.10 0.05 0.036 0.025 0.05 0.08 0.151 0.147 0.07 0.07 0.740 0.747 
IL1R1 rs3917225 G 0.47 0.41 0.169 0.351 0.45 0.53 0.031 0.083 0.46 0.47 0.515 0.799 
IL1RAP rs9845825 A 0.40 0.30 0.015 0.011 0.35 0.30 0.132 0.311 0.37 0.30 0.007 0.018 
IL1RN rs315920 T 0.24 0.21 0.276 0.040 0.18 0.22 0.198 0.108 0.21 0.21 0.783 0.013 
IL2RA rs12722596 G 0.08 0.13 0.026 0.084 0.13 0.08 0.035 0.081 0.11 0.11 0.924 0.847 
IL4R rs1805015 C 0.23 0.18 0.096 0.228 0.16 0.11 0.039 0.103 0.19 0.14 0.013 0.044 
IL4R rs3024676 A 0.24 0.19 0.099 0.149 0.17 0.11 0.031 0.076 0.20 0.15 0.012 0.038 
MMP1 rs1155764 G 0.20 0.12 0.011 0.019 0.11 0.15 0.109 0.091 0.15 0.14 0.618 0.558 
MTHFR rs1476413 A 0.26 0.31 0.197 0.427 0.25 0.31 0.049 0.021 0.26 0.31 0.019 0.026 
MTHFR rs1994798 C 0.39 0.45 0.131 0.281 0.37 0.47 0.004 0.013 0.38 0.46 0.001 0.006 
MTHFR rs4846048 G 0.28 0.33 0.189 0.352 0.25 0.31 0.047 0.101 0.26 0.32 0.016 0.054 
MTHFR rs4846052 T 0.39 0.46 0.085 0.205 0.36 0.45 0.009 0.010 0.37 0.46 0.002 0.003 
NFKB1 rs13117745 T 0.18 0.14 0.149 0.375 0.17 0.11 0.011 0.019 0.18 0.12 0.005 0.016 
NFKB1 rs4648141 A 0.20 0.15 0.067 0.140 0.19 0.14 0.047 0.102 0.19 0.14 0.007 0.026 
NR3C1 rs9324918 G 0.21 0.14 0.031 0.076 0.21 0.18 0.380 0.036 0.21 0.16 0.036 0.005 
176 
PGR rs11224589 C 0.26 0.34 0.024 0.078 0.34 0.28 0.085 0.231 0.31 0.31 0.875 0.752 
PGR rs555572 C 0.26 0.34 0.023 0.055 0.33 0.28 0.117 0.294 0.30 0.31 0.755 0.690 
PON1 rs2272365 G 0.19 0.13 0.046 0.052 0.17 0.12 0.041 0.121 0.18 0.13 0.005 0.014 
PON1 rs854552 C 0.22 0.28 0.120 0.248 0.21 0.30 0.002 0.006 0.21 0.29 0.001 0.002 
PON2 rs2286233 A 0.91 0.84 0.009 0.041 0.10 0.15 0.037 0.106 0.43 0.46 0.236 0.018 
PTGER2 rs1254600 T 0.15 0.20 0.131 0.157 0.20 0.16 0.112 0.042 0.18 0.18 0.825 0.089 
SLC6A4 rs1042173 G 0.40 0.47 0.093 0.211 0.40 0.49 0.008 0.032 0.40 0.48 0.002 0.008 
SLC6A4 rs140701 A 0.38 0.43 0.159 0.322 0.39 0.47 0.022 0.074 0.38 0.45 0.009 0.028 
SLC6A4 rs3794808 A 0.37 0.45 0.044 0.109 0.39 0.47 0.018 0.062 0.38 0.46 0.002 0.007 
SLC6A4 rs7224199 T 0.42 0.47 0.175 0.359 0.40 0.49 0.008 0.032 0.41 0.48 0.004 0.013 
TREM1 rs4711668 T 0.27 0.36 0.017 0.030 0.34 0.28 0.072 0.134 0.31 0.32 0.818 0.382 
TSHR rs179247 G 0.51 0.42 0.024 0.024 0.42 0.46 0.174 0.141 0.46 0.45 0.680 0.121 
UGT1A1 rs11888492 C 0.85 0.90 0.044 0.117 0.13 0.11 0.449 0.033 0.42 0.47 0.070 0.041 
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Appendix Figure 1: Significant cytokine correlation patterns a) BV- EA, b) BV+ EA, c) 
BV- AA and d) BV+
 
 AA. Shaded cell denotes a significant correlation for given pair of cytokines with the 
darker shade representing stronger correlation coefficients as indicated in the key. White boxes denote that 
the correlation between the two cytokines was not significant. Sideways slash denotes a negative 
correlation. 
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a)      b) 
   
 
c)      d) 
   
 
e)      f) 
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g)      h) 
  
 
i)          j) 
 
 
 
k)      l) 
   
 
Appendix Figure 2: LD patterns. a) maternal COL1A2 cases b) maternal COL1A2 controls c) 
maternal IL1RAP cases d) maternal IL1RAP controls e) fetal SLC6A4 cases f) fetal SLC6A4 controls g) 
fetal TFPI cases h) fetal TFPI controls, i) fetal COL1A2 cases, j) fetal COL1A2 controls k) maternal TFPI 
cases, l) maternal TFPI controls. Red shading denotes strength of LD. D′ values are shown. 
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